NZ623846B2 - Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(bi phenyl-4-yl) -1h-imidazo-2-yl] pyrrolidine-1-carbonlymethyl} amine - Google Patents
Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(bi phenyl-4-yl) -1h-imidazo-2-yl] pyrrolidine-1-carbonlymethyl} amine Download PDFInfo
- Publication number
- NZ623846B2 NZ623846B2 NZ623846A NZ62384612A NZ623846B2 NZ 623846 B2 NZ623846 B2 NZ 623846B2 NZ 623846 A NZ623846 A NZ 623846A NZ 62384612 A NZ62384612 A NZ 62384612A NZ 623846 B2 NZ623846 B2 NZ 623846B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- mmol
- methyl
- optionally substituted
- clf
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title claims abstract description 74
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 45
- 239000003112 inhibitor Substances 0.000 title claims abstract description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 237
- 239000000203 mixture Substances 0.000 claims abstract description 152
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 74
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 239000011780 sodium chloride Substances 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 36
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 21
- 230000017613 viral reproduction Effects 0.000 claims abstract description 20
- 206010047461 Viral infection Diseases 0.000 claims abstract description 19
- 208000001756 Virus Disease Diseases 0.000 claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 281
- -1 -SR Chemical group 0.000 claims description 223
- 229920000728 polyester Polymers 0.000 claims description 170
- 229910052739 hydrogen Inorganic materials 0.000 claims description 111
- 239000001257 hydrogen Substances 0.000 claims description 109
- 125000000623 heterocyclic group Chemical group 0.000 claims description 69
- 229910052757 nitrogen Inorganic materials 0.000 claims description 68
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 67
- 125000005843 halogen group Chemical group 0.000 claims description 50
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 47
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 36
- 241000124008 Mammalia Species 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 150000002431 hydrogen Chemical group 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 23
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 108010050904 Interferons Proteins 0.000 claims description 19
- 102000014150 Interferons Human genes 0.000 claims description 19
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 19
- 239000002777 nucleoside Substances 0.000 claims description 19
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 19
- 125000004429 atoms Chemical group 0.000 claims description 18
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 18
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 18
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 17
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 229960000329 Ribavirin Drugs 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims description 13
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 13
- 125000002883 imidazolyl group Chemical group 0.000 claims description 12
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229940047124 Interferons Drugs 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 9
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 claims description 6
- 239000000134 cyclophilin inhibitor Substances 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 203
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 419
- 229910020313 ClF Inorganic materials 0.000 description 325
- 230000037283 Clf Effects 0.000 description 325
- 239000011541 reaction mixture Substances 0.000 description 192
- 235000019439 ethyl acetate Nutrition 0.000 description 184
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 173
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 118
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 116
- 239000000243 solution Substances 0.000 description 111
- 238000002360 preparation method Methods 0.000 description 109
- 239000007787 solid Substances 0.000 description 95
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 93
- 239000000047 product Substances 0.000 description 92
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 80
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 67
- 239000012044 organic layer Substances 0.000 description 66
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 64
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 61
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 61
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- 238000010898 silica gel chromatography Methods 0.000 description 54
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 54
- 239000008079 hexane Substances 0.000 description 52
- 239000012267 brine Substances 0.000 description 50
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 50
- 229910052938 sodium sulfate Inorganic materials 0.000 description 50
- 235000011152 sodium sulphate Nutrition 0.000 description 50
- 239000003921 oil Substances 0.000 description 47
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 46
- 235000019198 oils Nutrition 0.000 description 46
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 46
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 40
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 39
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 38
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 36
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 32
- 239000002253 acid Substances 0.000 description 30
- 239000003795 chemical substances by application Substances 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 238000004007 reversed phase HPLC Methods 0.000 description 30
- 239000000741 silica gel Substances 0.000 description 29
- 229910002027 silica gel Inorganic materials 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 26
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 26
- 238000004166 bioassay Methods 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 20
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 239000003208 petroleum Substances 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 17
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 16
- 229910052799 carbon Inorganic materials 0.000 description 16
- 239000001184 potassium carbonate Substances 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- 238000002390 rotary evaporation Methods 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 14
- 239000012043 crude product Substances 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- UKFTXWKNVSVVCJ-UHFFFAOYSA-N 2-[(6-hydrazinylpyridazin-3-yl)-(2-hydroxyethyl)amino]ethanol;hydron;dichloride Chemical class Cl.Cl.NNC1=CC=C(N(CCO)CCO)N=N1 UKFTXWKNVSVVCJ-UHFFFAOYSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000002609 media Substances 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- IPWKHHSGDUIRAH-UHFFFAOYSA-N Bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 230000002829 reduced Effects 0.000 description 11
- 125000001246 bromo group Chemical group Br* 0.000 description 10
- 125000004432 carbon atoms Chemical group C* 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 229940079322 interferon Drugs 0.000 description 10
- 239000011570 nicotinamide Substances 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 230000036515 potency Effects 0.000 description 10
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 9
- 239000005695 Ammonium acetate Substances 0.000 description 9
- WKVOHIORHLIYNK-MLWJPKLSSA-N COC(=O)N[C@H](C(=O)O)C1OCCCC1 Chemical compound COC(=O)N[C@H](C(=O)O)C1OCCCC1 WKVOHIORHLIYNK-MLWJPKLSSA-N 0.000 description 9
- 238000006069 Suzuki reaction reaction Methods 0.000 description 9
- USFZMSVCRYTOJT-UHFFFAOYSA-N ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 9
- 235000019257 ammonium acetate Nutrition 0.000 description 9
- 229940043376 ammonium acetate Drugs 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- PWEGVZDXTQLFLQ-UHFFFAOYSA-N dioxidoboron Chemical compound [O-][B][O-] PWEGVZDXTQLFLQ-UHFFFAOYSA-N 0.000 description 9
- 125000004043 oxo group Chemical group O=* 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 8
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 8
- 229910014264 BrF Inorganic materials 0.000 description 8
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 235000011056 potassium acetate Nutrition 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- BSXPDVKSFWQFRT-UHFFFAOYSA-N 1-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CC=C2N(O)N=NC2=N1 BSXPDVKSFWQFRT-UHFFFAOYSA-N 0.000 description 7
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 201000009910 diseases by infectious agent Diseases 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 229960004063 Propylene glycol Drugs 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000004305 biphenyl Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
- 239000001187 sodium carbonate Substances 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- DATRVIMZZZVHMP-MRVPVSSYSA-N tert-butyl (2R)-2-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-MRVPVSSYSA-N 0.000 description 6
- BFNMOMYTTGHNGJ-SCSAIBSYSA-N (1S)-2,2-dimethylcyclopropane-1-carboxylic acid Chemical compound CC1(C)C[C@@H]1C(O)=O BFNMOMYTTGHNGJ-SCSAIBSYSA-N 0.000 description 5
- 102000033147 ERVK-25 Human genes 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 108091005771 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 230000000111 anti-oxidant Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 150000002829 nitrogen Chemical group 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102220082228 rs863224038 Human genes 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- PIBXOBCFOCDTJF-UHFFFAOYSA-N tert-butyl 4-(1H-imidazol-5-ylmethyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CC1=CN=CN1 PIBXOBCFOCDTJF-UHFFFAOYSA-N 0.000 description 5
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 4
- XXTXDVUAHROLBN-UHFFFAOYSA-N 2-(trifluoromethoxy)benzamide Chemical compound NC(=O)C1=CC=CC=C1OC(F)(F)F XXTXDVUAHROLBN-UHFFFAOYSA-N 0.000 description 4
- DWOZNANUEDYIOF-UHFFFAOYSA-L 4-ditert-butylphosphanyl-N,N-dimethylaniline;dichloropalladium Chemical compound Cl[Pd]Cl.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 DWOZNANUEDYIOF-UHFFFAOYSA-L 0.000 description 4
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 4
- QTMDXZNDVAMKGV-UHFFFAOYSA-L Copper(II) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 102000016600 Inosine-5'-monophosphate dehydrogenase Human genes 0.000 description 4
- 108050006182 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 description 4
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 4
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 108060001084 Luciferase family Proteins 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000010976 amide bond formation reaction Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000007819 coupling partner Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002960 lipid emulsion Substances 0.000 description 4
- QWWIUYXPVVJVNS-UHFFFAOYSA-N methyl 4-bromo-2-(trifluoromethoxy)benzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1OC(F)(F)F QWWIUYXPVVJVNS-UHFFFAOYSA-N 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- PGZCVLUQTJRRAA-BDAKNGLRSA-N tert-butyl (2S,5R)-2,5-dimethylpiperazine-1-carboxylate Chemical group C[C@@H]1CN(C(=O)OC(C)(C)C)[C@@H](C)CN1 PGZCVLUQTJRRAA-BDAKNGLRSA-N 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- YFXGICNMLCGLHJ-RSKRLRQZSA-N 2,2-dimethylpropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate Chemical compound C1=CC=C2C(OP(=O)(N[C@@H](C)C(=O)OCC(C)(C)C)OC[C@H]3O[C@H]([C@]([C@@H]3O)(C)O)N3C=4N=C(N)N=C(C=4N=C3)OC)=CC=CC2=C1 YFXGICNMLCGLHJ-RSKRLRQZSA-N 0.000 description 3
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 3
- XTDKZSUYCXHXJM-UHFFFAOYSA-N 2-methoxyoxane Chemical compound COC1CCCCO1 XTDKZSUYCXHXJM-UHFFFAOYSA-N 0.000 description 3
- 102200028147 APOBEC4 L31V Human genes 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 230000036850 Cld Effects 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M Potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- ZHHGTMQHUWDEJF-UHFFFAOYSA-N [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 ZHHGTMQHUWDEJF-UHFFFAOYSA-N 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 239000012268 protein inhibitor Substances 0.000 description 3
- 229940121649 protein inhibitors Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- RICZEKWVNZFTNZ-LFGITCQGSA-N (1R,2S,5S)-3-[(2S)-2-[[1-(tert-butylsulfonylmethyl)cyclohexyl]carbamoylamino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical compound N([C@H](C(=O)N1C[C@H]2[C@H](C2(C)C)[C@H]1C(=O)N[C@@H](CCCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1 RICZEKWVNZFTNZ-LFGITCQGSA-N 0.000 description 2
- MHFMTUBUVQZIRE-WINRQGAFSA-N (2S,4R)-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-1-[(2S)-3,3-dimethyl-2-(2-oxo-2-piperidin-1-ylethyl)butanoyl]-4-(7-methoxy-2-phenylquinolin-4-yl)oxypyrrolidine-2-carboxamide Chemical compound C([C@H](C(=O)N1[C@@H](C[C@H](C1)OC=1C2=CC=C(C=C2N=C(C=1)C=1C=CC=CC=1)OC)C(=O)N[C@]1([C@@H](C1)C=C)C(=O)NS(=O)(=O)C1CC1)C(C)(C)C)C(=O)N1CCCCC1 MHFMTUBUVQZIRE-WINRQGAFSA-N 0.000 description 2
- UPBHYYJZVWZCOZ-QMMMGPOBSA-N 1-O-tert-butyl 2-O-methyl (2S)-4-oxopyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@@H]1CC(=O)CN1C(=O)OC(C)(C)C UPBHYYJZVWZCOZ-QMMMGPOBSA-N 0.000 description 2
- HBNJDBHDJUHLHN-UWVGGRQHSA-N 1-O-tert-butyl 2-O-methyl (2S,4S)-4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate Chemical compound COC[C@H]1C[C@@H](C(=O)OC)N(C(=O)OC(C)(C)C)C1 HBNJDBHDJUHLHN-UWVGGRQHSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- KMOOCZWLFBSQCW-WZVSWZHRSA-N 2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(2-hydroxyethyl)-3-(methylaminomethyl)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-dimethy Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.CNC[C@H]1[C@H](O)[C@@H](O)[C@H](CCO)O[C@H]1O[C@@H]1C(C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O KMOOCZWLFBSQCW-WZVSWZHRSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- ZANPJXNYBVVNSD-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)C=C1 ZANPJXNYBVVNSD-UHFFFAOYSA-N 0.000 description 2
- NYVWYZMUMRFMRR-UHFFFAOYSA-N 4-(iminomethylideneamino)-N,N-dimethylpentan-1-amine Chemical compound N=C=NC(C)CCCN(C)C NYVWYZMUMRFMRR-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- CMTZTHDQTYHVFR-UHFFFAOYSA-N 4-amino-2-(trifluoromethoxy)benzoic acid Chemical compound NC1=CC=C(C(O)=O)C(OC(F)(F)F)=C1 CMTZTHDQTYHVFR-UHFFFAOYSA-N 0.000 description 2
- XBEQSQDCBSKCHJ-UHFFFAOYSA-N 5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine Chemical compound FC1=CC=CC=C1C1=NC2=CN(CC=3N=NC(=CC=3)C=3C(=CC(=CC=3)C(F)(F)F)C(F)(F)F)C=CC2=N1 XBEQSQDCBSKCHJ-UHFFFAOYSA-N 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N Asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 229950010541 Beclabuvir Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- OHPUCEUCBHBIAW-UHFFFAOYSA-M COCC1CC(C([O-])=O)N(C(=O)OC(C)(C)C)C1 Chemical compound COCC1CC(C([O-])=O)N(C(=O)OC(C)(C)C)C1 OHPUCEUCBHBIAW-UHFFFAOYSA-M 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- ZVTDLPBHTSMEJZ-UPZRXNBOSA-N DANOPREVIR Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCC[C@H](C(N1C[C@@H](C[C@H]1C(=O)N2)OC(=O)N1CC2=C(F)C=CC=C2C1)=O)NC(=O)OC(C)(C)C)NS(=O)(=O)C1CC1 ZVTDLPBHTSMEJZ-UPZRXNBOSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000408223 Eggplant mottled crinkle virus Species 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- JPYIOYAFWKZWKG-UHFFFAOYSA-N FC1=C(NOC(F)(F)F)C=CC=C1 Chemical compound FC1=C(NOC(F)(F)F)C=CC=C1 JPYIOYAFWKZWKG-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 108010093497 Hepatitis C virus nucleocapsid protein Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102100008763 IFNA2 Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 description 2
- 102100011960 MIR7-3HG Human genes 0.000 description 2
- 101710008473 MIR7-3HG Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 101800001019 Non-structural protein 4B Proteins 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 101710043771 PDCL Proteins 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- VPHXUNBMNWOYNQ-XLBCSPGISA-N SETROBUVIR Chemical compound N1([C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)/C(C1=O)=C1/NC2=CC=C(C=C2S(=O)(=O)N1)NS(=O)(=O)C)CC1=CC=C(F)C=C1 VPHXUNBMNWOYNQ-XLBCSPGISA-N 0.000 description 2
- JTZZSQYMACOLNN-VDWJNHBNSA-N Simeprevir Chemical compound O=C([C@@]12C[C@H]1\C=C/CCCCN(C)C(=O)[C@H]1[C@H](C(N2)=O)C[C@H](C1)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)NS(=O)(=O)C1CC1 JTZZSQYMACOLNN-VDWJNHBNSA-N 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N Sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M Sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N Taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 2
- 229940116362 Tragacanth Drugs 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- HPAPGONEMPZXMM-CMWVUSIZSA-N Vaniprevir Chemical compound O=C([C@H]1C[C@@H]2OC(=O)N3CC=4C=CC=C(C=4C3)CCCCC(C)(C)COC(=O)N[C@@H](C(N1C2)=O)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C HPAPGONEMPZXMM-CMWVUSIZSA-N 0.000 description 2
- 229950000843 Vaniprevir Drugs 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- MLESJYFEMSJZLZ-MAAOGQSESA-N [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate Chemical compound C[C@@]1(F)[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 MLESJYFEMSJZLZ-MAAOGQSESA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000840 anti-viral Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229960002118 asunaprevir Drugs 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 150000005347 biaryls Chemical group 0.000 description 2
- 229960000517 boceprevir Drugs 0.000 description 2
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 2
- 125000005621 boronate group Chemical group 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000002519 immonomodulatory Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003452 intergenotypic Effects 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 229960002091 simeprevir Drugs 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- 229960002063 sofosbuvir Drugs 0.000 description 2
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229950006081 taribavirin Drugs 0.000 description 2
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- 239000012414 tert-butyl nitrite Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 239000003970 toll like receptor agonist Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- SLVAPEZTBDBAPI-GDLZYMKVSA-N (2R)-2-cyclopentyl-2-[2-(2,6-diethylpyridin-4-yl)ethyl]-5-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-3H-pyran-6-one Chemical compound CCC1=NC(CC)=CC(CC[C@]2(OC(=O)C(CC3=NN4C(C)=CC(C)=NC4=N3)=C(O)C2)C2CCCC2)=C1 SLVAPEZTBDBAPI-GDLZYMKVSA-N 0.000 description 1
- HDUCHXGIUDFNEP-MRVPVSSYSA-N (2R)-2-methyl-1-(5-nitropyridin-2-yl)piperazine Chemical compound C[C@@H]1CNCCN1C1=CC=C([N+]([O-])=O)C=N1 HDUCHXGIUDFNEP-MRVPVSSYSA-N 0.000 description 1
- IRZRJANZDIOOIF-GAJNKVMBSA-N (2R,3R,4R,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C=C1 IRZRJANZDIOOIF-GAJNKVMBSA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- QGHRBLCZXFQZBB-QMMMGPOBSA-N (2S)-1-methoxycarbonyl-2-methylpyrrolidine-2-carboxylic acid Chemical compound COC(=O)N1CCC[C@@]1(C)C(O)=O QGHRBLCZXFQZBB-QMMMGPOBSA-N 0.000 description 1
- HBICVCPHTYGKKD-BYPYZUCNSA-N (2S)-2-(azaniumylmethyl)butanoate Chemical compound CC[C@@H](CN)C(O)=O HBICVCPHTYGKKD-BYPYZUCNSA-N 0.000 description 1
- AQHMBDAHQGYLIU-XNFHFXFQSA-N (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10, Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)[C@@H](SCCN(C)C)N(C)C1=O AQHMBDAHQGYLIU-XNFHFXFQSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- YQUCBFIQSJVCOR-JOCHJYFZSA-N (7r)-14-Cyclohexyl-7-{[2-(Dimethylamino)ethyl](Methyl)amino}-7,8-Dihydro-6h-Indolo[1,2-E][1,5]benzoxazocine-11-Carboxylic Acid Chemical compound C([C@@H](CN1C2=CC(=CC=C22)C(O)=O)N(C)CCN(C)C)OC3=CC=CC=C3C1=C2C1CCCCC1 YQUCBFIQSJVCOR-JOCHJYFZSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- XSFVPTGDKAJZDH-VIFPVBQESA-N 1-O-tert-butyl 2-O-ethyl (2S)-3-oxopyrrolidine-1,2-dicarboxylate Chemical compound CCOC(=O)[C@H]1N(C(=O)OC(C)(C)C)CCC1=O XSFVPTGDKAJZDH-VIFPVBQESA-N 0.000 description 1
- UZQLHSFPEBCFEQ-DDXVTDLHSA-N 1-O-tert-butyl 2-O-methyl (2S,4E)-4-(methoxymethylidene)pyrrolidine-1,2-dicarboxylate Chemical compound CO\C=C1/C[C@@H](C(=O)OC)N(C(=O)OC(C)(C)C)C1 UZQLHSFPEBCFEQ-DDXVTDLHSA-N 0.000 description 1
- MZMNEDXVUJLQAF-SFYZADRCSA-N 1-O-tert-butyl 2-O-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)[C@@H]1C[C@@H](O)CN1C(=O)OC(C)(C)C MZMNEDXVUJLQAF-SFYZADRCSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FUHWWEDRJKHMKK-UHFFFAOYSA-N 1-hydroperoxy-2-methylpropane Chemical compound CC(C)COO FUHWWEDRJKHMKK-UHFFFAOYSA-N 0.000 description 1
- VZURHXVELPKQNZ-UHFFFAOYSA-N 1-hydroxyethyl 2-hydroxyoctadecanoate Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)OC(C)O VZURHXVELPKQNZ-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-Ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
- KYWMCFOWDYFYLV-UHFFFAOYSA-N 1H-imidazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CN1 KYWMCFOWDYFYLV-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-Aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- PYXQUININYNKRG-AWEZNQCLSA-N 2-O-[2-(4-bromophenyl)-2-oxoethyl] 1-O-tert-butyl (2S)-pyrrolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)OCC(=O)C1=CC=C(Br)C=C1 PYXQUININYNKRG-AWEZNQCLSA-N 0.000 description 1
- PANSTIDPOANYLJ-UHFFFAOYSA-N 2-[(methoxycarbonylamino)methyl]butanoic acid Chemical compound CCC(C(O)=O)CNC(=O)OC PANSTIDPOANYLJ-UHFFFAOYSA-N 0.000 description 1
- XNDDHFZKJNTAMK-JNDBSPSASA-N 2-[[2-[2-[6-[3-[4-[2-[(2S)-1-[(2S)-2-(carboxymethylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]thieno[3,2-b]thiophen-6-yl]-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]amino]acetic acid Chemical compound OC(=O)CN[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=CC(=CC=2)C=2C=3SC=C(C=3SC=2)C=2C=C3NC(=NC3=CC=2)C2N(CCC2)C(=O)C(NCC(O)=O)C=2C=CC=CC=2)N1 XNDDHFZKJNTAMK-JNDBSPSASA-N 0.000 description 1
- ZQFATRVLQKIVTH-UHFFFAOYSA-N 2-amino-1-(4-bromophenyl)ethanone Chemical compound NCC(=O)C1=CC=C(Br)C=C1 ZQFATRVLQKIVTH-UHFFFAOYSA-N 0.000 description 1
- IUEOLDWRICALIQ-UHFFFAOYSA-N 2-bromo-1-chloro-3-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=CC(Cl)=C1Br IUEOLDWRICALIQ-UHFFFAOYSA-N 0.000 description 1
- XRXMNWGCKISMOH-UHFFFAOYSA-N 2-bromobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Br XRXMNWGCKISMOH-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- LLLVHTWJGWNRBD-UHFFFAOYSA-N 2-fluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1F LLLVHTWJGWNRBD-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- UAVMXZQEEDWREU-UHFFFAOYSA-N 2H-benzotriazol-4-yloxy(tripyrrolidin-1-yl)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)OC1=CC=CC2=C1N=NN2 UAVMXZQEEDWREU-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- IXVLAJIQVJQKJZ-UHFFFAOYSA-N 3-bromo-4-chloro-5-(trifluoromethyl)aniline Chemical compound NC1=CC(Br)=C(Cl)C(C(F)(F)F)=C1 IXVLAJIQVJQKJZ-UHFFFAOYSA-N 0.000 description 1
- RDFQSFOGKVZWKF-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanoic acid Chemical compound OCC(C)(C)C(O)=O RDFQSFOGKVZWKF-UHFFFAOYSA-N 0.000 description 1
- SIAVMDKGVRXFAX-UHFFFAOYSA-N 4-Carboxyphenylboronic Acid Chemical compound OB(O)C1=CC=C(C(O)=O)C=C1 SIAVMDKGVRXFAX-UHFFFAOYSA-N 0.000 description 1
- MAQDQJWCSSCURR-UHFFFAOYSA-N 4-[5-(cyclopropanecarbonylamino)-2-(trifluoromethoxy)phenyl]-N-[4-[(4-propylsulfonylpiperazin-1-yl)methyl]phenyl]benzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1CC(C=C1)=CC=C1NC(=O)C1=CC=C(C=2C(=CC=C(NC(=O)C3CC3)C=2)OC(F)(F)F)C=C1 MAQDQJWCSSCURR-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- WTDWVLJJJOTABN-UHFFFAOYSA-N 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=CC(N(CCO)S(C)(=O)=O)=C1C1CC1 WTDWVLJJJOTABN-UHFFFAOYSA-N 0.000 description 1
- XHLKOHSAWQPOFO-UHFFFAOYSA-N 5-phenyl-1H-imidazole Chemical compound N1C=NC=C1C1=CC=CC=C1 XHLKOHSAWQPOFO-UHFFFAOYSA-N 0.000 description 1
- 101710027257 5a Proteins 0.000 description 1
- UJDLCTNVHJEBDG-UHFFFAOYSA-N 6-fluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(F)N=C1 UJDLCTNVHJEBDG-UHFFFAOYSA-N 0.000 description 1
- 101710036216 ATEG_03556 Proteins 0.000 description 1
- 229940099550 Actimmune Drugs 0.000 description 1
- 229940060516 Alferon N Drugs 0.000 description 1
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- ZTTKEBYSXUCBSE-VSBZUFFNSA-N Beclabuvir Chemical compound C1([C@@H]2C[C@@]2(CN2C3=CC(=CC=C33)C(=O)NS(=O)(=O)N(C)C)C(=O)N4C5CCC4CN(C)C5)=CC(OC)=CC=C1C2=C3C1CCCCC1 ZTTKEBYSXUCBSE-VSBZUFFNSA-N 0.000 description 1
- ZTTKEBYSXUCBSE-QDFUAKMASA-N Beclabuvir Chemical compound C1([C@@H]2C[C@@]2(CN2C3=CC(=CC=C33)C(=O)NS(=O)(=O)N(C)C)C(=O)N4[C@@H]5CC[C@H]4CN(C)C5)=CC(OC)=CC=C1C2=C3C1CCCCC1 ZTTKEBYSXUCBSE-QDFUAKMASA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 description 1
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- MCWCLPMNVBBHEI-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1C(CCC1)N(C)C Chemical compound C(C)(C)(C)OC(=O)N1C(CCC1)N(C)C MCWCLPMNVBBHEI-UHFFFAOYSA-N 0.000 description 1
- ZONQQZBFKZJBNB-UHFFFAOYSA-N COC(C1=C(C(=CC=C1)OC(F)(F)F)Cl)=O Chemical compound COC(C1=C(C(=CC=C1)OC(F)(F)F)Cl)=O ZONQQZBFKZJBNB-UHFFFAOYSA-N 0.000 description 1
- FAJSCWKIKNGLRM-UHFFFAOYSA-N COCOC(=O)N1CCCC1 Chemical compound COCOC(=O)N1CCCC1 FAJSCWKIKNGLRM-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- WZNRVWBKYDHTKI-UHFFFAOYSA-N Cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
- 229940055354 Copegus Drugs 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N Copper(I) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 229910017541 Cu-K Inorganic materials 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 229960001305 Cysteine Hydrochloride Drugs 0.000 description 1
- 229950002891 DANOPREVIR Drugs 0.000 description 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N Daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 1
- 229960005449 Daclatasvir Drugs 0.000 description 1
- UDMJANYPQWEDFT-ZAWFUYGJSA-N Deldeprevir Chemical compound C([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(=O)NS(=O)(=O)C1CC1)=O)C[C@H](C2)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(C)C)C)OC)C(=O)N1CCCC(F)(F)C1 UDMJANYPQWEDFT-ZAWFUYGJSA-N 0.000 description 1
- BMAIGAHXAJEULY-UKTHLTGXSA-N Deleobuvir Chemical compound C12=CC=C(C(=O)NC3(CCC3)C=3N(C4=CC(\C=C\C(O)=O)=CC=C4N=3)C)C=C2N(C)C(C=2N=CC(Br)=CN=2)=C1C1CCCC1 BMAIGAHXAJEULY-UKTHLTGXSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 1
- BVAZQCUMNICBAQ-PZHYSIFUSA-N Elbasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=C3O[C@H](N4C5=CC=C(C=C5C=C4C3=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)C=2C=CC=CC=2)=CN1 BVAZQCUMNICBAQ-PZHYSIFUSA-N 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 229950011045 Filibuvir Drugs 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 102200101621 GLDC M28T Human genes 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- OBMNJSNZOWALQB-NCQNOWPTSA-N Grazoprevir Chemical compound O=C([C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCCC1=NC3=CC=C(C=C3N=C1O2)OC)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C OBMNJSNZOWALQB-NCQNOWPTSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000007475 Hemolytic Anemia Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- YEPBUHWNLNKZBW-FDVAVYTKSA-N IDX320 Chemical compound O=C([C@]12NC(=O)[C@H]3N(C(N(C)CCCC/C=C/[C@@H]1C2)=O)CC[C@@H](C3)OC=1C2=CC=C(C(=C2N=C(C=1)C=1SC=C(N=1)C(F)(F)F)C)OC)NS(=O)(=O)C1(C)CC1 YEPBUHWNLNKZBW-FDVAVYTKSA-N 0.000 description 1
- 229940084039 Incivek Drugs 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 229960004461 Interferon beta-1a Drugs 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 229940028862 Interferon gamma-1b Drugs 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 101710009221 LD Proteins 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 101710026373 MME Proteins 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 229950010383 Mericitabine Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229940071648 Metered Dose Inhaler Drugs 0.000 description 1
- XMZSTQYSBYEENY-RMKNXTFCSA-N N-[4-[(E)-2-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]ethenyl]phenyl]methanesulfonamide Chemical compound C1=C(N2C(NC(=O)C=C2)=O)C=C(C(C)(C)C)C(OC)=C1\C=C\C1=CC=C(NS(C)(=O)=O)C=C1 XMZSTQYSBYEENY-RMKNXTFCSA-N 0.000 description 1
- GRRYSIXDUIAUGY-UHFFFAOYSA-N N-methylcarbamoyl chloride Chemical compound CNC(Cl)=O GRRYSIXDUIAUGY-UHFFFAOYSA-N 0.000 description 1
- RPJPZDVUUKWPGT-FOIHOXPVSA-N NIM811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101700027419 NS2 Proteins 0.000 description 1
- 229950003504 Narlaprevir Drugs 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N Nitazoxanide Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- 101710003000 ORF1/ORF2 Proteins 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940100467 POLYVINYL ACETATE PHTHALATE Drugs 0.000 description 1
- 235000003177 Panax trifolius Nutrition 0.000 description 1
- 229960002754 Paritaprevir Drugs 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940002988 Pegasys Drugs 0.000 description 1
- 229940106366 Pegintron Drugs 0.000 description 1
- 101700030467 Pol Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 description 1
- 102000011587 Polyproteins Human genes 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229940075579 Propyl Gallate Drugs 0.000 description 1
- 229940053146 Rebetol Drugs 0.000 description 1
- 108010012770 Rebetron Proteins 0.000 description 1
- 229940038850 Rebif Drugs 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N Resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229950010550 Resiquimod Drugs 0.000 description 1
- FGHMGRXAHIXTBM-TWFJNEQDSA-N S-[2-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-(benzylamino)phosphoryl]oxyethyl] 3-hydroxy-2,2-dimethylpropanethioate Chemical compound C([C@@H]1[C@H]([C@@](C)(O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1)O)OP(=O)(OCCSC(=O)C(C)(CO)C)NCC1=CC=CC=C1 FGHMGRXAHIXTBM-TWFJNEQDSA-N 0.000 description 1
- 101710026336 S5 Proteins 0.000 description 1
- 108010090287 SCY-635 Proteins 0.000 description 1
- 229950004113 SETROBUVIR Drugs 0.000 description 1
- 229940100996 SODIUM BISULFATE Drugs 0.000 description 1
- 229950010695 SOVAPREVIR Drugs 0.000 description 1
- 101700042956 SYNC2 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 101710017905 Segment 6 Proteins 0.000 description 1
- 101710033766 Segment-10 Proteins 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L Silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- CSMWJXBSXGUPGY-UHFFFAOYSA-L Sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- UOBYJVFBFSLCTQ-UHFFFAOYSA-N TMC647055 Chemical compound C12=CC=C(C(NS(=O)(=O)N(C)CCOCCN(C)C3=O)=O)C=C2N2CC3=CC3=CC(OC)=CC=C3C2=C1C1CCCCC1 UOBYJVFBFSLCTQ-UHFFFAOYSA-N 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 229950004886 Tegobuvir Drugs 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N Tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N Trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229940100050 Virazole Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 101700052963 WOX3B Proteins 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N [(1R)-1-carboxy-2-sulfanylethyl]azanium;chloride;hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- XJBILYMRFVHPJB-XJQUKVTJSA-N [(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate Chemical compound C[C@H]1[C@H](OC(=O)C(C)C)[C@](COC(=O)C(C)C)(N=[N+]=[N-])O[C@H]1N1C(=O)N=C(N)C=C1 XJBILYMRFVHPJB-XJQUKVTJSA-N 0.000 description 1
- AIJCNTOYZPKURP-UHFFFAOYSA-N [2-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1OC(F)(F)F AIJCNTOYZPKURP-UHFFFAOYSA-N 0.000 description 1
- AVFUHBJCUUTGCD-UHFFFAOYSA-M [Br-].[Mg+]C Chemical compound [Br-].[Mg+]C AVFUHBJCUUTGCD-UHFFFAOYSA-M 0.000 description 1
- CWTUREABAILGIK-UHFFFAOYSA-L [Li+].[Cl-].[Cl-].CC(C)[Mg+] Chemical compound [Li+].[Cl-].[Cl-].CC(C)[Mg+] CWTUREABAILGIK-UHFFFAOYSA-L 0.000 description 1
- JMBZZRVUHMFSTF-UHFFFAOYSA-N [N+](=[N-])=C(CC=O)P(OC)(OC)=O Chemical compound [N+](=[N-])=C(CC=O)P(OC)(OC)=O JMBZZRVUHMFSTF-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- RAFKCLFWELPONH-UHFFFAOYSA-N acetonitrile;dichloromethane Chemical compound CC#N.ClCCl RAFKCLFWELPONH-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 229940087168 alpha Tocopherol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- VNNIBQJAWHQNPA-UHFFFAOYSA-N aniline;1,1'-biphenyl Chemical compound NC1=CC=CC=C1.C1=CC=CC=C1C1=CC=CC=C1 VNNIBQJAWHQNPA-UHFFFAOYSA-N 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 229920002847 antisense RNA Polymers 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical compound N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- NBRBXGKOEOGLOI-UHFFFAOYSA-N dasabuvir Chemical compound C1=C(C(C)(C)C)C(OC)=C(C=2C=C3C=CC(NS(C)(=O)=O)=CC3=CC=2)C=C1N1C=CC(=O)NC1=O NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 description 1
- 229960001418 dasabuvir Drugs 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- AJDPNPAGZMZOMN-UHFFFAOYSA-N diethyl (4-oxo-1,2,3-benzotriazin-3-yl) phosphate Chemical compound C1=CC=C2C(=O)N(OP(=O)(OCC)OCC)N=NC2=C1 AJDPNPAGZMZOMN-UHFFFAOYSA-N 0.000 description 1
- OUSQOGBNXCLZOG-UHFFFAOYSA-N dihydroxyboron;2,3-dimethylbutane-2,3-diol Chemical compound O[B]O.CC(C)(O)C(C)(C)O OUSQOGBNXCLZOG-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- NUCWDCRUEIUKPN-UHFFFAOYSA-J ethane-1,2-diamine;palladium(2+);phosphonato phosphate Chemical compound [Pd+2].[Pd+2].NCCN.NCCN.[O-]P([O-])(=O)OP([O-])([O-])=O NUCWDCRUEIUKPN-UHFFFAOYSA-J 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 101710009721 hupS Proteins 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- JYLMWUZJMRNMDA-SPRBZRACSA-N methyl N-[(2S)-1-[(2S)-2-[5-[6-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]naphthalen-2-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride Chemical compound Cl.Cl.COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(C=2C=C3C=CC(=CC3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)N1 JYLMWUZJMRNMDA-SPRBZRACSA-N 0.000 description 1
- LBWDUXHLFJNSJJ-ZYADHFCISA-N methyl N-[(2S)-1-[(6S)-6-[5-[4-[2-[2-[(6S)-5-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-5-azaspiro[2.4]heptan-6-yl]-3H-benzimidazol-5-yl]ethynyl]phenyl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=CC(=CC=2)C#CC=2C=C3NC(=NC3=CC=2)[C@H]2N(CC3(CC3)C2)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 LBWDUXHLFJNSJJ-ZYADHFCISA-N 0.000 description 1
- ZPJZSEHCMJYUPI-UHFFFAOYSA-N methyl piperazine-1-carboxylate Chemical compound COC(=O)N1CCNCC1 ZPJZSEHCMJYUPI-UHFFFAOYSA-N 0.000 description 1
- UWHWNFVVODLFIQ-UHFFFAOYSA-N methyl pyrrolidine-1-carboxylate Chemical compound COC(=O)N1CCCC1 UWHWNFVVODLFIQ-UHFFFAOYSA-N 0.000 description 1
- UAVOCTDYPKOULU-UHFFFAOYSA-N methylchloranuidyl formate Chemical compound C[Cl-]OC=O UAVOCTDYPKOULU-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 108010008475 narlaprevir Proteins 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229960000518 ombitasvir Drugs 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- UAUIUKWPKRJZJV-MDJGTQRPSA-N paritaprevir Chemical compound C1=NC(C)=CN=C1C(=O)N[C@@H]1C(=O)N2C[C@H](OC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C[C@H]2C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@@H]2\C=C/CCCCC1 UAUIUKWPKRJZJV-MDJGTQRPSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical compound N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-M pyrrolidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-M 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 101710004466 rgy Proteins 0.000 description 1
- 101710030364 rgy1 Proteins 0.000 description 1
- 101710030359 rgy2 Proteins 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 102220100737 rs141577476 Human genes 0.000 description 1
- 102220041209 rs142135772 Human genes 0.000 description 1
- 102220059798 rs56203955 Human genes 0.000 description 1
- 102220266584 rs747575706 Human genes 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- FMLPQHJYUZTHQS-MRVPVSSYSA-N tert-butyl (3R)-3-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-MRVPVSSYSA-N 0.000 description 1
- PPUYUEPZGGATCN-UHFFFAOYSA-N tert-butyl 2-methylpyrrolidine-1-carboxylate Chemical compound CC1CCCN1C(=O)OC(C)(C)C PPUYUEPZGGATCN-UHFFFAOYSA-N 0.000 description 1
- IYWRCNFZPNEADN-CXODAYGWSA-N tert-butyl N-[(2S)-1-[(2S,4R)-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]-4-(6-methoxyisoquinolin-1-yl)oxypyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC=1C2=CC=C(C=C2C=CN=1)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C IYWRCNFZPNEADN-CXODAYGWSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
Disclosed herein are compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof. The compounds are inhibitors of replication of the hepatitis C virus and are intended for use for treating hepatitis C. Also disclosed are pharmaceutical compositions comprising the compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds. Examples of the compounds of formula I include ((S)-1-{(2S,4S)-2-[4-(5'-chloro-4'-{[6-((2R,5S)-2,5-dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2'-trifluoromethoxybiphenyl-4-yl)-1H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl}-2-methylpropyl)-carbamic acid methyl ester and Methyl (S)-2-((2S,4S)-2-(4-(5'-chloro-4'-(6-((R)-2-methyl-4-pivaloylpiperazin-1-yl)pyridin-3-ylcarbamoyl)-2'-(trifluoromethoxy)biphenyl-4-yl)1H-imidazol-2-yl)-4-methylpyrrolidin-1-yl)-1-((2S,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxoethylcarbamate. cal compositions comprising the compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds. Examples of the compounds of formula I include ((S)-1-{(2S,4S)-2-[4-(5'-chloro-4'-{[6-((2R,5S)-2,5-dimethyl-4-methylcarbamoyl-piperazin-1-yl)-pyridine-3-carbonyl]-amino}-2'-trifluoromethoxybiphenyl-4-yl)-1H-imidazol-2-yl]-4-methyl-pyrrolidine-1-carbonyl}-2-methylpropyl)-carbamic acid methyl ester and Methyl (S)-2-((2S,4S)-2-(4-(5'-chloro-4'-(6-((R)-2-methyl-4-pivaloylpiperazin-1-yl)pyridin-3-ylcarbamoyl)-2'-(trifluoromethoxy)biphenyl-4-yl)1H-imidazol-2-yl)-4-methylpyrrolidin-1-yl)-1-((2S,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-2-oxoethylcarbamate.
Description
ROD-LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE
FRAGMENT {2-[4-(BI PHENYLYL) -1H-IMIDAZOYL] PYRROLIDINE CARBONLYMETHYL} AMINE
BACKGROUND OF THE INVENTION
Field of the Invention
The invention is directed to compounds useful as inhibitors of replication of the
hepatitis C virus (HCV). The invention is also directed to pharmaceutical compositions
comprising such compounds, methods of using such compounds to treat HCV infection,
and processes and intermediates useful for preparing such compounds.
State of the Art
Recent estimates place the number of people infected with the hepatitis C virus
(HCV) worldwide at more than 170 million, including 3 million people in the United
States. The infection rate is thought to be roughly 4 to 5 times that of the human
immunodeficiency virus (HIV). While in some individuals, the natural immune response
is able to overcome the virus, in the majority of cases, a chronic infection is established,
leading to increased risk of developing cirrhosis of the liver and hepatocellular
carcinomas. Infection with hepatitis C, therefore, presents a serious public health
problem.
Prior to mid-2011, the accepted standard of care for HCV involved the use of a
pegylated interferon which is believed to act by boosting the body’s immune response,
together with ribavirin. Unfortunately, the course of treatment is lengthy, typically 48
weeks, often accompanied by serious adverse side effects, including depression, flu-like
symptoms, fatigue, and hemolytic anemia, and ineffective in up to 50 % of patients. In
mid-2011, two HCV protease inhibitors were approved in the United States to be used in
combination with interferon and ribavirin. Although better cure rates have been reported,
the course of therapy is still lengthy and accompanied by undesirable side effects.
Accordingly, there remains a serious unmet need in HCV treatment.
The virus responsible for HCV infection has been identified as a positive-strand
RNA virus belonging to the family Flaviviridae. The HCV genome encodes a
polyprotein that during the viral lifecycle is cleaved into ten individual proteins, including
both structural and non-structural proteins. The six non-structural proteins, denoted as
NS2, NS3, NS4A, NS4B, NS5A, and NS5B have been shown to be required for RNA
replication. In particular, the NS5A protein appears to play a significant role in viral
replication, as well as in modulation of the physiology of the host cell. Effects of NS5A
on interferon signaling, regulation of cell growth and apoptosis have also been identified.
(Macdonald et al., Journal of General Virology (2004), 85, 2485-2502.) Compounds
which inhibit the function of the NS5A protein are expected to provide a new approach to
HCV therapy.
SUMMARY OF THE INVENTION
The specification is directed to novel compounds which inhibit replication of the
HCV virus.
Accordingly, in a first aspect the invention provides a compound of formula (I):
wherein
R is selected from C alkyl, C alkoxy, phenyl, C cycloalkyl, heterocycle, and
1-6 1-6 3-6
heteroaryl, wherein C alkyl is optionally substituted with –OR amino, –SR ,
1-6 ,
heterocycle, or heteroaryl, C alkoxy is optionally substituted with –OR , and heterocycle
is optionally substituted with –OR amino,–C(O)OC alkyl, or with one or two
, 1-6
C alkyl;
R is selected from hydrogen and C alkyl;
3 m n
R is selected from hydrogen, C alkyl, -C(O)OC alkyl, -C(O)NR R ,
1-6 1-6
-C(O)C cycloalkyl, and -S(O) C alkyl;
3-6 2 1-3
or R and R together with the nitrogen atom to which they are attached form a
heterocycle;
4 b c d e
R is selected from C alkyl, -NR R , -OR , -SR , -S(O)C alkyl, -S(O) C alkyl,
1-6 1-3 2 1-3
a b 5 6
-CN, -C(O)NR R , heterocycle, heteroaryl, and halo; and R and R are hydrogen;
4 5 6
or R and R are independently C alkyl or halo and R is hydrogen;
4 5 6
or R and R taken together form –(CH ) –, wherein n is 2, 3, 4, or 5 and R is
hydrogen;
4 5 6
or R and R taken together form –O-(CH ) -O- and R is hydrogen;
4 5 6
or R is hydrogen and R and R taken together form –(CH ) –, wherein m is 1, 2,
3, or 4;
4 5 6
or R and R are each hydrogen and R is C alkyl;
R is selected from halo, C alkyl, and C alkoxy wherein C alkyl and
1-3 1-3 1-3
C alkoxy are optionally substituted with one, two, three, four, or five halo;
R is C alkyl, optionally substituted with -OR ;
9 f g
R is selected from C alkyl, C cycloalkyl, C alkoxy, -NR R , heteroaryl,
1-6 3-6 1-6
heterocycle, and –CH -heteroaryl;
wherein:
C alkyl is optionally substituted with one or two substituents
h j k
independently selected from –OR , -NR R , -NHC(O)C alkyl, -NHC(O)OC
1-3 1-
alkyl, -NHC(O)C cycloalkyl, C cycloalkyl, and halo;
3 3-6 3-6
C alkoxy is optionally substituted with –OR ;
any C cycloalkyl is optionally substituted with one, two, or three
a b h
substituents independently selected from C alkyl, halo, -NR R , – OR , and
-CD , wherein any C alkyl is optionally substituted with one, two, or three halo;
3 1-3
any heterocycle is optionally substituted with one, two, or three
substituents independently selected from C alkyl, halo, -C(O)OC alkyl,
1-3 1-3
-C(O)C alkyl, -C(O)C cycloalkyl, –C(O)NHC alkyl,
1-6 3-6 1-6
-C(O)NHC cycloalkyl,–S(O) C alkyl, and -C(O)NH ;
3-6 2 1-6 2
wherein any –C(O)C alkyl is optionally substituted with
h j k
-NHC(O)OC alkyl, -OR , -NR R , or heterocycle,
any -C(O)C cycloalkyl is optionally substituted with one or two
C alkyl, and
any –C(O)NHC alkyl is optionally substituted with –OR or
C cycloalkyl;
any heteroaryl is optionally substituted with one or two C alkyl;
a b e h j k m n
R , R , R , R , R , R , R , and R are each independently hydrogen or C alkyl;
R is hydrogen or C alkyl, wherein C alkyl is optionally substituted with –OR
1-6 1-6
or amino;
R is hydrogen or C alkyl, wherein C alkyl is optionally substituted with –OR
1-6 1-6
or with heteroaryl optionally substituted with C alkyl;
R is hydrogen or C alkyl, wherein C alkyl is optionally substituted with –OR ;
1-6 1-6
g a b
R is selected from hydrogen, C alkyl, C alkoxy, C cycloalkyl, NR R , and
1-6 1-6 3-6
heterocycle, wherein C alkyl is optionally substituted with –OR and heterocycle is
optionally substituted with =O;
R is selected from hydrogen, halo, and C alkyl, wherein C alkyl is optionally
1-3 1-3
substituted with one, two, or three halo, or with –OR ;
A is –NHC(O)- or –C(O)NH-
a is 0, 1, or 2; and
b is 0, 1 or 2;
or a pharmaceutically-acceptable salt or stereoisomer thereof.
In a second aspect, the invention provides a pharmaceutical composition
comprising a compound of the invention and a pharmaceutically-acceptable
carrier.
In a third aspect, the invention provides a process for preparing a compound of
formula (1-5)
where G represents the group
, and
1 2 3 4 5 6 7 8 9
wherein R , R , R , R , R , R , R , R , R , a, and b are defined above, or a
pharmaceutically-acceptable salt or stereoisomer thereof, the process comprising:
(a) reacting a compound of formula 3-3
with a compound of formula 3-4
wherein Pg is an amino-protecting group,
to provide a protected intermediate 1-3
(b) deprotecting intermediate 1-3 to provide a deprotected intermediate 1-4:
(c) reacting intermediate 1-4 with a carboxylic acid or carboxylic acid
chloride:
HO R
Cl R
to provide a compound of formula 1-5 or a pharmaceutically-acceptable
salt or stereoisomer thereof.
In a fourth aspect, the invention provides a compound of formula 3-4:
wherein Pg is an amino-protecting group, R is fluoro, chloro, or –OCF ,
R is methyl, R is tert-butyl or 3-hydroxy-2,2-dimethylpropyl, a is 1 or 2, and b is
In a fifth aspect, the invention provides a use of a compound of the invention for
manufacture of a medicament for inhibiting replication of the hepatitis C virus in a
mammal.
In a sixth aspect, the invention provides a use of a compound of the invention in
combination with at least one other therapeutic agent for manufacture of a medicament
for inhibiting replication of the hepatitis C virus in a mammal.
In a seventh aspect, the invention provides a use of a compound of the invention
for manufacture of a medicament for the treatment of a hepatitis C viral infection in a
mammal.
In an eighth aspect, the invention provides a use of a compound of the invention in
combination with at least one other therapeutic agent for manufacture of a medicament
for the treatment of a hepatitis C viral infection in a mammal.
Also described is a compound of formula (I):
wherein
R is selected from C alkyl, C alkoxy, phenyl, C cycloalkyl, heterocycle, and
1-6 1-6 3-6
heteroaryl, wherein C alkyl is optionally substituted with –OR amino, –SR ,
1-6 ,
heterocycle, or heteroaryl, C alkoxy is optionally substituted with –OR , and heterocycle
is optionally substituted with –OR amino, or –C(O)OC alkyl, or with one or two
, 1-6
C alkyl or =O;
R is selected from hydrogen and C alkyl;
3 m n
R is selected from hydrogen, C alkyl, -C(O)OC alkyl, -C(O)NR R ,
1-6 1-6
-C(O)C cycloalkyl, and -S(O) C alkyl;
3-6 2 1-3
or R and R together with the nitrogen atom to which they are attached form a
heterocycle;
4 b c d e
R is selected from C alkyl, -NR R , -OR , -SR , -S(O)C alkyl, -S(O) C alkyl,
1-6 1-3 2 1-3
-CN, -C(O)NR R , heterocycle, heteroaryl, and halo, wherein C alkyl is optionally
a 5 6
substituted with -OR ; and R and R are hydrogen;
4 5 6
or R and R are independently C alkyl or halo and R is hydrogen;
4 5 6
or R and R taken together form –(CH ) –, wherein n is 2, 3, 4, or 5 and R is
hydrogen;
4 5 6
or R and R taken together form –O-(CH ) -O- and R is hydrogen;
4 5 6
or R is hydrogen or C alkyl and R and R taken together form –(CH ) –,
1-3 2 m
wherein m is 1, 2, 3, or 4;
4 5 6
or R and R are each hydrogen and R is C alkyl;
R is selected from halo, C alkyl, and C alkoxy wherein C alkyl and
1-3 1-3 1-3
C alkoxy are optionally substituted with one, two, three, four, or five halo;
R is C alkyl, optionally substituted with -OR ;
9 f g
R is selected from C alkyl, C cycloalkyl, C alkoxy, -NR R , heteroaryl,
1-6 3-6 1-6
heterocycle, and –CH -heteroaryl;
wherein:
C alkyl is optionally substituted with one or two substituents
h j k
independently selected from –OR , -NR R , -NHC(O)C alkyl,
-NHC(O)OC alkyl, -NHC(O)C cycloalkyl, C cycloalkyl, halo,
1-3 3-6 3-6
-NHC(O)C alkylC(O)OR , -NHC(O)C alkylOR , -NHC(O)NHC alkyl,
1-3 1-3 1-3
-NHS(O) C alkyl, and heterocycle;
2 1-3
C alkoxy is optionally substituted with –OR ;
any C cycloalkyl is optionally substituted with one, two, or three
a b h
substituents independently selected from C alkyl, halo, -NR R , – OR , and
-CD , wherein any C alkyl is optionally substituted with one, two, or three halo;
3 1-3
any heterocycle is optionally substituted with one, two, or three
substituents independently selected from C alkyl, halo, -C(O)OC alkyl,
1-3 1-3
-C(O)C alkyl, -C(O)C cycloalkyl, –C(O)NHC alkyl,
1-6 3-6 1-6
-C(O)NHC cycloalkyl,–S(O) C alkyl, and -C(O)NH ;
3-6 2 1-6 2
wherein any –C(O)C alkyl is optionally substituted with
h j k
-NHC(O)OC alkyl, -OR , -NR R , or heterocycle,
any -C(O)C cycloalkyl is optionally substituted with one or two
C alkyl, and
any –C(O)NHC alkyl is optionally substituted with –OR or
C cycloalkyl;
any heteroaryl is optionally substituted with one or two C alkyl;
a b e h j k m n
R , R , R , R , R , R , R , and R are each independently hydrogen or C alkyl;
R is hydrogen or C alkyl, wherein C alkyl is optionally substituted with –OR
1-6 1-6
or amino;
R is hydrogen or C alkyl, wherein C alkyl is optionally substituted with –OR
1-6 1-6
or with heteroaryl optionally substituted with C alkyl;
R is hydrogen or C alkyl, wherein C alkyl is optionally substituted with –OR ;
1-6 1-6
g a b
R is selected from hydrogen, C alkyl, C alkoxy, C cycloalkyl, NR R , and
1-6 1-6 3-6
heterocycle, wherein C alkyl is optionally substituted with –OR and heterocycle is
optionally substituted with one or two =O;
R is selected from hydrogen, halo, and C alkyl, wherein C alkyl is optionally
1-3 1-3
substituted with one, two, or three halo, or with –OR ;
A is –NHC(O)- or –C(O)NH-
a is 0, 1, or 2; and
b is 0, 1 or 2;
or a pharmaceutically-acceptable salt of stereoisomer thereof.
As used hereinafter, the phrase “compound of formula (I)” means a compound of
formula (I) or a pharmaceutically acceptable salt thereof; i.e., this phrase means a
compound of formula (I) in free base form or in a pharmaceutically acceptable salt form
unless otherwise indicated.
Also described is a pharmaceutical composition comprising a compound
described herein and a pharmaceutically-acceptable carrier. Also described is a
pharmaceutical composition comprising a compounddescribed herein, a
pharmaceutically-acceptable carrier and one or more other therapeutic agents useful for
treating hepatitis C viral infections.
Also described is a method of treating a hepatitis C viral infection in a mammal,
the method comprising administering to the mammal a therapeutically effective amount
of a compound or of a pharmaceutical composition described herein. Also described is a
method of treating a hepatitis C viral infection in a mammal, the method comprising
administering to the mammal a compound or a pharmaceutical composition described
herein and one or more other therapeutic agents useful for treating hepatitis C viral
infections. Also described is a method of inhibiting replication of the hepatitis C virus in
a mammal, the method comprising administering a compound or a pharmaceutical
composition described herein.
Also described are synthetic processes and intermediates described herein, which
are useful for preparing compounds described herein.
Also described is a compound as described herein for use in medical therapy, as
well as the use of a compound described herein in the manufacture of a formulation or
medicament for treating a hepatitis C viral infection in a mammal.
BRIEF DESCRIPTION OF THE DRAWING
The figure shows a powder x-ray diffraction (PXPD) pattern of crystalline (R)
chloro(6-(2-methylpivaloylpiperazinyl)nicotinamido)(trifluoromethoxy)-
phenylboronic acid.
DETAILED DESCRIPTION OF THE INVENTION
Among other aspects, described are inhibitors of HCV replication of formula (I),
pharmaceutically-acceptable salts thereof, and intermediates for the preparation thereof.
The following substituents and values are intended to provide representative examples of
various aspects of this disclosure. These representative values are intended to further
define such aspects and are not intended to exclude other values or limit the scope of the
invention.
In a specific aspect, R is selected from C alkyl, C alkoxy, phenyl,
1-6 1-6
C cycloalkyl, heterocycle, and heteroaryl, wherein C alkyl is optionally substituted
3-6 1-6
with –OR amino, –SR , heterocycle, or heteroaryl, C alkoxy is optionally substituted
, 1-6
with –OR , and heterocycle is optionally substituted with –OR amino, or
-C(O)OC alkyl, or with one or two C alkyl or =O.
1-6 1-3
In another specific aspect, R is selected from C alkyl, C alkoxy, phenyl,
1-6 1-6
C cycloalkyl, heterocycle, and heteroaryl, wherein C alkyl is optionally substituted
3-6 1-6
with -OR amino, –SR , heterocycle, or heteroaryl, C alkoxy is optionally substituted
, 1-6
with –OR , and heterocycle is optionally substituted with –OR amino, or
-C(O)OC alkyl, or with one or two C alkyl, wherein R is hydrogen or C alkyl.
1-6 1-3 1-3
In another specific aspect, R is selected from C alkyl, phenyl, C cycloalkyl,
1-3 5-6
and heterocycle, wherein C alkyl is optionally substituted with –OR , wherein R is
hydrogen or C alkyl, and any heterocycle has six ring atoms and is optionally
substituted with one or two C alkyl or =O.
In another specific aspect, R is selected from C alkyl, phenyl, and heterocycle,
wherein C alkyl is optionally substituted with –OR , and heterocycle has six ring atoms
and is optionally substituted with –OR or amino or with one or two methyl. In another
specific aspect, R is selected from C alkyl, phenyl, and C cycloalkyl; wherein
1-6 3--6
C alkyl is optionally substituted with –OR ; wherein R is hydrogen or C alkyl.
1-6 1-3
In another specific aspect, R is selected from C alkyl, phenyl, and
tetrahydropyranyl, wherein C alkyl is optionally substituted with –OR ; wherein R is
hydrogen or C alkyl.
In another specific aspect, R is selected from C alkyl, optionally substituted
with hydroxy or methoxy, tetrahydropyran, and phenyl. In another specific aspect, R is
selected from C alkyl and phenyl.
Specific R values include isopropyl, phenyl, tetrahydropyranyl, 2,6-
dimethyltetrahydropyranyl, 1,1-dioxo-hexahydro-1l -thiopyranyl, oxetanyl,
1-hydroxyethyl, 1-methoxyethyl, 2-hydroxypropanyl, cyclohexyl, cyclopentyl,
thiphenyl, and furanylmethyl.
In a specific aspect, R is C alkyl.
In another specific aspect, R is isopropyl.
In yet another specific aspect, R is phenyl.
In still another specific aspect, R is tetrahydropyranyl.
In still another specific aspect, R is tetrahydropyranyl.
In a specific aspect, R is hydrogen or C alkyl.
In other specific aspects, R is hydrogen or C alkyl; or R is hydrogen.
In a specific aspect, R is selected from hydrogen, C alkyl, -C(O)OC alkyl,
1-6 1-6
m n 2 3
-C(O)NR R , -C(O)C cycloalkyl, and -S(O) C alkyl; or R and R together with the
3-6 2 1-3
nitrogen atom to which they are attached form a heterocycle;
In another specific aspect, R is selected from hydrogen, C alkyl,
-C(O)OC alkyl, -C(O)NR R , -C(O)C cycloalkyl, and -S(O) C alkyl;
1-6 3-6 2 1-3
In another specific aspect, R is selected from hydrogen, C alkyl, and
-C(O)OC alkyl.
In yet another specific aspect, R is -C(O)OC alkyl.
In another specific aspect, R and R together with the nitrogen atom to which
they are attached form a heterocycle.
In yet another specific aspect, R and R together with the nitrogen atom to which
they are attached form a piperidinyl ring.
1 2 3
In a specific aspect, R is C alkyl, R is hydrogen. and R is -C(O)OC alkyl.
1-6 1-6
1 2 3
In another specific aspect, R is isopropyl, R is hydrogen, and R is –C(O)OCH .
1 2 3 1
In yet other specific aspects, R is phenyl and R and R are each C alkyl; or R
2 3 1 2
is phenyl, R is hydrogen, and R is -C(O)OC alkyl; or R is tetrahydropyranyl, R is
hydrogen, and R is -C(O)OC alkyl.
4 b c d e
In a specific aspect, R is selected from C alkyl, -NR R , -OR , -SR ,
-S(O)C alkyl, -S(O) C alkyl, -CN, -C(O)NR R , heterocycle, heteroaryl, and halo; and
1-3 2 1-3
R and R are hydrogen;
4 b c d e
In another specific aspect, R is selected from C alkyl, -NR R , -OR , -SR ; and
R and R are hydrogen.
4 d a b
In another specific aspect, R is selected from C alkyl, -OR , and -C(O)NR R
and R and R are hydrogen.
In another specific aspect, R is selected from C alkyl and –OR , wherein
a a d
C alkyl is optionally substituted with –OR , wherein R and R are independently
hydrogen or C alkyl; and R and R are hydrogen.
In another specific aspect, R is selected from methyl, methoxy, fluoro,
-CH OCH , -C(O)NH , -CN, -NH ,-NH(CH ) , -SCH , -S(O)CH , -S(O) CH ,
2 3 2 2 3 2 3 3 2 3
morpholinyl, and pyrrolidinyl and R and R are hydrogen.
In another specific aspect, R is selected from methyl, methoxy, and –C(O)NH ,
and R and R are hydrogen.
4 5 6
In still another aspect, R is methyl or methoxy, and R and R are hydrogen.
4 5 6
In a further aspect, R is methyl and R and R are hydrogen.
4 5 6
In another specific aspect, R and R are independently C alkyl and R is
hydrogen.
In yet another specific aspect, R and R are each fluoro.
4 5 6
In yet another specific aspect, R and R taken together form –O-(CH ) -O- and R
is hydrogen.
In still another specific aspect, R and R taken together form –(CH ) –, wherein n
is 2, 3, 4, or 5.
4 5 6
In additional aspects, R is hydrogen and R and R taken together form –(CH ) –,
4 5 6
wherein n is 1 or 4; or R is hydrogen and R and R taken together form –(CH ) –.
4 5 6 4
In still further aspects, R and R are each hydrogen and R is C alkyl, or R and
R are each hydrogen and R is methyl.
In a specific aspect, R is selected from halo, C alkyl, and C alkoxy wherein
1-3 1-3
C alkyl and C alkoxy are optionally substituted with one, two, three, four, or five halo.
1-6 1-6
In another specific aspect R is selected from halo, C alkyl, and C alkoxy
1-3 1-3
wherein C alkyl and C alkoxy are substituted with one, two, or three halo.
1-6 1-6
In yet another specific aspect, R is selected from fluoro, chloro, -CF and –OCF .
3, 3
8 h h
In a specific aspect, R is C alkyl, optionally substituted with -OR ; wherein R
is hydrogen or C alkyl.
In a specific aspect, R is C alkyl.
In another specific aspect, R is methyl or hydroxymethyl.
In another specific aspect, R is methyl.
In a specific aspect, R is defined as in formula (I).
In another specific aspect, R is selected from C alkyl, C cycloalkyl,
1-6 3-6
C alkoxy, -NR R , heteroaryl, heterocycle, and –CH -heteroaryl; wherein C alkyl is
1-6 2 1-6
optionally substituted with one or two substituents independently selected from –OR ,
-NR R , -NHC(O)C alkyl, -NHC(O)OC alkyl, -NHC(O)C cycloalkyl,
1-3 1-3 3-6
C cycloalkyl, and halo; C alkoxy is optionally substituted with –OR ; any
3-6 1-6
C cycloalkyl is optionally substituted with one, two, or three substituents independently
a b h
selected from C alkyl, halo, -NR R , – OR , and -CD , wherein any C alkyl is
1-3 3 1-3
optionally substituted with one, two, or three halo; any heterocycle is optionally
substituted with one, two, or three substituents independently selected from C alkyl,
halo, -C(O)OC alkyl , -C(O)C alkyl, -C(O)C cycloalkyl, –C(O)NHC alkyl,
1-3 1-6 3-6 1-6
-C(O)NHC cycloalkyl,–S(O) C alkyl, and -C(O)NH ; wherein any –C(O)C alkyl is
3-6 2 1-6 2 1-6
h j k
optionally substituted with -NHC(O)OC alkyl, -OR , -NR R , or heterocycle, any
-C(O)C cycloalkyl is optionally substituted with one or two C alkyl, and any
3-6 1-3
-C(O)NHC alkyl is optionally substituted with –OR or C cycloalkyl; any heteroaryl is
1-6 3-6
a b h j k
optionally substituted with one or two C alkyl; R , R , R , R , and R are defined as in
formula (I), and R is selected from hydrogen, C alkyl, C alkoxy, C cycloalkyl,
1-6 1-6 3-6
a b h
NR R , and heterocycle, wherein C alkyl is optionally substituted with –OR and
heterocyle is optionally substituted with =O.
9 f g
In another specific aspect, R is selected from C alkyl, C cycloalkyl, -NR R ,
1-6 3-6
heteroaryl, heterocycle, and -CH -heteroaryl; wherein any heteroaryl or heterocycle has 5
or 6 ring atoms; any heteroaryl is optionally substituted with C alkyl; C alkyl is
1-3 1-6
optionally substituted with one or two substituents independently selected from –OR ,
-NR R , -NHC(O)C alkyl, and -NHC(O)OC alkyl; any C cycloalkyl is optionally
1-3 1-3 3-6
substituted with one or two C alkyl; any heterocycle is optionally substituted with one,
or two substituents independently selected from C alkyl, -C(O)OC alkyl ,
1-3 1-3
-C(O)C alkyl, -C(O)C cycloalkyl, -C(O)NHC alkyl, and -C(O)NHC cycloalkyl;
1-6 3-6 1-6 3-6
wherein any -C(O)C alkyl is optionally substituted with -NHC(O)OC alkyl,
1-6 1-3
h j k
-OR ,-NR R , or heterocycle; any -C(O)C cycloalkyl is optionally substituted with one
or two C alkyl; and any -C(O)NHC alkyl is optionally substituted with –OR or
1-3 1-6
C cycloalkyl.
9 j k f g
In yet another aspect, R is selected from C cycloalkyl, -CH NR R , -NR R ,
3-4 2
imidazolyl, pyrazolyl, pyrimidinyl, and pyrrolidinyl; wherein C cycloalkyl is optionally
substituted with one or two C alkyl; pyrrolidinyl is optionally substituted with methyl
and substituted with a substituent selected from -C(O)OC alkyl , -C(O)C alkyl,
1-3 1-6
-C(O)NHC alkyl, wherein -C(O)C alkyl is substituted with -NHC(O)OC alkyl, -OR ,
1-6 1-6 1-3
-NR R , or heterocycle.
9 f g
In another specific aspect, R is selected from C alkyl, C cycloalkyl, NR R ,
1-6 3-6
wherein R and R are independently hydrogen or C alkyl, heteroaryl, and heterocycle,
wherein C alkyl is optionally substituted with -OR , C cycloalkyl is optionally
1-6 3-6
substituted with one or two C alkyl or halo, any heteroaryl has five or six ring atoms,
and any heterocycle has five ring atoms and is optionally substituted with one or two
substituents selected from C alkyl, -C(O)OC alkyl , -C(O)C alkyl, -C(O)NHC
1-3 1-3 1-6 1-
alkyl, and -C(O)C alkylNHC(O)OCH
6 1-3 3.
Exemplary specific values of R within this aspect include–NHCH cyclopropyl,
2,2-dimethylcyclopropyl, tert-butyl, 3-hydroxy-2,2-dimethylpropyl, imidazolyl,
2,2-difluorocyclopropyl, 2,2-dichlorocylopropyl, and 2 methylpyrrolidinyl substituted
at the nitrogen with –C(O)NHCH , -C(O)t-Bu, -C(O)CH ,-C(O)iPr, C(O)CH OCH .
3 3 2 3
C(O)t-Bu, or -C(O)CH(iPr)NHC(O)OCH
In yet another aspect, R is selected from C alkyl, optionally substituted
with-OR wherein R is hydrogen or C alkyl, and C cycloalkyl, optionally substituted
1-3 3-4
with one or two C alkyl.
In still another aspect, R is selected from –NHCH 2,2-dimethylcyclopropyl,
tert-butyl, and imidazolyl.
In another specific aspect, R is selected from –NHCH cyclopropyl,
2,2-dimethylcyclopropyl, tert-butyl, 3-hydroxy-2,2-dimethylpropyl, and imidazolyl.
In a still further aspect, R is selected from cyclopropyl, 2,2-dimethylcyclopropyl,
tert-butyl, and 3-hydroxy-2,2-dimethylpropyl.
In a specific aspect, R is hydrogen, halo, C alkyl, wherein C alkyl is
1-3 1-3
optionally substituted with one, two, or three halo, or with –OR .
In a specific aspect, R is hydrogen, halo, or C alkyl substituted with one, two,
or three halo.
10
In other specific aspects, R is hydrogen or halo; or R is hydrogen, chloro, or
fluoro; or R is hydrogen or –CH OH.
In another specific aspect, R is –CF .
In another specific aspect, R is chloro.
In yet another specific aspect, R is hydrogen.
In a still further aspect, R is –CH OH.
In a specific aspect, a is 0, 1, or 2.
In another specific aspect, a is 1 or 2.
In a specific aspect, b is 0, 1, or 2.
In another specific aspect, b is 1 or 2.
In yet another specific aspect, b is 1.
Also described are compounds of formula (II):
NH R
(II)
wherein the variables of formula (II) are as defined herein.
Also described are compounds of formula (III)
R N O
HN N N
(III)
wherein the variables of formula (III) are as defined herein.
Also described are compounds of formula (IV):
NH R
(IV)
wherein:
R is selected from C alkyl, optionally substituted with hydroxy or methoxy,
tetrahydropyran, and phenyl;
R is hydrogen;
R is -C(O)OC alkyl;
R is methyl or methoxy;
R is selected from fluoro, chloro, -CF and –OCF ;
3, 3
R is independently methyl or hydroxymethyl;
R is selected from –NHCH cyclopropyl, 2,2-dimethylcyclopropyl, tert-butyl,
3-hydroxy-2,2-dimethylpropyl, and imidazolyl;
R is hydrogen or hydroxymethyl;
a is 1 or 2; and
b is 1 or 2;
or a pharmaceutically-acceptable salt thereof.
Within this aspect, are compounds of formula (IVa) and of (IVb):
NH R
NH R N
7d O
HN 1
(IVa) (IVb)
1 7d 9
wherein R is isopropyl or tetrahydropyranyl, R is fluoro or chloro, and R is tert-butyl
or 3-hydroxy-2,2-dimethylpropyl.
Also described are compounds of formula (V):
R N O
HN N N
wherein:
R is selected from C alkyl, optionally substituted with hydroxy or methoxy,
tetrahydropyran, and phenyl;
R is hydrogen;
R is -C(O)OC alkyl;
R is methyl or methoxy;
R is selected from fluoro, chloro, -CF and –OCF ;
3, 3
R is independently methyl or hydroxymethyl;
R is selected from –NHCH cyclopropyl, 2,2-dimethylcyclopropyl, tert-butyl,
3-hydroxy-2,2-dimethylpropyl, and imidazolyl;
R is hydrogen or hydroxymethyl;
a is 1 or 2; and
b is 1 or 2;
or a pharmaceutically-acceptable salt thereof.
In one aspect, described are the compounds of Examples 1-24 and Tables 1-29
below
In another aspect, described is a compound selected from the following
compounds
CF 3
N O O O
O Cl
N N N
HN HN
N N O
O O O
Cl Cl
Cl F
OH HN
O CF
O N O
HN N N
N HN
O NH
N O O N
N N N N
HN HN
HN HN
N O N
Cl Cl
NH NH
HO 3 HO 3
O N O N
N N N N
HN HN
NH NH
Cl Cl
NH NH
O O O O
CF 3
O F N
O N O
N HN
HN N
N O N
NH O
HN N
HN N
O NH
and pharmaceutically-acceptable salts thereof.
Chemical structures are named herein according to IUPAC conventions as
implemented in available software packages. For example, the compound of Example 1:
HN N
is designated as ((S){(2S,4S)[4-(5'-chloro-4'-{[6-((2R,5S)-2,5-dimethyl
methylcarbamoyl-piperazinyl)-pyridinecarbonyl]-amino}-2'-trifluoromethoxy-
biphenylyl)-1H-imidazolyl]methyl-pyrrolidinecarbonyl}methyl-propyl)-
carbamic acid methyl ester by AutoNom software, (MDL Information Systems, GmbH,
Frankfurt, Germany). Equivalently, the compound may be named as methyl (S)
((2S,4S)(4-(5'-chloro-4'-(6-((2R,5S)-2,5-dimethyl(methylcarbamoyl)piperazin
yl)nicotinamido)-2'-(trifluoromethoxy)biphenylyl)-1H-imidazolyl)
methylpyrrolidinyl)methyloxobutanylcarbamate, as provided by ChemDraw
software (PerkinElmer, Inc., Cambridge, MA).
Furthermore, the imidazole moiety in the structure of formula (I) exists in
tautomeric forms, illustrated below for a fragment of the compound of Example 1
HN N
N NH
HN HN
According to the IUPAC convention, these representations give rise to different
numbering of the atoms of the imidazole moiety: methyl (S)methyl((2S,4S)
methyl(4-phenyl-1H-imidazolyl)pyrrolidinyl)oxobutanylcarbamate
(structure A) vs.methyl (S)methyl((2S,4S)methyl(5-phenyl-1H-imidazol
yl)pyrrolidinyl)oxobutanylcarbamate (structure B). It will be understood that
although structures are shown, or named, in a particular form, the invention also includes
the tautomer thereof.
The compounds described herein contain one or more chiral centers and therefore,
such compounds (and intermediates thereof) can exist as racemic mixtures; pure
stereoisomers (i.e., enantiomers or diastereomers); stereoisomer-enriched mixtures and
the like. Chiral compounds shown or named herein without a defined stereochemistry at
a chiral center are intended to include any or all possible stereoisomer variations at the
undefined stereocenter unless otherwise indicated. The depiction or naming of a
particular stereoisomer means the indicated stereocenter has the designated
stereochemistry with the understanding that minor amounts of other stereoisomers may
also be present unless otherwise indicated, provided that the utility of the depicted or
named compound is not eliminated by the presence of another stereoisomer.
Compounds of formula (I) also contain several basic groups (e.g., amino groups)
and therefore, such compounds can exist as the free base or in various salt forms, such a
mono-protonated salt form, a di-protonated salt form, a tri-protonated salt form, or
mixtures thereof. All such forms are included within the scope of this invention, unless
otherwise indicated.
Also described are isotopically-labeled compounds of formula (I), i.e., compounds
of formula (I) where an atom has been replaced or enriched with an atom having the same
atomic number but an atomic mass different from the atomic mass that predominates in
nature. Examples of isotopes that may be incorporated into a compound of formula (I)
2 3 11 13 14 13 15 15 17 18 35 36
include, but are not limited to, H, H, C, C, C, N, N, O, O, O, S, Cl, and
F. Of particular interest are compounds of formula (I) enriched in tritium or carbon-14,
which compounds can be used, for example, in tissue distribution studies. Also of
particular interest are compounds of formula (I) enriched in deuterium especially at a site
of metabolism, which compounds are expected to have greater metabolic stability.
Additionally of particular interest are compounds of formula (I) enriched in a positron
11 18 15 13
emitting isotope, such as C, F, O and N, which compounds can be used, for
example, in Positron Emission Tomography (PET) studies.
Definitions
When describing this invention including its various aspects and embodiments,
the following terms have the following meanings, unless otherwise indicated.
The term “comprising” as used in this specification means “consisting at least in
part of”. When interpreting each statement in this specification that includes the term
“comprising”, features other than that or those prefaced by the term may also be present.
Related terms such as “comprise” and “comprises” are to be interpreted in the same
manner.
The term "alkyl" means a monovalent saturated hydrocarbon group which may be
linear or branched or combinations thereof. Unless otherwise defined, such alkyl groups
typically contain from 1 to 10 carbon atoms. Representative alkyl groups include, by way
of example, methyl (Me), ethyl (Et), n-propyl (n-Pr) or (nPr), isopropyl (i-Pr) or (iPr),
n-butyl (n-Bu) or (nBu), sec-butyl, isobutyl, tert-butyl (t-Bu) or (tBu), n-pentyl, n-hexyl,
2,2-dimethylpropyl, 2-methylbutyl, 3-methylbutyl, 2-ethylbutyl, 2,2-dimethylpentyl,
2-propylpentyl, and the like
When a specific number of carbon atoms are intended for a particular term, the
number of carbon atoms is shown preceding the term. For example, the term “C alkyl”
means an alkyl group having from 1 to 3 carbon atoms wherein the carbon atoms are in
any chemically-acceptable configuration, including linear or branched configurations..
The term "alkoxy" means the monovalent group –O-alkyl, where alkyl is defined
as above. Representative alkoxy groups include, by way of example, methoxy, ethoxy,
propoxy, butoxy, and the like.
The term "cycloalkyl" means a monovalent saturated carbocyclic group which
may be monocyclic or multicyclic. Unless otherwise defined, such cycloalkyl groups
typically contain from 3 to 10 carbon atoms. Representative cycloalkyl groups include,
by way of example, cyclopropyl (cPr), cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
cyclooctyl, adamantyl, and the like.
The term "heterocycle", "heterocyclic", or "heterocyclic ring" means a
monovalent saturated or partially unsaturated cyclic non-aromatic group, having from 3 to
total ring atoms, wherein the ring contains from 2 to 9 carbon ring atoms and from 1 to
4 ring heteroatoms selected from nitrogen, oxygen, and sulfur. Heterocyclic groups may
be monocyclic or multicyclic (i.e., fused or bridged). Representative heterocyclic groups
include, by way of example, pyrrolidinyl, piperidinyl, piperazinyl, imidazolidinyl,
morpholinyl, thiomorpholyl, indolinyl, 2-imidazolinyl, tetrahydropyranyl, 1,2,3,4-
tetrahydroisoquinolinyl, quinuclidinyl, 7-azanorbornanyl, nortropanyl, and the like,
where the point of attachment is at any available carbon or nitrogen ring atom. Where the
context makes the point of attachment of the heterocyclic group evident, such groups may
alternatively be referred to as a non-valent species, i.e. pyrrolidine, piperidine, piperazine,
imidazole,tetrahydropyran etc.
The term "heteroaryl" or "heteroaryl ring" means a monovalent aromatic group
having from 5 to 10 total ring atoms, wherein the ring contains from 1 to 9 carbon ring
atoms and from 1 to 4 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
Heteroaryl groups may be monocyclic or multicyclic. Representative heteroaryl groups
include, by way of example, pyrroyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl,
oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl,
thienyl, pyridyl (or, equivalently, pyridinyl), pyrimidyl, pyridazinyl, pyrazinyl, indolyl,
benzofuranyl, benzothienyl, benzimidazolyl, benzthiazolyl, and the like, where the point
of attachment is at any available carbon or nitrogen ring atom. Where the context makes
the point of attachment of the heteroaryl group evident, such groups may alternatively be
referred to as a non-valent species, i.e.pyrrole, isoxazole, isothiazole, pyrazole, imidazole,
etc.
The term “halo” means fluoro, chloro, bromo or iodo.
The term “therapeutically effective amount” means an amount sufficient to effect
treatment when administered to a patient in need of treatment.
The term “treatment” as used herein means the treatment of a disease, disorder, or
medical condition in a patient (such as hepatitis C viral infection), such as a mammal
(particularly a human) which includes one or more of the following:
(a) preventing the disease, disorder, or medical condition from occurring, i.e.,
preventing the reoccurrence of the disease or medical condition or prophylactic treatment
of a patient that is pre-disposed to the disease or medical condition;
(b) ameliorating the disease, disorder, or medical condition, i.e., eliminating or
causing regression of the disease, disorder, or medical condition in a patient, including
counteracting the effects of other therapeutic agents;
(c) suppressing the disease, disorder, or medical condition, i.e., slowing or
arresting the development of the disease, disorder, or medical condition in a patient; or
(d) alleviating the symptoms of the disease, disorder, or medical condition in a
patient.
The term “pharmaceutically acceptable salt” means a salt that is acceptable for
administration to a patient or a mammal, such as a human (e.g., salts having acceptable
mammalian safety for a given dosage regime). Representative pharmaceutically
acceptable salts include salts of acetic, ascorbic, benzenesulfonic, benzoic,
camphorsulfonic, citric, ethanesulfonic, edisylic, fumaric, gentisic, gluconic, glucoronic,
glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, lactobionic, maleic,
malic, mandelic, methanesulfonic, mucic, naphthalenesulfonic, naphthalene-1,5-
disulfonic, naphthalene-2,6-disulfonic, nicotinic, nitric, orotic, pamoic, pantothenic,
phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic and xinafoic acid, and the like.
The term “salt thereof” means a compound formed when the hydrogen of an acid
is replaced by a cation, such as a metal cation or an organic cation and the like. For
example, the cation can be a protonated form of a compound of formula (I), i.e. a form
where one or more amino groups have been protonated by an acid. Typically, the salt is a
pharmaceutically acceptable salt, although this is not required for salts of intermediate
compounds that are not intended for administration to a patient.
The term "amino-protecting group" means a protecting group suitable for
preventing undesired reactions at an amino nitrogen. Representative amino-protecting
groups include, but are not limited to, formyl; acyl groups, for example alkanoyl groups,
such as acetyl and tri-fluoroacetyl; alkoxycarbonyl groups, such as tert butoxycarbonyl
(Boc); arylmethoxycarbonyl groups, such as benzyloxycarbonyl (Cbz) and
9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl groups, such as benzyl (Bn), trityl (Tr),
and 1,1-di-(4’-methoxyphenyl)methyl; silyl groups, such as trimethylsilyl (TMS), tert-
butyldimethylsilyl (TBDMS), [2-(trimethylsilyl)ethoxy]methyl (SEM); and the like.
Numerous protecting groups, and their introduction and removal, are described in T. W.
Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley,
New York
General Synthetic Procedures
Compounds described herein, and intermediates thereof, can be prepared
according to the following general methods and procedures using commercially-available
or routinely-prepared starting materials and reagents. The substituents and variables (e.g.,
1 2 3 4
R , R , R , R , etc.) used in the following schemes have the same meanings as those
defined elsewhere herein unless otherwise indicated. Additionally, compounds having an
acidic or basic atom or functional group may be used or may be produced as a salt unless
otherwise indicated (in some cases, the use of a salt in a particular reaction will require
conversion of the salt to a non-salt form, e.g., a free base, using routine procedures before
conducting the reaction).
Although a particular embodiment of the present disclosure may be shown or
described in the following procedures, those skilled in the art will recognize that other
embodiments or aspects of the present invention can also be prepared using such
procedures or by using other methods, reagents, and starting materials know to those
skilled in the art. In particular, it will be appreciated that compounds of the invention
may be prepared by a variety of process routes in which reactants are combined in
different orders to provide different intermediates en route to producing final products.
In one exemplary method of synthesis, compounds of formula (1-5) in which A
is defined as –NHC(O)- are prepared as shown in Scheme 1:
Scheme 1
N N Pg
1-1 1-2
N N Pg
HO R
Cl R
N NH
O N O
where G represents the group
and Pg represents an amino-protecting group. Aniline intermediate 1-1 is reacted with
carboxylic acid 1-2 according to typical amide bond formation conditions to provide a
protected intermediate of formula 1-3 In some instances, the carboxylic acid 1-2 is first
converted to an acid chloride and then reacted with aniline intermediate 1-1 to provide a
compound of formula 1-3. As shown in the examples below, the amide bond formation
reaction may utilize coupling agents, such as N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-
1-yl)uronium hexafluorophosphate (HATU), or as 1,3-dicyclohexylcarbodiimide (DCC),
1-(3-dimethylaminopropyl)ethylcarbodiimide (EDC), or benzotriazol
yloxytripyrrolidino-phosphonium hexafluorophosphate (PyBop), optionally combined
with 1-hydroxyazabenzotriazole (HOAt). Preferably, the process of Scheme 1 is used
to prepare compounds of formula 1-3 in which R is absent (a is 0) or R is an electron
rich substituent such as an unsubstituted-alkyl or unsubstituted-alkoxy, and the reaction is
performed in the presence of coupling agents EDC and HOAt at a temperature of about
50 to about 60 °C. Intermediate 1-3 is then deprotected, for example, by treatment with
an acid to to provide compound 1-4, which is reacted with an acid chloride in the
presence of base or with a carboxylic acid under amide bond formation conditions to
prepare a compound of the invention of formula 1-5.
It will be readily understood that the final product 1-5 could alternatively be
prepared directly by reaction of aniline 1-1 with a compound of formula 1-2'
Protected intermediate 1-3 may also be conveniently prepared by alternative
processes, for example, as shown in Scheme 2:
Scheme 2
N 2-1
N Pg
R 2-3
N N Pg
In a first step, biphenyl aniline 1-1 is reacted with a fluoropyridine carbonyl
chloride 2-1 in the presence of base to provide fluoro intermediate 2-2. The fluoro
intermediate is then reacted with an excess of protected piperazine 2-3 to provide
protected intermediate 1-3. The reaction typically is performed in the presence of base
with heating to a temperature of about 80 °C to about 120 °C for a period of about 4 to
about 48 hours.
Yet another alternative process for the preparation of intermediate 1-3 utilizes a
Suzuki coupling reaction in the presence of a palladium catalyst (Miyaura and Suzuki,
Chem. Rev. 1995, 95, 2457-2483). As shown in Scheme 3 below, either coupling partner
may bear the boronate moiety. Alternatively, a boronic acid reagent may be used in place
of a boronate reagent, such as the pinacol boronate depicted below.
Scheme 3A
O N N Pg
O N N Pg
N N Pg
If protected intermediate 3-2 were replaced by an intermediate 3-2'
then the Suzuki coupling of the boronate 3-1 in the first alternative of Scheme 3 would
directly provide a final compound of the invention.
Analogously, if protected intermediate 3-4 were replaced by a boronate
intermediate 3-4' or equivalently a boronic acid intermediate 3-4",
HO N N
O N N
NH R
NH R
3-4"
3-4'
then the Suzuki coupling of the bromo intermediate shown in the second alternative initial
step of Scheme 3 would directly provide a compound of the invention. The boronic acid
3-4" advantageously may be prepared in crystalline form. See, for example, Preparation
44 below.
Another useful sequence for preparation of final compounds of the invention is
illustrated in Scheme 3B.
Scheme 3B
O N N
Br NH
4 7 R
R R b
3-2'
3-1'
O N N
B NH
Br 7 3-4'
3-3'
HO N N
B NH
3-4"
O N O
O N O
(i) deprotect HN
(ii) 7 b
HO G R
(II')
where a protected form of the Suzuki coupling partners 3-1' or 3-3' in which the nitrogen
on the proline bears a protecting group Pg , and intermediates 3-2', 3-4, or 3-4", bearing
the substituent R , are used in the first step to form a protected intermediate 3-5. The
protected intermediate 3-5 is (i) deprotected conventionally, and then (ii) reacted with a
reagent HO-G to provide a compound of the invention.
The bromo intermediate 3-2 of Scheme 3A may be prepared, for example, by
amide coupling of arylamine 4-1 with a fluoropyridine carbonyl chloride 2-1, followed by
reaction with a protected piperazine 2-3 as shown in Scheme 4.
Scheme 4
F Br NH
Br NH
NN Pg
HN N Pg
Br NH
Alternatively, intermediate 3-2 may be prepared by the reaction of 4-1 with the carboxylic
acid intermediate 1-2 as given in Scheme 5.
Scheme 5
NN Pg
Br NH
Br NH
N N Pg
4-1 1-2 3-2
It will be readily understood that intermediates bearing the substituent R may be
prepared from the corresponding protected compound. For example, the bromo
intermediate 3-2', may be prepared by deprotecting intermediate 3-2 and then reacting
with an acid chloride or carboxylic acid as in Scheme 1.
Processes for the preparation of intermediates 1-1 and 1-2 used in process Scheme
1 are given in the following schemes.
Scheme 6
N N Pg
HN N Pg
6-1 2-3 1-2
The reaction in Scheme 6 of a fluoronicotinic acid 6-1 with the protected piperazine 2-3
to provide intermediate 1-2 is typically performed using a Grignard reagent such as
isopropylmagnesium chloride at a temperature below about -20 °C.
The biaryl aniline intermediate 1-1 may be prepared by the Suzuki coupling
reaction of Scheme 7, where, as shown, either coupling partner may bear the boronate
moiety.
Scheme 7
B NH
R G N
7-1 7
6 3-3
Br NH
Intermediates 3-1 and 3-3 used in the Suzuki reaction of Schemes 3 and 7 may be
prepared, for example, as shown in Schemes 8 and 9.
Scheme 8
OH 6 O
Pg Pg
8-1 8-2
HO G
Reagent 8-1, where X represents bromo or chloro, is reacted with a protected
proline carboxylic acid 8-2 to provide intermediate 8-3 which is converted to intermediate
8-4 in the presence of an excess of ammonium acetate. The ring closure reaction
typically is performed at a temperature between about 100 °C and about 120 °C for a
period of about 4 to about 24 hours. To provide compound 3-3, intermediate 8-4 is
typically deprotected and coupled with a reagent HO-G to provide compound 3-3.
Finally, the boronate intermediates of Scheme 3 may be prepared from the
corresponding bromo compounds. For example, to provide boronate intermediate 3-1,
intermediate 3-3 is reacted with bis(pinacolato)diboron, 9-1, in the presence of a
palladium catalyst as shown in Scheme 9.
Scheme 9
HN O O
4 O O
Similarly, the boronate intermediate 3-4 may be prepared by the reaction of bromo
intermediate 3-2 with the diboron 9-1 under similar conditions. Further, a boronic acid
Suzuki coupling partner may also be prepared from the corresponding bromo compound
by reaction with a borate ester in the presence of a Grignard reagent, e.g.
isopropylmagnesium chloride. See, for example, Preparation 44 below.
Compounds of Formula 10-5 in which the variable Am is defined as –C(O)NH- are
prepared by processes analogous to those described above. One exemplary process for
the preparation of compounds of Formula 10-5 is shown in Scheme 10.
Scheme 10
N N Pg
-1 10-2
N N N Pg
-3
HO R
Cl R
N N NH
-4
N N N
-5
The acid 10-1 and aminopyridine 10-2 are reacted under amide bond formation
conditions to provides a protected intermediate of formula 10-3 which is then deprotected
and reacted with an acid chloride or carboxylic acid as in Scheme 1 to provide final
compounds of the invention.
The intermediates of Scheme 10 may be prepared by conventional synthetic
reactions. For example, the biaryl acid 10-1 may be prepared by the Suzuki coupling of
boronate intermediate 3-1 with a bromobenzoic acid ester 11-1 followed by hydrolysis
(not shown) to the acid to provide the biaryl acid, as shown in Scheme 11.
Scheme 11
3-1 10-1
11-1
Alternatively, compounds of formula 10-3 may be prepared by the reaction
illustrated in Scheme 12:
Scheme 12
HN NN Pg
B Br
6 12-1
N N N Pg
-3
or, alternatively, by the Suzuki coupling reaction of bromo intermediate 3-3 with a
boronate or boronic acid analog of 12-1.
Analogously, to the process described in Scheme 3 above, if the protected
intermediate 12-1 were replaced by an intermediate 12-1'
HN NN
Br R
12-1'
then the reaction of Scheme 12 would directly provide a final compound of the invention.
Bromo intermediate 12-1 may be prepared by the amide coupling of a bromo-
benzoic acid 13-1 with intermediate 10-2 as illustrated in Scheme 13.
Scheme 13
HN NN Pg
H N N N Pg Br
13-1 10-2 12-1
and the corresponding intermediate 12-1' is prepared from 12-1 by deprotection of 12-1
and reaction with an appropriate acid chloride or carboxylic acid.
Finally, amine intermediate 10-2 is conveniently prepared from a nitro-
substituted chloropyridine which is reacted with a protected piperazine 2-3 to provide a
protected intermediate 14-2 as shown in Scheme 14.
Scheme 14
N N Pg
Cl HN N Pg
14-1 2-3 14-2
N N Pg
-2
Reduction of the nitro group to the amine provides intermediate 10-2.
Details regarding specific reaction conditions and other procedures for preparing
representative compounds described herein or intermediates thereto are described in the
examples below.
Thus, also described are the processes of Schemes 1-14 and variations thereto
described above as well as the processes exemplified below.
In a particular method aspect, described is a process illustrated in Scheme 3B, the
process comprising: (a) reacting a protected bromo intermediate 3-3' with a boronate 3-4'
or boronic acid 3-4" intermediate, to provide a protected intermediate 3-5, (b)
deprotecting intermediate 3-5, and (c) reacting the deprotected intermediate with a
reagent HO-G, to provide a compound of the invention of the formula (II') or a
pharmaceutically-acceptable salt thereof. This aspect includes a process of preparing a
1 2 3
compound of formula (II') in which R is C alkyl or tetrahydropyran, R is hydrogen, R
4 5 6 7
is -C(O)OC alkyl, R is methyl or methoxy, R and R are both hydrogen, R is fluoro,
chloro, or –OCF , R is methyl, R is tert-butyl or 3-hydroxy-2,2-dimethylpropyl, a is 1
or 2, and b is 1. In a particular aspect, a boronic acid 3-4" is used in step (a).
It will further be understood, this disclosure encompasses compounds of
formula (I) when prepared by synthetic processes such as those described above and
below or by metabolic processes including those occurring in vivo in human or animal
body or in vitro.
Pharmaceutical Compositions
The compounds described herein and pharmaceutically-acceptable salts thereof
are typically used in the form of a pharmaceutical composition or formulation. Such
pharmaceutical compositions may be administered to a patient by any acceptable route of
administration including, but not limited to, oral, rectal, vaginal, nasal, inhaled, topical
(including transdermal) and parenteral modes of administration.
Accordingly, in one of its compositions aspects, described is a pharmaceutical
composition comprising a pharmaceutically-acceptable carrier or excipient and a
compound of formula (I), where, as defined above, "compound of formula (I)" means a
compound of formula (I) or a pharmaceutically-acceptable salt thereof. Optionally, such
pharmaceutical compositions may contain other therapeutic and/or formulating agents if
desired. When discussing compositions and uses thereof, the "compound of the
invention" may also be referred to herein as the "active agent". As used herein, the term
"compound of the invention" is intended to include all compounds encompassed by
formula (I) as well as the species embodied in formulas (II), (II'), (III), (IV), (IVa), (IVb),
and (V) and pharmaceutically-acceptable salts thereof
The pharmaceutical compositions described herein typically contain a
therapeutically effective amount of a compound described herein. Those skilled in the art
will recognize, however, that a pharmaceutical composition may contain more than a
therapeutically effective amount, i.e., bulk compositions, or less than a therapeutically
effective amount, i.e., individual unit doses designed for multiple administration to
achieve a therapeutically effective amount.
Typically, such pharmaceutical compositions will contain from about 0.1 to about
95% by weight of the active agent; preferably, from about 5 to about 70% by weight; and
more preferably from about 10 to about 60% by weight of the active agent.
Any conventional carrier or excipient may be used in the pharmaceutical
compositions described herein. The choice of a particular carrier or excipient, or
combinations of carriers or excipients, will depend on the mode of administration being
used to treat a particular patient or type of medical condition or disease state. In this
regard, the preparation of a suitable pharmaceutical composition for a particular mode of
administration is well within the scope of those skilled in the pharmaceutical arts.
Additionally, the carriers or excipients used in the pharmaceutical compositions described
herein are commercially-available. By way of further illustration, conventional
formulation techniques are described in Remington: The Science and Practice of
Pharmacy, 20th Edition, Lippincott Williams & White, Baltimore, Maryland (2000); and
H.C. Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition,
Lippincott Williams & White, Baltimore, Maryland (1999).
Representative examples of materials which can serve as pharmaceutically
acceptable carriers include, but are not limited to, the following: sugars, such as lactose,
glucose and sucrose; starches, such as corn starch and potato starch; cellulose, such as
microcrystalline cellulose, and its derivatives, such as sodium carboxymethyl cellulose,
ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients,
such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil,
safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene
glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such
as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide
and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's
solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible
substances employed in pharmaceutical compositions.
Pharmaceutical compositions are typically prepared by thoroughly and intimately
mixing or blending the active agent with a pharmaceutically-acceptable carrier and one or
more optional ingredients. The resulting uniformly blended mixture can then be shaped
or loaded into tablets, capsules, pills and the like using conventional procedures and
equipment.
The pharmaceutical compositions described herein are preferably packaged in a
unit dosage form. The term "unit dosage form" refers to a physically discrete unit
suitable for dosing a patient, i.e., each unit containing a predetermined quantity of active
agent calculated to produce the desired therapeutic effect either alone or in combination
with one or more additional units. For example, such unit dosage forms may be capsules,
tablets, pills, and the like, or unit packages suitable for parenteral administration.
In one embodiment, the pharmaceutical compositions described herein are suitable
for oral administration. Suitable pharmaceutical compositions for oral administration
may be in the form of capsules, tablets, pills, lozenges, cachets, dragees, powders,
granules; or as a solution or a suspension in an aqueous or non-aqueous liquid; or as an
oil-in-water or water-in-oil liquid emulsion; or as an elixir or syrup; and the like; each
containing a predetermined amount of a compound described herein as an active
ingredient.
When intended for oral administration in a solid dosage form (i.e., as capsules,
tablets, pills and the like), the pharmaceutical compositions described herein will
typically comprise the active agent and one or more pharmaceutically-acceptable carriers,
such as sodium citrate or dicalcium phosphate. Optionally or alternatively, such solid
dosage forms may also comprise: fillers or extenders, such as starches, microcrystalline
cellulose, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as
carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia;
humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate,
potato or tapioca starch, alginic acid, certain silicates, and/or sodium carbonate; solution
retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium
compounds; wetting agents, such as cetyl alcohol and/or glycerol monostearate;
absorbents, such as kaolin and/or bentonite clay; lubricants, such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and/or mixtures
thereof; coloring agents; and buffering agents.
Release agents, wetting agents, coating agents, sweetening, flavoring and
perfuming agents, preservatives and antioxidants can also be present in the
pharmaceutical compositions described herein. Examples of pharmaceutically-acceptable
antioxidants include: water-soluble antioxidants, such as ascorbic acid, cysteine
hydrochloride, sodium bisulfate, sodium metabisulfate, sodium sulfite and the like; oil-
soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole, butylated
hydroxytoluene, lecithin, propyl gallate, alpha-tocopherol, and the like; and metal-
chelating agents, such as citric acid, ethylenediamine tetraacetic acid, sorbitol, tartaric
acid, phosphoric acid, and the like. Coating agents for tablets, capsules, pills and like,
include those used for enteric coatings, such as cellulose acetate phthalate, polyvinyl
acetate phthalate, hydroxypropyl methylcellulose phthalate, methacrylic
acidmethacrylic acid ester copolymers, cellulose acetate trimellitate, carboxymethyl
ethyl cellulose, hydroxypropyl methyl cellulose acetate succinate, and the like.
Pharmaceutical compositions described herein may also be formulated to provide
slow or controlled release of the active agent using, by way of example, hydroxypropyl
methyl cellulose in varying proportions; or other polymer matrices, liposomes and/or
microspheres. In addition, the pharmaceutical compositions described herein may
optionally contain opacifying agents and may be formulated so that they release the active
ingredient only, or preferentially, in a certain portion of the gastrointestinal tract,
optionally, in a delayed manner. Examples of embedding compositions which can be
used include polymeric substances and waxes. The active agent can also be in micro-
encapsulated form, if appropriate, with one or more of the above-described excipients.
Suitable liquid dosage forms for oral administration include, by way of
illustration, pharmaceutically-acceptable emulsions, microemulsions, solutions,
suspensions, syrups and elixirs. Liquid dosage forms typically comprise the active agent
and an inert diluent, such as, for example, water or other solvents, solubilizing agents and
emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl
alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (esp., cottonseed,
groundnut, corn, germ, olive, castor and sesame oils), oleic acid, glycerol, tetrahydrofuryl
alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Alternatively, certain liquid formulations can be converted, for example, by spray drying,
to a powder, which is used to prepare solid dosage forms by conventional procedures.
Suspensions, in addition to the active ingredient, may contain suspending agents
such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and
sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar
and tragacanth, and mixtures thereof.
The compounds described herein can also be administered parenterally (e.g. by
intravenous, subcutaneous, intramuscular or intraperitoneal injection). For parenteral
administration, the active agent is typically admixed with a suitable vehicle for parenteral
administration including, by way of example, sterile aqueous solutions, saline, low
molecular weight alcohols such as propylene glycol, polyethylene glycol, vegetable oils,
gelatin, fatty acid esters such as ethyl oleate, and the like. Parenteral formulations may
also contain one or more anti-oxidants, solubilizers, stabilizers, preservatives, wetting
agents, emulsifiers, buffering agents, or dispersing agents. These formulations may be
rendered sterile by use of a sterile injectable medium, a sterilizing agent, filtration,
irradiation, or heat.
Alternatively, the pharmaceutical compositions described herein are formulated
for administration by inhalation. Suitable pharmaceutical compositions for administration
by inhalation will typically be in the form of an aerosol or a powder. Such compositions
are generally administered using well-known delivery devices, such as a metered-dose
inhaler, a dry powder inhaler, a nebulizer or a similar delivery device.
When administered by inhalation using a pressurized container, the
pharmaceutical compositions described herein will typically comprise the active
ingredient and a suitable propellant, such as dichlorodifluoromethane,
trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
Additionally, the pharmaceutical composition may be in the form of a capsule or cartridge
(made, for example, from gelatin) comprising a compound described herein and a powder
suitable for use in a powder inhaler. Suitable powder bases include, by way of example,
lactose or starch.
The compounds described herein can also be administered transdermally using
known transdermal delivery systems and excipients. For example, the active agent can be
admixed with permeation enhancers, such as propylene glycol, polyethylene glycol
monolaurate, azacycloalkanones and the like, and incorporated into a patch or similar
delivery system. Additional excipients including gelling agents, emulsifiers and buffers,
may be used in such transdermal compositions if desired.
The following non-limiting examples illustrate representative pharmaceutical
compositions described herein.
Oral solid dosage form
A compound described herein is dissolved in polyethylene glycol acidified to
pH ≤ 2 with optional heating to form a solution comprising 10 % w/w or 40 % w/w active
agent. The solution is spray dried to form a powder. The resulting powder is loaded into
capsules, for example gelatin or hydroxypropyl methylcellulose capsules, to provide a
unit dosage of 14 mg or 56 mg, respectively, active agent per capsule,.
Oral liquid formulation
A compound described herein (100 mg) is added to a mixture of ethanol (5 mL),
propylene glycol (10 mL), and polyethylene glycol (25 mL). Once dissolution is
achieved, acidified distilled water (q.s. to 100 mL) is added to provide a liquid
formulation at a concentration of 1 mg/mL active agent.
Lipid emulsion formulation
A lipid emulsion formulation comprising a compound described herein (10 %),
oleic acid (78 %) polyethylene glycol (10 %), and polysorbate 20 (2 %) w/w is formed by
adding a compound of the invention to a mixture of the remaining ingredients.
Lipid emulsion formulation
A lipid emulsion formulation comprising a compound described herein (10 %)
and oleic acid (90 %) w/w is formed by adding a compound of the invention to oleic acid.
Micro-emulsion formulation
A compound described herein (1 g) is dissolved in a mixture of ethanol (2 mL),
propylene glycol (2 mL), polyethylene glycol 400 (4 mL), and polyethylene glycol
hydroxystearate (4 mL). Acidified distilled water (q.s. to 100 mL) is added to form a
self-emulsifying micro-emulsion formulation.
Utility
The compounds described herein have been shown to inhibit viral replication in
HCV replicon assays and therefore are expected to be useful for the treatment of hepatitis
C viral infections.
In one aspect, therefore, described is a method of inhibiting replication of the
hepatitis C virus in a mammal (e.g., a human), the method comprising administering to
the mammal a therapeutically-effective amount of a compound of the invention or of a
pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a
compound described herein.
Also described is a method of treating hepatitis C viral infections in a mammal
(e.g., a human), the method comprising administering to the mammal a therapeutically-
effective amount of compound described hereinor of a pharmaceutical composition
comprising a pharmaceutically-acceptable carrier and a compound described herein.
The compounds described herein may inhibit viral replication by inhibiting the
function of the NS5A protein encoded by the HCV genome. In one aspect, therefore,
described is a method of inhibiting the NS5A protein of HCV in a mammal, the method
comprising administering to the mammal, a compound or a compositiondescribed herein.
When used to treat HCV infections, the compounds described herein will typically
be administered orally in a single daily dose or in multiple doses per day, although other
forms of administration may be used. The amount of active agent administered per dose
or the total amount administered per day will typically be determined by a physician, in
the light of the relevant circumstances, including the condition to be treated, the chosen
route of administration, the actual compound administered and its relative activity, the
age, weight, and response of the individual patient, the severity of the patient's symptoms,
and the like.
Suitable doses for treating HCV infections will range from about 1 to about
2000 mg/day of active agent, including from about 5 to about 300 mg/day and from about
10 to about 200 mg per day of active agent for an average 70 kg human.
Combination therapy
Compounds described herein may also be used in combination with one or more
agents which act by the same mechanism or by different mechanisms to effect treatment
of HCV. Useful classes of agents for combination therapy include, but are not limited to,
HCV NS3 protease inhibitors, HCV NS5B nucleoside and non-nucleoside polymerase
inhibitors, helicase inhibitors, NS4B protein inhibitors, HCV viral entry inhibitors,
cyclophyllin inhibitors, toll-like receptor agonists, inhibitors of heat shock proteins,
interfering RNA, antisense RNA, HCV internal ribosome entry site (IRES) inhibitors,
thiazolides, nucleoside analogs such as ribavirin and related compounds, interferons and
other immunomodulatory agents, inosine 5’-monophosphate dehydrogenase (IMPDH)
inhibitors, and other NS5A protein inhibitors. Agents which act to inhibit HCV
replication by any other mechanism may also be used in combination with the present
compounds.
HCV NS3 protease inhibitors which may be used in combination therapy include,
but are not limited to, Incivek® (telaprevir,VX-950), boceprevir (SCH-503034),
simeprevir (TMC-435), narlaprevir (SCH-900518), vaniprevir (MK-7009), danoprevir
(ITMN-191, R-7227), BI-201335, ABT-450/r, asunaprevir (BMS-650032), GS-9256,
GS-9451, sovaprevir (ACH-1625), ACH-2684, BMS-605339, VX-985, PHX-1766,
BMS-791325, IDX-320, and MK-5172.
Examples of HCV NS5B nucleoside polymerase inhibitors include, but are not
limited to, mericitabine (RG7128), IDX-184, sofosbuvir (GS-7977, PSI-7977), PSI-7851,
PSI-938, BMS-986094 (INX-189, INX-08189), RG7348, MK-0608, TMC-649128,
HCV-796, and ALS-2200 (VX-135),while, non-nucleoside HCV NS5B polymerase
inhibitors, include but are not limited to, filibuvir (PF-8685540), tegobuvir (GS-9190),
VX-222, VX-759, setrobuvir (ANA-598), ABT-072, ABT-333, BI-207127, BMS-
791325, MK-3281, IDX-37, BMS-824393, TMC-647055.
A wide variety of interferons and pegylated interferons, including alpha, beta,
omega, and gamma interferons, having antiviral, antiproliferative or immunomodulatory
effects, can be combined with the present compounds. Representative examples include,
but are not limited to, Intron® A (interferon-alpha2b), Actimmune® (interferon-gamma-
1b), Alferon N, Advaferon®, Roferon-A (interferon alpha-2a) PegIntron® (peginterferon-
alpha 2b), Alfaferone, Pegasys® (peginterferon alpha-2a), Alfanative (interferon alpha),
Zalbin™ (albinterferon alpha-2b), Infergon® (interferon alfacon-1), Omega DUROS®
(omega interferon), Locteron™ (interferon alpha), PEG-rIL-29 (pegylated interferon
lambda), and Rebif® (interferon beta-1a).
Nucleoside analog antiviral agents include, but are not limited to, ribavirin
(Copegus®, Rebetol®,Virazole®) and Viramidine (taribavirin). Interferons and ribavirin
are also provided in in the form of kits which include, for example, but are not limited to,
Rebetron® (interferon alpha-2b/ribavirin) and Pegetron® (Peginterferon alpha-
2b/ribavirin)
Useful compounds acting by other mechanisms include, but are not limited to:
cyclophilin inhibitors, such as DEB-025, SCY-635, NIM-811, and cyclosporine and
derivatives; toll-like receptor agonists, such as resiquimod, IMO-2125, and ANA-773,
HCV viral entry inhibitors, such as civacir, thiazolides, such as nitazoxanide, and broad-
spectrum viral inhibitors, such as, inosine-5’-monophosphate dehydrogenase (IMPDH)
inhibitors.
In addition, compounds described herein may be combined with an NS5A
inhibitor, for example, daclatasvir (BMS-790052), AZD-7295, PPI-461, PPI-1301, GS-
5885, GSK2336805, ABT-267, ACH-2928, ACH-3102, EDP-239, IDX-719, MK-8742,
or PPI-668.
Also described is a therapeutic combination for use in the treatment of hepatitis C
viral infections, the combination comprising a compound described herein and one or
more other therapeutic agents useful for treating HCV. For example, described is a
combination comprising a compound of the invention and one or more agents selected
from HCV NS3 protease inhibitors, HCV NS5B nucleoside and non-nucleoside
polymerase inhibitors, interferons and pegylated interferons, cyclophilin inhibitors, HCV
NS5A inhibitors, and ribavirin and related nucleoside analogs. Also described, therefore,
is a pharmaceutical composition comprising a compound described herein and one or
more other therapeutic agents useful for treating HCV.
Further, described is a method of treating a hepatitis C viral infection in a
mammal, the method comprising administering to the mammal a compound described
herein and one or more other therapeutic agents useful for treating HCV.
Also described is a method of inhibiting replication of the hepatitis C virus in a
mammal, the method comprising administering to the mammal a compound described
herein and one or more other therapeutic agents useful for inhibiting replication of the
hepatitis C virus.
For example, in one method aspect, described is a method of treating a hepatitis C
viral infection in a mammal, the method comprising administering to the mammal a
compounddescribed herein, an interferon or pegylated interferon, and ribavirin.
Also described is a method of treating a hepatitis C viral infection in a mammal,
the method comprising administering to the mammal a compounddescribed herein, an
interferon or pegylated interferon, ribavirin, and an HCV NS3 protease inhibitor.
Also described is a method of treating a hepatitis C viral infection in a mammal,
the method comprising administering to the mammal a compounddescribed herein, an
HCV NS3 protease inhibitor, and ribavirin.
Still other all-oral combination therapies useful in other method aspects, include,
for example, a compound described herein and an HCV NS3 protease inhibitor; a
compound described herein and an HCV NS5B nucleoside polymerase inhibitor; a
compounddescribed herein, an HCV NS5B nucleoside polymerase inhibitor, and
ribavirin; a compounddescribed herein, an HCV NS3 protease inhibitor, and an HCV
NS5B nucleoside polymerase inhibitor; a compounddescribed herein, an HCV NS3
protease inhibitor, an HCV NS5B nucleoside polymerase inhibitor and ribavirin; a
compounddescribed herein, an HCV NS3 protease inhibitor, and an HCV NS5B non-
nucleoside polymerase inhibitor; and a compounddescribed herein, an HCV NS3 protease
inhibitor, an HCV NS5B non-nucleoside polymerase inhibitor and ribavirin.
Also described is a method of inhibiting replication of the hepatitis C virus in a
mammal, using a compound described herein in combination with other agents, as
described above.
When used in combination therapy, the agents may be formulated in a single
pharmaceutical composition, as disclosed above, or the agents may be provided in
separate compositions that are administered simultaneously or at separate times, by the
same or by different routes of administration. When administered separately, the agents
are administered sufficiently close in time so as to provide a desired therapeutic effect.
Such compositions can be packaged separately or may be packaged together as a kit. The
two or more therapeutic agents in the kit may be administered by the same route of
administration or by different routes of administration.
Finally, the compounds described herein may also find utility as research tools, for
example, for discovering new HCV NS5A protein inhibitors or explicating mechanisms
of HCV replication.
Compounds described herein have been demonstrated to be potent inhibitors of
HCV replication in HCV replicon assays, as described in the following examples.
EXAMPLES
The following synthetic and biological examples are offered to illustrate the
invention, and are not to be construed in any way as limiting the scope of the invention.
In the examples below, the following abbreviations have the following meanings unless
otherwise indicated. Abbreviations not defined below have their generally accepted
meanings.
ACN = acetonitrile
DCM = dichloromethane
DIPEA = N,N-diisopropylethylamine
DMA = N,N-dimethylacetamide
DMF = N,N-dimethylformamide
DMP = 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (Dess-
Martin periodinane)
DMSO = dimethyl sulfoxide
EDC = N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride
EtOAc = ethyl acetate
h = hour(s)
HATU = N,N,N',N'-tetramethyl-O-(7-azabenzotriazolyl)uronium
hexafluorophosphate
HCTU = 2-(6-chloro-1H-benzotriazole yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate
HOAt = 1-hydroxyazabenzotriazole
min = minute(s)
Pd(dppf)Cl = dichloro(1,1’-bis(diphenylphosphino)-
ferrocene)dipalladium(II)
MTBE = methyl tert-butyl ether
RT = room temperature
TFA = trifluoroacetic acid
THF = tetrahydrofuran
bis(pinacolato)diboron = 4,4,5,5,4',4',5',5'-octamethyl-
[2,2']bi[[1,3,2]dioxaborolanyl]
Reagents and solvents were purchased from commercial suppliers (Aldrich, Fluka,
Sigma, etc.), and used without further purification. Reactions were run under nitrogen
atmosphere, unless noted otherwise. Progress of reaction mixtures was monitored by thin
layer chromatography (TLC), analytical high performance liquid chromatography (anal.
HPLC), and mass spectrometry. Reaction mixtures were worked up as described
specifically in each reaction; commonly they were purified by extraction and other
purification methods such as temperature-, and solvent-dependent crystallization, and
precipitation. In addition, reaction mixtures were routinely purified by preparative
HPLC, typically using C18 or BDS column packings and conventional eluents. Typical
preparative HPLC conditions are described below.
Characterization of reaction products was routinely carried out by mass and
40 H-NMR spectrometry. For NMR analysis, samples were dissolved in deuterated solvent
( such as CD OD, CDCl , or d -DMSO), and H-NMR spectra were acquired with a
3 3 6
Varian Gemini 2000 instrument (400 MHz) under standard observation conditions. Mass
spectrometric identification of compounds was performed by an electrospray ionization
method (ESMS) with an Applied Biosystems (Foster City, CA) model API 150 EX
instrument or an Agilent (Palo Alto, CA) model 1200 LC/MSD instrument.
General Preparative HPLC Conditions
Column: C18, 5 mm. 21.2 x 150 mm or C18, 5 mm 21 x 250 or C14 21x150
Column temperature: Room Temperature
Flow rate: 20.0 mL/min
Mobile Phases: A = Water + 0.05 % TFA
B = ACN + 0.05 % TFA,
Injection volume: (100-1500 µL)
Detector wavelength: 214 nm
Crude compounds were dissolved in 1:1 water:acetic acid at about 50 mg/mL . A
4 minute analytical scale test run was carried out using a 2.1 x 50 mm C18 column
followed by a 15 or 20 minute preparative scale run using 100 mL injection with the
gradient based on the % B retention of the analytical scale test run. Exact gradients were
sample dependent. Samples with close running impurities were checked with a 21 x 250
mm C18 column and/or a 21 x 150 mm C14 column for best separation. Fractions
containing desired product were identified by mass spectrometric analysis.
Analytical HPLC
Column: Zorbax Bonus-RP 3.5 mm. 4.6 x 150 mm
Column temperature: 35 ºC
Flow rate: 1.0 mL/min
Injection volume: 5 mL
Sample preparation: Dissolve in 1:1 ACN:water
Method A
Mobile Phases: A = Water/ACN (98:2) + 0.1 % TFA
B = Water/ACN (10:90) + 0.1 % TFA
Detector wavelength: 254 nm
Gradient: 21 min total (time (min)/ % B): 0.5/10, 15/60, 16.5/80,
17/80, 18/10, 21/10
Method B
Mobile Phases: A = Water/ACN (98:2) + 0.1 % TFA
B = Water/ACN (2:98) + 0.5 % TFA
Detector wavelength: 214 nm
Gradient: 29 min total (time (min)/ % B): 0.5/10, 24/90, 25/90,
26/10, 29/10
Preparation 1: (R)[5-(4-Bromochlorotrifluoromethoxy-
phenylcarbamoyl)-pyridinyl]methyl-piperazinecarboxylic acid tert-butyl
ester
(a) 4-Bromochlorotrifluoromethoxy-phenylamine
To a mixture of 4-bromotrifluoromethoxy-phenylamine (2.0 g, 7.8 mmol) in
ACN (60 mL) was slowly added a solution of N-chlorosuccinimide (1.0 g, 7.8 mmol) in
ACN (40 mL). The reaction mixture was heated at 60 °C overnight and extracted with
ethyl actetate/water. The organic layer was dried over sodium sulfate and purified by
flash chromatography (40 g column, 100% hexanes to 10% EtOAc: hexanes) to produce
the desired product as an orange-ish colored oil (1.4 g, 64 % yield).
(b) N-(4-Bromochlorotrifluoromethoxy-phenyl)fluoro-nicotinamide
To a solution of the product of the previous step (1.2 g, 4.1 mmol) in DCM (5 mL)
was slowly added a solution of 2-fluoropyridinecarbonyl chloride (0.66 g, 4.1 mmol)
in DCM (3 mL) and 20 drops of DMA were added. The reaction mixture was
concentrated to form a yellowish solid (2 g). (m/z): [M+H] calcd for C H BrClF N O
13 6 4 2 2
412.92, 414.92 found 413, 415.
(c) (R)[5-(4-Bromochlorotrifluoromethoxy-phenylcarbamoyl)-pyridinyl]
methyl-piperazinecarboxylic acid tert-butyl ester
To a reaction mixture of the product of the previous step (999 mg, 2.42 mmol) in a
mixture of N,N-diisopropylethylamine (0.84 mL, 4.83 mmol;) and DMSO (0.86 mL,
12.08 mmol) was added (R)methyl-piperazinecarboxylic acid tert-butyl ester (726
mg, 3.62 mmol) and the reaction mixture was heated at 120 °C overnight and extracted
with ethyl acetate/water. The organic layer was dried over sodium sulfate and
concentrated under vacuum. The dark oil was dissolved in a small amount of DCM and
purified by silica gel chromatography (24 g column, 0-40% ethyl acetate:hexanes) to
produce the title intermediate as a white solid (916 mg, 64 % yield). (m/z): [M+H] calcd
for C H BrClF N O 593.07, 595.07 found 595.4.
23 25 3 4 4
Preparation 2: (R)[5-(4-Bromochlorotrifluoromethoxy-
phenylcarbamoyl)-pyridinyl]methyl-piperazinecarboxylic acid tert-butyl
ester
Following the procedure of Preparation 1 step (c) substituting (2S,5R)-2,5-
dimethyl-piperazinecarboxylic acid tert-butyl ester (777 mg, 3.62 mmol) for (R)
methyl-piperazinecarboxylic acid tert-butyl ester, the title intermediate was prepared
as a light yellow solid (1118 mg, 76 % yield). (m/z): [M+H] calcd for C H BrClF N O
24 27 3 4 4
607.09, 609.08 found 609.3.
Preparation 3: (S)Methoxycarbonylaminomethyl-butyric acid
Methylchloroformate (14.5 mL, 0.188 mol) was added over 15 min to a cooled (0-
6 C) mixture of (S)aminomethyl-butyric acid (20.0 g, 0.171 mol), NaOH (6.80 g,
0.171 mol) and sodium carbonate (18.1 g, 0.171 mol) in water (200 mL). The cooling
bath was removed and the mixture was stirred at ambient temperature overnight. Conc.
aqueous HCl (30 mL) was added to the reaction mixture to adjust pH to ~1. A solid
formed and the mixture was stirred for 90 min. The mixture was filtered and the solid was
dried overnight under reduced pressure at 40 C to provide the title intermediate (27.8 g,
93 % yield). H NMR (CD3OD, 400 MHz) d (ppm) 4.87 (br. s, 4H), 4.05 (d, J = 5.49, 1
H), 3.65 (s, 3 H), 2.25-2.05 (m, 1 H), 0.98 (d, J = 6.87, 3 H), 0.94 (d, J = 6.87, 3 H).
Preparation 4: 4-(4-Bromo-phenyl)((2S,4S)methyl-pyrrolidinyl)-1H-
imidazole
(a) (S)-Pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)oxo-ethyl] ester 1-tert-
butyl ester
To a mixture of p-bromophenacyl bromide (242 mg, 0.87 mmol) in DCM (1.5
mL) and DMA (1.5 mL), under nitrogen, was added (2S,4S)methyl-pyrrolidine-1,2-
dicarboxylic acid 1-tert-butyl ester (200 mg, 0.87 mmol) and N,N-diisopropylethylamine
(531.8 µL, 3.05 mmol) and the resulting mixture was stirred at 35 °C for 3 h,
concentrated under vacuum, dissolved in DCM (30 mL), and washed with water (2 x 5
ml). The organic layer was dried over magnesium sulfate, filtered, and concentrated under
vacuum to provide the title intermediate.
(b) (2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]methyl-pyrrolidinecarboxylic
acid tert-butyl ester
The product of the previous step was dissolved in toluene (20.0 mL), ammonium
acetate (1.345 g, 17.45 mmol) was added, and resulting mixture was stirred at 95 °C
overnight, concentrated and purified by silica gel chromatography (24 g, 0-80%
EtOAc/hexanes)) to give the title product (265 mg) (m/z): [M+H] calcd for
C H BrN O 406.11, 408.11 found 408.5.
19 24 3 2
(c) 4-(4-Bromo-phenyl)((2S,4S)methyl-pyrrolidinyl)-1H-imidazole
The product of the previous step was treated with 4 M HCl in 1,4-dioxane (2.0
mL) for 1 h and concentrated by rotary evaporation to provide the di-HCl salt of the title
intermediate (224 mg, 68 % yield). (m/z): [M+H] calcd for C H BrN 306.06, 308.06
14 16 3
found 306.3.
Preparation 5: ((S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]
methyl-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
A mixture of (S)methoxycarbonylaminomethyl-butyric acid (103 mg, 0.59
mmol, Preparation 3) and HATU (270 mg, 0.71 mmol) were stirred in DMA (2 mL) for
min and then 4-(4-Bromo-phenyl)((2S,4S)methyl-pyrrolidinyl)-1H-imidazole
2 HCl (224 mg, 0.59 mmol, Preparation 4) and N,N-diisopropylethylamine (0.31 mL, 1.8
mmol) were added. The resulting mixture was stirred at RT overnight, diluted with ethyl
acetate (50 mL), and washed with water (2 x 5 mL). The organic layer was dried over
magnesium sulfate, filtered, concentrated and purified by silica gel chromatography (0-
100% EtOAc/hexanes)). Fractions with desired product were combined and concentrated
to give the title compound (183 mg, 66 % yield) (m/z): [M+H] calcd for C H BrN O
21 27 4 3
463.13, 465.12 found 465.3.
Preparation 6: [(S)Methyl((2S,4S)methyl{4-[4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidine
carbonyl)-propyl]-carbamic acid methyl ester
To a solution of ((S){(2S,4S)[4-(4-bromo-phenyl)-1H-imidazolyl]
methyl-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester (183 mg,
0.39 mmol; Preparation 5) and 4,4,5,5,4',4',5',5'-octamethyl-
[2,2']bi[[1,3,2]dioxaborolanyl] (120 mg, 0.47mmol) in 1,4-dioxane (5 mL) was added
potassium acetate (56 mg, 0.59 mmol). The resulting mixture was sparged with nitrogen,
Pd(dppf)Cl .CH Cl (27 mg, 0.033 mmol) was added, and the reaction mixture was
2 2 2
capped and heated at 100 °C overnight. The reaction was cooled to RT and partitioned
between EtOAc (50 mL) and water (10 mL). The organic layer was washed with water (5
mL), brine (2 mL), dried over magnesium sulfate, filtered ,and concentrated to give a
dark-brown oil, which was purified by silica gel chromatography (24g silica gel, 0-100%
EtOAc/hexanes). Fractions with desired product were combined and dried to give the title
compound (94 mg, 47 % yield) as a white foam. (m/z): [M+H] calcd for C H BN O
27 39 4 5
511.30 found 511.7.
Preparation 7: (2S,5R)[5-(4-Bromochlorotrifluoromethyl-
phenylcarbamoyl)-pyridinyl]-2,5-dimethyl-piperazinecarboxylic acid tert-butyl
ester
To a solution of 5-aminobromochlorobenzotrifluoride (466 mg, 1.70 mmol)
dissolved in DCM (1 mL) was slowly added a solution of 2-fluoropyridinecarbonyl
chloride (270 mg, 1.70 mmol) in DCM (1 mL). A few drops of DMA were added and the
reaction mixture was concentrated to form N-(4-bromochlorotrifluoromethyl-
phenyl)fluoro-nicotinamide as a purple solid.
Half of the solid from the previous step was treated with N,N-
diisopropylethylamine (0.5 mL, 3 mmol), DMSO (0.5 mL, 7 mmol) and (2S,5R)-2,5-
dimethyl-piperazinecarboxylic acid tert-butyl ester (273 mg, 1.27 mmol) and the
reaction mixture was heated at 120 °C overnight, concentrated by rotary evaporation,
dissolved in a small amount of DCM and purified by silica gel chromatography (0-50%
ethyl acetate:hexanes) to produce the title intermediate (288 mg, 29 % yield) as a yellow
solid. (m/z): [M+H] calcd for C H F N O 591.09, 593.09 found 593.2.
24 27 4 4 4
Preparation 8: ((S){(S)[4-(4-Bromo-phenyl)-1H-imidazolyl]-1,4-
dioxaaza-spiro[4.4]nonanecarbonyl}methyl-propyl)-carbamic acid methyl
ester
(a) (2S,4R)Hydroxy((S)methoxycarbonylaminomethyl-butyryl)-pyrrolidine
carboxylic acid methyl ester
To a solution of (2S,4R)hydroxy-pyrrolidinecarboxylic acid methyl ester in
dry DCM (200 mL) was added (S)methoxycarbonylaminomethyl-butyric acid (10 g,
55 mmol), HATU (24 g, 63.25 mmol), and triethylamine (16.7 g, 165 mmol. The reaction
mixture was stirred at RT overnight. DCM (200 mL) was added and the solution was
washed with brine, dried, concentrated and purified by silica gel column chromatography
(eluted with petroleum ether:EtOAc 10:1 to 1:4)) to give the title intermediate as a yellow
oil (20 g). (m/z): [M+H] calcd for C H N O 303.15 found 303.1.
13 22 2 6
(b) (S)((S)Methoxycarbonylaminomethyl-butyryl)oxo-pyrrolidine
carboxylic acid methyl ester
To a solution of the product of the previous step (15 g, 50 mmol) in DCM
(500mL) was added DMP (60 g) and the reaction mixture was stirred at RT overnight,
washed with saturated sodium bicarbonate (3 x 100 mL), brine (100 mL), dried,
concentrated, and purified by silica gel column chromatography (eluted with petroleum
ether:EtOAc 1:2) to provide the title intermediate as a yellow oil (7.5 g, 50 % yield).
(m/z): [M+H] calcd for C H N O 301.13 found 301.1.
13 20 2 6
(c) (S)((S)Methoxycarbonylaminomethyl-butyryl)-1,4-dioxaaza-
spiro[4.4]nonanecarboxylic acid methyl ester
To a solution of the product of the previous step (7.5 g, 24.9 mmol) in toluene
(100 mL) was added ethane-1,2-diol (7.75 g, 125 mol) and 4-methylbenzenesulfonic acid
(860 mg, 5 mmol) and the mixture was stirred at reflux overnight. Ethyl acetate (300 mL)
was added and the solution was washed with saturated sodium bicarbonate, dried,
concentrated, and purified by silica gel column chromatography (eluted with petroleum
ether:EtOAc 1:1) to provide the title intermediate as a yellow solid (3.5 g, 41 % yield).
(m/z): [M+H] calcd for C H N O 345.16 found 345.1.
24 2 7
(d) (S)((S)Methoxycarbonylaminomethyl-butyryl)-1,4-dioxaaza-
spiro[4.4]nonanecarboxylic acid
Lithium hydroxide (730 mg, 30.5 mmol) was added to a solution of the product of
the previous step (3.0 g, 7.1 mmol) in THF (40 mL) and water (30 mL). The reaction
mixture was stirred at RT for 3h and washed with EtOAc (2 x 10 mL). The aqueous layer
was adjusted to pH 1 with 2 M HCl and extracted with EtOAc (4 x 50 mL); portions were
combined, dried, and concentrated to give the product as a white solid (3 g, 89 % yield).
(m/z): [M+H] calcd for C H N O 331.14 found 331.1.
14 22 2 7
(e) (S)((S)Methoxycarbonylaminomethyl-butyryl)-1,4-dioxaaza-
spiro[4.4]nonanecarboxylic acid 2- (4-bromo-phenyl)oxo-ethyl ester
To a solution of the product of the previous step (2.7 g, 8.17 mmol) in DMF(30
mL) was added 2-bromo(4-bromo-phenyl)-ethanone (2.5 g, 8.99 mmol) and cesium
carbonate (5.3 g, 16.34 mmol) and the reaction mixture was stirred at RT for 4 h. Ethyl
acetate (150 mL) was added and the solution was washed with brine (3 x 20 mL), dried,
filtered, concentrated, and purified by silica gel column chromatography (eluted with 0 to
50 % EtOAc in petroleum ether) to provide the title intermediate as a yellow solid (1.6 g,
37 % yield). (m/z): [M+H] calcd for C H BrN O 527.11, 529.10 found 527.0, 529.0.
22 27 2 8
(f) ((S){(S)[4-(4-Bromo-phenyl)-1H-imidazolyl]-1,4-dioxaaza-
spiro[4.4]nonanecarbonyl}methyl-propyl)-carbamic acid methyl ester
To a solution of the product of the previous step (1.5 g, 2.84 mmol) in toluene
(50 mL) was added ammonium acetate (3.3 g, 42.7 mmol) and the solution was stirred at
reflux overnight. Ethyl acetate (100 mL) was added and the solution was washed with
brine (3 x 20 mL), dried, filtered, concentrated, and purified by silica gel column
chromatography (eluted with 0 to 50 % EtOAc in petroleum ether) to provide the title
intermediate as a yellow solid (1.0 g, 69 % yield). (m/z): [M+H] calcd for C H BrN O
22 27 4 5
507.12, 509.11 found 507.0, 509.0. H NMR (CH OD, 400 ) d (ppm) 7.58-7.52 (m, 2
H), 7.49-7.42 (m, 2 H), 7.31 (s, 1H), 5.18-5.11 (m, 1 H), 4.17-3.78 (m, 7 H), 3.63 (s, 3 H),
2.52-2.42 (m, 2H), 2.01-1.92 (m, 1H), 0.92-0.82 (m, 6H).
Preparation 9: ((S){(S)[4-(4'-Amino-2'-trifluoromethoxy-biphenyl
yl)-1H-imidazolyl]-1,4-dioxaaza-spiro[4.4]nonanecarbonyl}methyl-
propyl)-carbamic acid methyl ester
(a) (4'-{2-[(S)((S)Methoxycarbonylaminomethyl-butyryl)-1,4-dioxaaza-
spiro[4.4]nonyl]-1H-imidazolyl}trifluoromethoxy-biphenylyl)-carbamic
acid tert-butyl ester
To a solution of ((S){(S)[4-(4-bromo-phenyl)-1H-imidazolyl]-1,4-dioxa-
7-aza-spiro[4.4]nonanecarbonyl}methyl-propyl)-carbamic acid methyl ester (350
mg, 0.69 mmol) in dioxane (8 mL) and water (4 mL) was added [4-(4,4,5,5-tetramethyl-
[1,3,2]dioxaborolanyl)trifluoromethoxy-phenyl]-carbamic acid tert-butyl ester (334
mg, 0.83 mmol), sodium carbonate (148 mg, 1.4 mmol), and
tetrakis(triphenylphosphine)-palladium(0) (81 mg, 0.07 mmol). The reaction mixture was
stirred at reflux for 3 h under nitrogen. Ethyl acetate (50 mL) was added and the solution
was washed with brine, dried over sodium sulfate, filtered, and concentrated to give the
title intermediate as a yellow solid (650 mg). (m/z): [M+H] calcd for C H N O 704.28
34 40 5 8
found 704.3.
(b) ((S){(S)[4-(4'-Amino-2'-trifluoromethoxy-biphenylyl)-1H-imidazolyl]-
1,4-dioxaaza-spiro[4.4]nonanecarbonyl}methyl-propyl)-carbamic acid
methyl ester
To a solution of the product of the previous step (610 mg, 0.87 mmol) in DCM
(8 mL) was added TFA (1.6 mL) and the reaction mixture was stirred at RT for 1 h.
Saturated sodium bicarbonate was added (10 mL) and the solution was extracted with
DCM (3 x 20 mL). The organic layers were combined, dried over sodium sulfate,
concentrated and purified by HPLC under acid conditions (0.075 % HCl) to provide the
di-HCl salt of the title intermediate as a white solid (92 mg). (m/z): [M+H] calcd for
C H F N O 604.23 found 604.2. H NMR (CH OD, 400 ) d (ppm) 7.88 (s, 1H), 7.80
29 32 3 5 6 3
(d, 2H), 7.61 (d, 2H), 7.52-7.49 (m, 1H), 7.21-7.16 (m, 2H), 5.38-5.34 (m, 1 H), 4.18-4.02
(m, 6 H), 3.96-3.90 (m, 1 H), 3.65 (s, 3 H), 2.71-2.63 (m, 1 H), 2.46-2.39 (m, 1H), 2.07-
1.94 (m, 1H), 0.93-0.85 (m, 6 H).
Preparation 10: ((S){(2S,4S)[4-(4'-Amino-biphenylyl)-1H-imidazol
yl]hydroxy-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
To a solution of ((S){(2S,4S)[4-(4-bromo-phenyl)-1H-imidazolyl]
hydroxy-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester (1.8 g,
3.87 mmol) in dioxane (30 mL) and water (10 mL), 4-(4,4,5,5-tetramethyl-
[1,3,2]dioxaborolanyl)-phenylamine (848 mg, 3.87 mmol), sodium carbonate (820 mg,
7.74 mmol) and Pd(dppf)Cl (316 mg, 0.39 mmol) were added and the reaction mixture
was heated at reflux for 3 h, cooled to RT, filtered and concentrated, extracted with
EtOAc (50 mL), and washed with water (50 mL). The organic layer was dried over
sodium sulfate, filtered, concentrated and purified by silica gel column chromatography
(eluted with 1 % to 3 % methanol in DCM) to give the title intermediate (1.45 g, 65 %
yield). H NMR (CH OD, 400 ) d (ppm) 7.70 (m, 2H), 7.67 (m, 2H), 7.45 (m, 2H), 7.29
(s, 1H), 6.80 (d, J = 6.8 Hz, 1H), 5.82(d, J = 9.2 Hz, 1H),5.29 (d, J = 8.8 Hz, 1H), 4.59 (s,
1H), 4.34 (d, J = 8.8 Hz, 1H), 4.16(d, J = 8.0Hz, 1H), 3.95~4.04 (m, 1H), 3.79~3.83 (m,
1H), 3.76 (s, 3H), 2.55~2.69 (m, 1H), 2.32 (m, 1H), 1.60~2.03 (m, 1H), 1.00 (m, 3H),
0.3~0.85 (m, 3H).
Preparation 11: (R)(5-Carboxy-pyridinyl)methyl-piperazine
carboxylic acid tert-butyl ester
A mixture of 6-fluoronicotinic acid (150 g, 1.063 mol) and (R)methyl-
piperazinecarboxylic acid tert-butyl ester (234.2 g, 1.169 mol) in tetrahydrofuran (1.75
L) was cooled to -40 °C and then 2 M isopropylmagnesium chloride in tetrahydrofuran
(1.196 L, 2.39 mol) was added slowly maintaining the temperature less than -20 °C. The
reaction mixture was slowly warmed to RT, stirred at RT for 4 h and then 1 N HCl (1.75
L) and water (1.l75 L) were added. The reaction mixture was extracted with ethyl acetate
(4 L). The organic phase was evaporated to provide crude solid (534 g). To the crude
solid was added acetone (2 L) and water (200 mL). The resulting reaction mixture was
heated to 50 °C and then water (2.8 L) was added slowly. Seed crystals from a previous
run at smaller scale were added after ~ 1 L of water. The reaction mixture was cooled to
°C over 3 h, stirred at 20 °C overnight and filtered. The solid was washed with 2:3
acetone:water (2 x 500 mL) and dried under vacuum to provide the title compound (329
g, 96 % yield) as an off-white solid. HPLC Method A: Retention time 9.73 min.
Preparation 12: ((S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]
dimethylamino-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl
ester
(a) (2S,4R)Methanesulfonyloxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-
methyl ester
To a solution of (2S,4R)hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl
ester 2-methyl ester (50 g, 0.2 mol), triethylamine (50.5 g, 0.5 mol) in DCM was added
methanesulfonyl chloride (28 g, 0.25 mol) in portions and the reaction mixture was stirred
at 0 °C for 20 min and at RT for 1.5 h, and washed with citric acid solution and water.
The organic layer was dried over sodium sulfate and concentrated to give the title
intermediate (70 g, 97 % yield). H NMR (CDCl , 400 MHz) d (ppm) 5.23 (m, 1H), 4.44
(m, 1H), 3.75 (m, 5H), 3.04 (s, 3H), 2.64 (m, 1H), 2.26 (m, 1H),1.43 (m, 9H).
(b) (2S,4S)Azido-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
A mixture of the product of the previous step (70 g, 0.2 mol) and sodium azide (26
g, 0.4 mol) in DMF (800 mL) was stirred at 80 °C overnight. The reaction mixture was
adjusted to pH 9-10 with sodium bicarbonate and extracted with DCM. The organic layer
was washed with water and brine, dried over sodium sulfate, concentrated, and purified
by silica gel chromatography (eluted with petroleum ether:EtOAc 5:1) to give the title
intermediate (60 g, 97 % yield) as a clear oil. H NMR (CDCl , 400 MHz) d (ppm) 4.33
(m, 1H), 4.11 (m, 1H), 3.73 (s, 3H), 3.44 (m, 1H), 2.44 (m, 1H), 2.16 (m, 1H),1.43 (m,
9H).
(c) (2S,4S)Amino-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
A mixture of the product of the previous step (60 g, 0.2 mol) and palladium on
carbon (7 g) in methanol (700 mL) was degassed under vacuum, purged with hydrogen
several times, stirred under hydrogen (40 psi) at RT overnight and filtered. The filtrate
was concentrated to give the title intermediate (45 g) as a brown oil. (m/z): [M+H] calcd
for C H N O 245.14 found 245.1.
11 20 2 4
(d) (2S,4S)Dimethylamino-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-
methyl ester
To a solution of the product of the previous step (28 g, 57 mmol) and
formaldehyde (20 g, 240 mmol) in methanol (500 mL) was added sodium
triacetoxyborohydride (36 g, 170 mmol) in portions at RT and the reaction mixture was
stirred at RT overnight under nitrogen and then concentrated. The residue was washed
with water and extracted with DCM (2 x 500 mL). The organic layer was washed with
water and brine, dried over sodium sulfate, concentrated, and purified by silica gel
chromatography (eluted with petroleum ether:EtOAc 1:2, 1 % NH OH) to give the title
product (8 g, 50 % yield) as a clear oil. H NMR (CDCl , 400 ) d (ppm) 4.09 (m, 2H),
3.73(s, 3H), 3.53(m, 1H), 2.58 (m, 2H), 2.26 (s, 6H), 1.88 (m, 1H),1.42(m, 9H).
(e) (2S,4S)Dimethylamino-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester
A solution of the product of the previous step (8.0 g, 30 mmol) and sodium
hydroxide (5.8 g, 150 mmol) in methanol:water 3:1 (120 mL) was stirred at RT overnight
under nitrogen and concentrated. The water phase was adjusted to pH 5-6 with 3 N HCl
and lyophilized. The solid was washed with methanol and filtered. The filtrate was
concentrated to give the title intermediate (8 g) as a white solid. H NMR (CDCl , 400 )
d (ppm) 4.09 (m, 2H), 3.73(m, 2H), 3.53(m, 1H), 2.78 (s, 6H), 2.58 (m, 1H), 2.21 (m,
1H),1.42(m, 9H).
(f) (2S,4S)[2-(4-Bromo-phenyl)oxo-ethylcarbamoyl]dimethylamino-pyrrolidine-
1-carboxylic acid tert-butyl ester
A mixture of the product of the previous step (5.0 g, 16 mmol), 2-amino(4-
bromo-phenyl)-ethanone HCl (4.0 g, 16 mmol) 3-(diethoxyphosphoryloxy)- 1,2,3-
benzotrazin-4(3H)-one (DEPBT) (6.0 g, 20 mmol), and DIPEA (6.0 g, 48 mmol) in DMF
(150 mL)was stirred at RT overnight. The reaction mixture was washed with water and
extracted with DCM (2 x 500 mL). The organic layer was washed with water and brine,
dried over sodium sulfate, concentrated, and purified by silica gel chromatography (eluted
with DCM:methanol 10:1) to give the title intermediate (2.3 g) which was purified by
HPLC to give the title intermediate as a clear oil (1 g, 97 % purity) and (750 mg, 70 %
purity).
(g) {(3S,5S)[4-(4-Bromo-phenyl)-1H-imidazolyl]-pyrrolidinyl}-dimethyl-amine
A mixture of the product of the previous step (1.25 g, 2.75 mmol) and ammonium
acetate (4.2 g, 55 mmol) in toluene (50 mL) was stirred at 100-120 °C overnight under
nitrogen. The reaction mixture was washed with water and the water phase was extracted
with DCM (2 x 100 mL). The organic layer was washed with water and brine, dried over
sodium sulfate, concentrated, and purified by silica gel chromatography (eluted with
DCM:methanol 10:1) to give (2S,4S)[4-(4-bromo-phenyl)-1H-imidazolyl]
dimethylamino-pyrrolidinecarboxylic acid tert-butyl ester (1.7 g) as a brown solid.
A mixture of the product of the previous step (1.7 g, 2.3 mmol) in HCl and
methanol (50 mL was stirred at RT for 1 h and concentrated to give the title intermediate
(1.5 g) as a brown solid. (m/z): [M+H] calcd for C H Br N 335.08 found 334.9.
19 4
(h) ((S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]dimethylamino-
pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
A mixture of the product of the previous step (1.5 g, 2.3 mmol), (S)
methoxycarbonyl-aminomethyl-butyric acid (0.6 g, 3.5 mmol), HATU (1.3 g, 3.5
mmol), and N,N-diisopropylethylamine (0.9 g, 6.9 mmol) in DCM (50 mL) was stirred at
RT overnight. The reaction mixture was washed with water and extracted with DCM (2 x
100 mL). The organic layer was washed with water and brine, dried over sodium sulfate,
concentrated, and purified by silica gel chromatography (eluted with DCM:methanol
:1) to give the title intermediate (0.8 g, 65 % yield) as a brown solid. (m/z): [M+H]
calcd for C H BrN O 492.15 found 492.1.
22 30 5 3
Preparation 13: (R)Methyl{5-[4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)-phenylcarbamoyl]- pyridinyl}-piperazinecarboxylic acid
tert-butyl ester
A solution of (R)(5-carboxy-pyridinyl)methyl-piperazinecarboxylic
acid tert-butyl ester (200 mg, 0.6 mmol) and EDC (140 mg, 0.75 mmol) and HOAt (100
mg, 0.75 mmol) dissolved in DMF (4.6 mL) was stirred for 30 min and 4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolanyl)aniline (140 mg, 0.62 mmol) and N,N-
diisopropylethylamine (130 µL, 0.75 mmol) were added. The reaction mixture was
stirred at RT overnight and extracted with ethyl acetate/water. The organic layer was
dried over sodium sulfate, filtered, concentrated, and purified by silica gel
chromatography (eluted with 0-70% ethyl acetate:hexanes) to provide the title
intermediate (250 mg, 80 % yield). (m/z): [M+H] calcd for C H BN O 523.30 found
28 39 4 5
523.5.
Preparation 14: 4-Bromotrifluoromethoxy-benzoic acid methyl ester
A mixture of 4-amino(trifluoromethoxy)benzoic acid (504.1 mg, 2.28 mmol),
methanol (7.6 mL) and 4.0 M HCl in 1,4-dioxane (5.7 mL) was stirred at RT over the
weekend, concentrated, evaporated with EtOAc (3 x 10 mL), and dried under vacuum to
give a brownish solid. The solid was dissolved in a mixture of acetonitrile (23 mL) and
water (2.3 mL). Copper(II) bromide (595 mg, 2.66 mmol) and tert-butyl nitrite (0.39 mL,
3.32 mmol) were added to the reaction mixture which was heated at 70 °C for 1.5 h,
cooled to RT and diluted with EtOAc (70 mL). The organic layer was washed with
saturated sodium bicarbonate (2 x 15 mL), brine (2 x 15 mL), dried over sodium sulfate,
filtered and concentrated to give a brownish oil., which was purified by silica gel
chromatography (24 g silica gel, 0-50% EtOAc/Hexanes). Desired fractions were
combined and concentrated to give the title intermediate (281 mg, 41 % yield) as a
yellowish oil.
Preparation 15: 4'-{2-[(2S,4S)((S)Methoxycarbonylaminomethyl-
butyryl)methyl-pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-biphenyl-
4-carboxylic acid
To a mixture of 4-bromotrifluoromethoxy-benzoic acid methyl ester (161 mg,
0.54 mmol; Preparation 14), [(S)methyl((2S,4S)methyl{4-[4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)-
propyl]-carbamic acid methyl ester (250 mg, 0.49 mmol) and potassium carbonate (304
mg, 2.20 mmol) at RT was added toluene (1.2 mL) followed by water (0.61 mL). The
resulting mixture was degassed and flushed with nitrogen and Pd(dppf)Cl2 (24 mg,
0.029 mmol) was added under an atmosphere of nitrogen. The reaction mixture was
capped and held at 100 °C overnight, cooled to RT and partitioned between EtOAc
(10 mL) and water (2 mL). The organic layer was dried over sodium sulfate, filtered and
concentrated to give a brownish oil which was purified by silica gel chromatograph (12 g
silica gel, 0-100% EtOAc/Hexanes). Desired fractions were combined and concentrated
to give a light reddish oil.
The oily residue from the previous step was dissolved in a mixture of methanol
(4.9 mL) and water (2 mL) and treated with lithium hydroxide monohydrate (123 mg,
2.94 mmol) at 65 °C for 1 hr. The reaction mixture was concentrated, dissolved in 1:1
acetic acid:water (1.5 mL), filtered and purified by reverse phase HPLC. Desired
fractions were combined and freeze dried to give the TFA salt of the title intermediate
(221 mg, 64 % yield) as a white solid. (m/z): [M+H] calcd for C H F N O 589.22
29 31 3 4 6
found 589.
Preparation 16: (2S,5R)(5-Amino-pyridinyl)-2,5-dimethyl-piperazine
carboxylic acid tert-butyl ester
(a) (2S,5R)-2,5-Dimethyl(5-nitro-pyridinyl)-piperazinecarboxylic acid tert-butyl
ester
A mixture of 2-chloronitropyridine (1.0 g, 6.3 mmol), (2S,5R)-2,5-dimethyl-
piperazinecarboxylic acid tert-butyl ester (1.4 g, 6.3 mmol), and potassium carbonate
(1.7 g, 13 mmol) was stirred in DMSO (5.0 mL, 70 mmol) at 100 °C overnight. The
reaction mixture was filtered thru a silica gel pad, which was washed with EtOAc
(200 mL). The filtrate was washed with water (2 x 10 mL), concentrated, and purified by
silica gel chromatography (eluted with ethyl acetate/ hexane = 0 to 80%) to give the title
intermediate (1.724 g, 81 % yield) as a yellow solid.
(b) (2S,5R)(5-Amino-pyridinyl)-2,5-dimethyl-piperazinecarboxylic acid tert-
butyl ester
A solution of the product of the previous step in methanol (250 mL) was
degassed, then 20% palladium hydroxide on carbon (170 mg, 10 % by weight) was added
and reaction mixture was degassed three times, and hydrogenated under a balloon of
hydrogen overnight. The reaction mixture was filtered thru a Celite® pad. The filtrate
was concentrated and purified by silica gel chromatography (eluted with 3 %
triethylamine in ethyl acetate/hexanes 0 to 80%) to give the title intermediate (1.3 g, 67 %
yield) as a dark purple solid . (m/z): [M+H] calcd for C H N O 307.21 found 307.6.
16 26 4 2
Preparation 17: [(R)(5-Amino-pyridinyl)methyl-piperazinyl]-((S)-
2,2-dimethyl-cyclopropyl)-methanone
(a) (R)Methyl(5-nitro-pyridinyl)-piperazinecarboxylic acid tert-butyl ester
In each of two separate reactions, a mixture of 2-chloronitropyridine (1.0 g, 6.3
mmol), (R)methyl-piperazinecarboxylic acid tert-butyl ester (1.4 g, 6.9 mmol), and
potassium carbonate (1.31 g, 9.46 mmol) in DMSO (20 mL) was heated at 100 °C
overnight. The reaction mixtures were cooled to RT, filtered through silica gel, and eluted
with EtOAc (150 mL). The filtrate was washed with water (2 x 20mL) and brine (20 mL),
dried over sodium sulfate, filtered, and concentrated to give a brownish oil, which was
purified by silica gel chromatography (40g silica gel, 0-60% EtOAc/Hexanes). Desired
fractions were combined and concentrated to provide the title intermediate (1.39 g each)
as a yellowish solid. (m/z): [M+H] calcd for C H N O 323.16 found 323.3.
22 4 4
(b) (R)Methyl(5-nitro-pyridinyl)-piperazine
The product of the previous step (2.79 g, 8.65 mmol) was treated with 4 M of HCl
in 1,4-dioxane(65 mL) and stirred at RT for 1 h, concentrated to produce a yellow solid
and evaporated twice with EtOAc to provide the di-HCl salt of the title intermediate
(2.20 g, 86 % yield).
(c) ((S)-2,2-Dimethyl-cyclopropyl)-[(R)methyl(5-nitro-pyridinyl)-piperazin-
1-yl]-methanone
The product of the previous step (1.5 g, 6.7 mmol) was dissolved in DMA
(65 mL) and N,N-Diisopropylethylamine (3.5 mL) was added followed by (S)-(+)-2,2-
dimethylcyclopropane carboxylic acid (0.93 mL, 8.1 mmol) and then HATU (3.1 g,
8.1 mmol). The reaction mixture was stirred at RT overnight, diluted in EtOAc and
washed with water and brine. The organic layer was dried over sodium sulfate, filtered
and concentrated to produce a yellow oil, which was purified by silica chromatography
(0-60% EtOAc:hexanes) to produce the title intermediate (1.29 g, 60 % yield) as a yellow
solid. (m/z): [M+H] calcd for C H N O 319.17 found 319.2.
16 22 4 3
(d) [(R)(5-Amino-pyridinyl)methyl-piperazinyl]-((S)-2,2-dimethyl-
cyclopropyl)-methanone
A solution of the product of the previous step (200 mg, 0.63 mmol) in methanol
(6 mL) was degassed with nitrogen for 15 min and then 5% platinum on Carbon wet
65.25% (491 mg, 0.063 mmol) was added and the reaction mixture was bubbled with
hydrogen for 15 min and stirred under hydrogen atmosphere for 1.5 h at RT. The reaction
mixture was degassed under nitrogen and filtered through Celite, washed with EtOAc and
concentrated to yield a dark red oil, which was purified by silica gel chromatography (0-
100% ethyl acetate:hexanes) to provide the title intermediate as a light red solid (83 mg,
46 % yield). (m/z): [M+H] calcd for C H N O 289.20 found 289.4.
16 24 4
Preparation 18: 4-(4-Bromo-phenyl)((2S,4S)methylsulfanyl-pyrrolidin-
2-yl)-1H-imidazole
(a) (2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]methylsulfanyl-pyrrolidine
carboxylic acid tert-butyl ester
To a solution of (2S,4S)methylsulfanyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-
butyl ester (250 mg, 0.96 mmol) and p-bromophenacyl bromide (266 mg, 0.96 mmol) in
DCM (10 mL) under nitrogen was added N,N-diisopropylethylamine (0.58 mL, 3.35
mmol) and the resulting mixture was stirred at 35 °C for 3 h, concentrated under vacuum,
dissolved in DCM (30 mL), and washed with water (2 x 5 mL). The organic layer was
dried over magnesium sulfate, filtered, and concentrated under vacuum.
The crude intermediate from the previous step was dissolved in toluene (75.0 mL),
and then ammonium acetate (1.475 g, 19.13 mmol) was added, and the resulting mixture
was stirred at 100 °C overnight, concentrated and purified by silica gel chromatograph
(12 g silica, 0 to 60 % EtOAc/hexane) to give the title intermediate (410 mg, 98% yield).
(m/z): [M+H] calcd for C H BrN O S 438.08, 440.08 found 440.
19 24 3 2
(b) 4-(4-Bromo-phenyl)((2S,4S)methylsulfanyl-pyrrolidinyl)-1H-imidazole
The product of the previous step was treated with 4 M HCl in 1,4-dioxane(2.0
mL) for 1 h and concentrated by rotary evaporation to provide the di-HCl salt of the title
intermediate (368 mg, 93 % yield). (m/z): [M+H] calcd for C H BrN S 338.02, 340.02
14 16 3
found 340.
Preparation 19: ((S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]
methylsulfanyl-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl
ester
A mixture of (S)methoxycarbonylaminomethyl-butyric acid (156 mg, 0.89
mmol) and HATU (407 mg, 1.07 mmol) was stirred in DMA (3.0 mL) for 10 min, then 4-
(4-bromo-phenyl)((2S,4S)methylsulfanyl-pyrrolidinyl)-1H-imidazole di-HCl
(367 mg, 0.89 mmol; Preparation 18) and N,N-diisopropylethylamine (777.3 µL,
4.46 mmol) were added. The resulting mixture was stirred at RT overnight, concentrated,
and purified by silica gel chromatography (0 to 90% EtOAc/hexane). Fractions with
desired product were combined and concentrated to give the title intermediate (366 mg,
82 % yield). (m/z): [M+H] calcd for C H BrN O S 495.10, 497.10 found 495.
21 27 4 3
Preparation 20: [(S)Methyl((2S,4S)methylsulfanyl{4-[4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidine
carbonyl)- propyl]-carbamic acid methyl ester
To a solution of ((S){(2S,4S)[4-(4-bromo-phenyl)-1H-imidazolyl]
methylsulfanyl-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
(320 mg, 0.65 mmol, Preparation 19) and 4,4,5,5,4',4',5',5'-octamethyl-
[2,2']bi[[1,3,2]dioxaborolanyl] (246 mg, 0.97 mmol in 1,4-dioxane (5 mL) was added
potassium acetate (114 mg, 1.16 mmol). The resulting mixture was sparged with nitrogen.
1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane (47 mg,
0.058 mmol) was added, and reaction mixture was capped and heated at 100 °C
overnight. The reaction mixture was cooled to RT and partitioned between EtOAc
(50 mL) and water (10 mL). The organic layer was washed with water (5 mL) and brine
(2 mL), dried over magnesium sulfate, filtered, and concentrated to give a dark-brown oil,
which was purified by silica gel chromatography (24g silica gel, 0-100%
EtOAc/Hexanes). Fractions with desired product were combined and dried to give the
title intermediate (120 mg, 34 % yield) (m/z): [M+H] calcd for C H BN O S 543.27
27 39 4 5
found 543.
Preparation 21: 4'-{2-[(2S,4S) ((S)Methoxycarbonylaminomethyl-
butyryl)methylsulfanyl-pyrrolidinyl]- 1H-imidazolyl}trifluoromethoxy-
biphenylcarboxylic acid
To a mixture of 4-bromotrifluoromethoxy-benzoic acid methyl ester (36 mg,
0.12 mmol; Preparation 14), [(S)methyl((2S,4S)methylsulfanyl{4-[4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)-
propyl]-carbamic acid methyl ester (60 mg, 0.11 mmol; Preparation 20) and potassium
carbonate (69 mg, 0.50 mmol) at RT was added toluene (0.27 mL) followed by water
(0.14 mL). The resulting mixture was degassed and flushed with nitrogen and
Pd(dppf)Cl (5.4 mg, 0.006 mmol) was added under an atmosphere of nitrogen. The
reaction mixture was capped and held at 100 °C overnight, cooled to RT and partitioned
between EtOAc (10 mL) and water (2 mL). The organic layer was dried over sodium
sulfate, filtered, and concentrated to give a brownish oil, which was purified by silica gel
chromatography (12 g silica gel, 0-100% EtOAc/Hexanes). Desired fractions were
combined and concentrated to give a light reddish oil.
The oily residue from previous step was dissolved in a mixture of methanol
(1.1 mL) and water (0.4 mL) and treated with lithium hydroxide monohydrate (28 mg,
0.66 mmol) at 65 °C for 1 h. The reaction mixture was concentrated, dissolved in 1:1
acetic acid:water (1.5 mL), filtered and purified by reverse phase HPLC. Desired
fractions were combined and freeze dried to give the TFA salt of the title intermediate
(37 mg, 46 % yield) as a white solid. (m/z): [M+H] calcd for C29H31F3N4O6S 621.19
found 621.
Preparation 22: (2S,5R)[5-(4-Bromofluorotrifluoromethoxy-
phenylcarbamoyl)-pyridinyl]-2,5-dimethyl-piperazinecarboxylic acid tert-butyl
ester
To a solution of 4-bromofluorotrifluoromethoxy-phenylamine (500 mg,
2 mmol) dissolved in DCM (1 mL) was slowly added a solution of 2-fluoropyridine
carbonyl chloride (290 mg, 1.8 mmol) in DCM (1 mL). A few drops of DMA were added
and the reaction mixture was concentrated to form N-(4-bromofluoro
trifluoromethoxy-phenyl)fluoro-nicotinamide as a purple solid.
The solid from the previous step was dissolved in a mixture of N,N-
diisopropylethylamine (0.7 mL, 4 mmol) and DMSO (0.7 mL, 10 mmol) and (2S,5R)-2,5-
dimethyl-piperazinecarboxylic acid tert-butyl ester (590 mg, 2.7 mmol) was added and
the reaction mixture heated at 120 °C overnight, concentrated by rotary evaporation,
dissolved in a small amount of DCM and purified by silica gel chromatography (0-40%
ethyl acetate:hexanes) to produce the title intermediate (613 mg, 57 % yield) as a white
solid. (m/z): [M+H] calcd for C H F N O 591.12 found 591.4.
24 27 4 4 4
Preparation 23: 4'-{2-[(S)((S)Methoxycarbonylaminomethyl-
butyryl)-1,4-dioxaaza-spiro[4.4]nonyl]-1H-imidazolyl}-biphenyl
carboxylic acid
To a solution of ((S){(S)[4-(4-Bromo-phenyl)-1H-imidazolyl]-1,4-dioxa-
7-aza-spiro[4.4]nonanecarbonyl}methyl-propyl)-carbamic acid methyl ester
(450 mg, 0.89 mmol) in dioxane (8 mL) and water (4 mL) was added 4-boronobenzoic
acid (154 mg, 0.93 mmol), sodium carbonate (189 mg, 1.78 mmol), and
tetrakis(triphenylphosphine)-palladium(0) (104 mg, 0.09 mmol) and the reaction mixture
was stirred at reflux for 3 h under nitrogen. The pH was adjusted to 1 with 2 M HCl, and
the reaction mixture was extracted with EtOAc (3 x 20 mL). The organic layers were
combined, dried over sodium sulfate, concentrated and purified by flash chromatography
(eluted with methanol in DCM, 0 to 7 %) to provide the title intermediate as a yellow
solid (330 mg, 68 % yield). (m/z): [M+H] calcd for C H N O 549.23 found 549.3.
29 32 4 7
H NMR (CH OD, 400 ) d (ppm) 8.13-8.11 (m, 2H), 7.90-7.78 (m, 7H), 5.39-5.34 (m, 1
H), 4.19-3.91 (m, 7 H), 3.66 (s, 3 H), 2.72-2.65 (m, 1 H), 2.48-2.41 (m, 1H), 2.12-1.95
(m, 1H), 0.92-0.85 (m, 6 H).
Preparation 24: (R)[5-(4-Bromofluorotrifluoromethoxy-
phenylcarbamoyl)-pyridinyl]methyl-piperazinecarboxylic acid tert-butyl
ester
Br NH
(a) 4-Bromofluorotrifluoromethoxy-phenylamine
To a mixture of 2-fluoro(trifluoromethoxy)aniline (2 g, 10 mmol) dissolved in
DMF (4 mL) was slowly added a solution of N-bromosuccinimide (2.2 g, 12 mmol)
dissolved in DMF (5 mL). The reaction mixture was stirred at RT for 1 h, concentrated
and extracted with ethyl acetate/water. The organic layer was washed with brine,
partitioned, dried over sodium sulfate, filtered, concentrated, and purified by silica
chromatography (100 % hexanes) to produce the title intermediate as a red oil (2 g, 70 %
yield). (m/z): [M+H] calcd for C H BrF NO 273.94, 275.94 found 276.2.
7 4 4
(b) N-(4-Bromofluorotrifluoromethoxy-phenyl)fluoro-nicotinamide
To a solution of the product of the previous step (2 g, 7 mmol) dissolved in DCM
(10 mL) was slowly added a solution of 2-fluoropyridinecarbonyl chloride (1.2 g,
7.3 mmol) in DCM (10 mL) and DMA (60 drops). The reaction mixture was concentrated
to provide the title intermediate as a purple solid. (m/z): [M+H] calcd for C H BrF N O
13 6 5 2 2
396.95, 398.95 found 399.0.
(c) (R)[5-(4-Bromofluorotrifluoromethoxy-phenylcarbamoyl)-pyridinyl]
methyl-piperazinecarboxylic acid tert-butyl ester
The solid from the previous step was dissolved in a mixture of
N,N-diisopropylethylamine (3 mL, 20 mmol) and DMSO (3 mL) and (R)methyl-
piperazinecarboxylic acid tert-butyl ester (2.2 g, 11 mmol) was added. The reaction
mixture was heated at 120 °C overnight, concentrated by rotary evaporation, dissolved in
a small amount of DCM, and purified by silica gel chromatography (0-40% ethyl
acetate:hexanes) to produce the title intermediate as a white solid (3.6 g, 80 % yield).
(m/z): [M+H] calcd for C H BrF N O 577.10, 579.10 found 577.5, 580.3.
23 25 4 4 4
Preparation 25: 4'-{5-Chloro[(2S,4S)((S)methoxycarbonylamino
methyl-butyryl)methyl-pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-
biphenylcarboxylic acid
A mixture of 4'-{2-[(2S,4S)((S)methoxycarbonylaminomethyl-butyryl)
methyl-pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-biphenylcarboxylic
acid (124 mg, 0.21 mmol) and N-chlorosuccinimide (28 mg, 0.21 mmol) was stirred in
acetonitrile (2.0 mL) and N,N-dimethylacetamide (0.2 mL) at 60 °C overnight. The
reaction mixture was concentrated by rotary evaporation, dissolved in 1:1 acetic
acid:water (8 mL) and purified by reverse phase HPLC to provide the TFA salt of the
title compound (48 mg). (m/z): [M+H] calcd for C H ClF N O 623.18 found 623.2.
29 30 3 4 6
Preparation 26: ((S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]
methoxy-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
(a) (2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]methoxy-pyrrolidine
carboxylic acid tert-butyl ester
To a solution of (2S,4S)methoxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl
ester (900 mg, 3.67 mmol), and p-bromophenacyl bromide (1.02 g, 3.67 mmol) in DCM
(20 mL) under nitrogen, was added N,N-diisopropylethylamine (1.92 mL, 11.01 mmol).
The resulting mixture was stirred at 35 °C for 3 h and concentrated under vacuum. The
crude intermediate was dissolved in toluene (150 mL), ammonium acetate (5.66 g,
73.39 mmol) was added, and the resulting mixture was stirred at 95 °C overnight, and
washed with water (2 x 10 mL). The organic layer was dried over magnesium sulfate,
filtered, concentrated and purified by silica gel chromatography (24 g, ethyl
acetate/hexanes 0 to 60%) to give the title intermediate (1.49 g, 96 % yield).
(b) 4-(4-Bromo-phenyl)((2S,4S)methoxy-pyrrolidinyl)-1H-imidazole
The product of the previous step was treated with 4 M HCl in 1,4-dioxane (2 mL)
for 1 h and concentrated by rotary evaporation to give the di-HCl salt of the title
intermediate (1.40 g, 97 % yield). (m/z): [M+H] calcd for C H BrN O 322.05, 324.05
14 16 3
found 324.
(c) ((S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]methoxy-pyrrolidine
carbonyl}methyl-propyl)-carbamic acid methyl ester
A mixture of (S)methoxycarbonylaminomethyl-butyric acid (643 mg,
3.67 mmol) and HATU (1.67 g, 4.40 mmol) were stirred in DMA (5 mL) for 10 min, and
then the product of the previous step (1.40 g, 3.54 mmol) and N,N-diisopropylethylamine
(1.92 mL, 11.01 mmol) were added, and the resulting mixture was stirrred at room
temperature overnight, concentrated by rotary evaporation, dissolved in ethyl acetate
(100 mL), and washed with water (2 x 10 mL). The organic layer was dried over
magnesium sulfate, filtered, concentrated, and purified by silica gel chromatography
(ethyl acetate/hexanes 30 to 80%) to give the title product (1.38 g, 79 % yield).
(m/z): [M+H] calcd for C H BrN O 479.12, 481.12 found 481.
21 27 4 4
Preparation 27: [(S)((2S,4S)Methoxy{4-[4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)methyl-
propyl]- carbamic acid methyl ester
A solution of ((S){(2S,4S)[4-(4-bromo-phenyl)-1H-imidazolyl]
methoxy-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester (1.05 g,
2.18 mmol; Preparation 26), 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2]dioxaborolanyl]
(0.83 g, 3.27 mmol), and potassium acetate (0.39 g, 3.93 mmol) in 1,4-dioxane (5 mL)
was purged with nitrogen for 5 min, then Pd(dppf)Cl (95.80 mg, 0.13 mmol) was added,
and the resulting mixture was stirred at 100 °C for 3 h, diluted with ethyl acetate (50 mL),
and filtered through a pad of celite and silica gel. The pad was washed with ethyl acetate
(150 ml); the filtrate was concentrated and purified by silica gel chromatography (ethyl
acetate/hexanes 30 to 100 %) to give the title intermediate (669 mg 58 % yield).
(m/z): [M+H] calcd for C H BN O 527.30 found 527.2.
27 39 4 6
Preparation 28: ((S){(2S,4S)[4-(5'-Chloro-4'-{[6-((R)methyl-
piperazinyl)-pyridinecarbonyl]-amino}-2'-trifluoromethoxy-biphenylyl)-1
imidazolyl]methoxy-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid
methyl ester
N NH
(a) (R)[5-(5-Chloro-4'-{2-[(2S,4S)methoxy((S)methoxycarbonylamino
methyl-butyryl)-pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-biphenyl
ylcarbamoyl)-pyridinyl]methyl-piperazinecarboxylic acid tert-butyl ester
To a solution of [(S)((2S,4S)methoxy{4-[4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)methyl-propyl]-
carbamic acid methyl ester (100 mg, 0.19 mmol, Preparation 27) and (R)[5-(4-bromo-
2-chlorotrifluoromethoxy-phenylcarbamoyl)-pyridinyl]methyl-piperazine
carboxylic acid tert-butyl ester (110 mg, 0.19 mmol) dissolved in toluene (1.18 mL) and
water (0.43 mL) was added potassium carbonate (127 mg, 0.92 mmol). The reaction
mixture was sparged under nitrogen for 15 min and Pd(dppf)Cl CH Cl (13.55 mg,
2 2 2
0.017 mmol) was added and the reaction mixture was sparged with nitrogen and heated at
90 °C overnight, cooled to RT, diluted with EtOAc and washed with water and brine to
produce a dark colored solid, which was purified by silica gel chromatography (12 g
silica, EtOAc/hexanes 40 to 100%) to produce the title intermediate (35.3 mg, 21 %
yield) as a yellowish colored solid. (m/z): [M+H] calcd for C H ClF N O 913.35
44 52 3 8 8
found 913.3.
(b) ((S){(2S,4S)[4-(5'-Chloro-4'-{[6-((R)methyl-piperazinyl)-pyridine
carbonyl]-amino}-2'-trifluoromethoxy-biphenylyl)-1H-imidazolyl]methoxy-
pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
The product of the previous step was treated with 4 M HCl in 1,4-dioxane
(0.92 mL) and HCl (0.28 mL) and the reaction mixture was stirred at RT for 1 h,
concentrated and evaporated with ethyl acetate (2 x) to produce the tri-HCl salt of the title
intermediate (38.5 mg, 23 % yield). (m/z): [M+H] calcd for C H ClF N O 813.30
39 44 3 8 6
found 813.3.
Preparation 29: (S)-Methoxycarbonylamino-(tetrahydro-pyranyl)-acetic
acid
A solution of (S)-amino-(tetrahydro-pyranyl)-acetic acid (200 mg, 1.26 mmol)
in saturated aqueous sodium bicarbonate solution (2.46 mL, 25.13 mmol) was stirred until
all solids were dissolved. Methyl chloroformate (0.19 mL, 2.51 mmol) was added
dropwise, the reaction mixture was stirred for 30 min, and 1N HCl was added to adjust
pH to 1. The reaction mixture was extracted with ethyl acetate (3 x 5 mL) and the organic
extracts were dried over sodium sulfate, filtered, concentrated and dried overnight under
vacuum to give the title intermediate (248 mg, 91 % yield) as a white, sticky solid.
(m/z): [M+H] calcd for C H NO 218.10 found 218.1.
9 15 5
Preparation 30: N-(4-Bromochlorotrifluoromethoxy-phenyl)[(R)
(2,2-dimethyl-propionyl)- 2-methyl-piperazinyl]-nicotinamide
(a) N-(4-Bromochlorotrifluoromethoxy-phenyl)((R)methyl-piperazinyl)-
nicotinamide
A solution of (R)[5-(4-bromochlorotrifluoromethoxy-phenylcarbamoyl)-
pyridinyl]methyl-piperazinecarboxylic acid tert-butyl ester (600 mg, 1.01 mmol)
and 4 M HCl in 1,4-dioxane(5.05 mL) and HCl (1.55 mL) was stirred at RT for 1 h,
concentrated, and evaporated with ethyl acetate (2 x) to produce the di-HCl salt of the
title intermediate (625.5 mg),. (m/z): [M+H] calcd for C H BrClF N O 493.02, 495.02
18 17 3 4 2
found 494.9.
(b) N-(4-Bromochlorotrifluoromethoxy-phenyl)[(R)(2,2-dimethyl-propionyl)-
2-methyl-piperazinyl]-nicotinamide
The solid from the previous step was dissolved in DMA (6.58 mL) and DIPEA
(0.88 mL, 5.05 mmol) was added, followed by 2,2-dimethylpropanoyl chloride (130.53
µL, 1.06 mmol) and the reaction mixture was stirred at RT for 1 h. The reaction mixture
was concentrated by rotary evaporation, to produce a yellow oil which was dissolved in a
small amount of DCM and purified by silica gel chromatography (24 g column, 0-40%
ethyl acetate:hexanes) to produce the title intermediate (552 mg, 94 % yield) as a white
solid. (m/z): [M+H] calcd for C H BrClF N O 577.08, 579.08 found 579.0.
23 25 3 4 3
Preparation 31: N-{5-Chloro-4'-[2-((2S,4S)methyl-pyrrolidinyl)-1H-
imidazolyl]trifluoromethoxy-biphenylyl}[(R)(2,2-dimethyl-propionyl)-
2-methyl-piperazinyl]-nicotinamide
(a) (2S,4S)methyl{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolanyl)-phenyl]-1H-
imidazolyl}-pyrrolidinecarboxylic acid tert-butyl ester
To a solution of (2S,4S)[4-(4-bromo-phenyl)-1H-imidazolyl]methyl-
pyrrolidinecarboxylic acid tert-butyl ester (1.0 g, 2.5 mmol) and
bis(pinacolato)diboron (656 mg, 2.58 mmol) and potassium acetate (362 mg, 3.69 mmol)
was added degassed toluene (5.77 mL). The reaction mixture was sparged with nitrogen
for 15 min and 1,1'-bis(diphenylphosphino)ferrocene-palladium(ii)dichloride
dichloromethane (60.3 mg, 0.074 mmol) was added and the reaction mixture was stirred,
purged with nitrogen, and heated to 90 °C for 3 h to provide the title intermediate.
(b) (2S,4S){4-[5'-Chloro-4'-({6-[(R)(2,2-dimethyl-propionyl)methyl-piperazin
yl]-pyridinecarbonyl}-amino)-2'-trifluoromethoxy-biphenylyl]-1H-imidazol
yl}methyl-pyrrolidinecarboxylic acid tert-butyl ester
To the reaction mixture of the previous step was added degassed water (2.75 mL)
and potassium carbonate (1.87 g, 13.54 mmo), and N-(4-bromochloro
trifluoromethoxy-phenyl)[(R)(2,2-dimethyl-propionyl)methyl-piperazinyl]-
nicotinamide (1.49 g, 2.58 mmol; Preparation 30). The reaction mixture was purged with
nitrogen, Pd(dppf)Cl CH Cl (30.2 mg, 0.037 mmol) was added and the mixture was
2 2 2
purged again, heated to 95 °C overnight, cooled to RT, diluted with EtOAc, filtered
through a combined pad of Celite® and silica gel, flushed several times with EtOAc, and
washed with water and brine to produce a dark colored solid. The residue was purified by
silica gel chromatography (40 g column, 40% to 100% EtOAc/hexane,) to provide the
title intermediate (890 mg, 44 % yield) as a yellow solid. (m/z): [M+H] calcd for
C H ClF N O 824.34 found 824.3
42 49 3 7 5
(c) N-{5-Chloro-4'-[2-((2S,4S)methyl-pyrrolidinyl)-1H-imidazolyl]
trifluoromethoxy-biphenylyl}[(R)(2,2-dimethyl-propionyl)methyl-
piperazinyl]-nicotinamide
The solid from the previous step was treated with 4 M HCl in 1,4-dioxane
(12.3 mL) and HCl (3.8 mL) and the reaction mixture was stirred at RT for 1 h,
concentrated and evaporated with ethyl acetate (2 x) to produce the tri-HCl salt of the title
intermediate (913 mg, 44 % yield). (m/z): [M+H] calcd for C H ClF N O 724.29
37 41 3 7 3
found 724.3.
Preparation 32 N-{5-Chloro-4'-[2-((2S,4S)methoxy-pyrrolidinyl)-1H-
imidazolyl]trifluoromethoxy-biphenylyl}[(R)(2,2-dimethyl-propionyl)-
2-methyl-piperazinyl]-nicotinamide
Following a process analogous to that of Preparation 31 at the 0.71 mmol scale,
substituting (2S,4S)[4-(4-bromo-phenyl)-1H-imidazolyl]methoxy-pyrrolidine
carboxylic acid tert-butyl ester for (2S,4S)[4-(4-bromo-phenyl)-1H-imidazolyl]
methyl-pyrrolidinecarboxylic acid tert-butyl ester in step (a), the tri-HCl salt of the
title intermediate was prepared (146 mg, 24 % yield). (m/z): [M+H] calcd for
C37H41ClF3N7O4 740.29 found 740.2.
Preparation 33: N-(4-Bromochlorotrifluoromethoxy-phenyl)[(R)
(3-hydroxy-2,2-dimethyl-propionyl)methyl-piperazinyl]-nicotinamide
Br NH OH
(a) N-(4-Bromochlorotrifluoromethoxy-phenyl)((R)methyl-piperazinyl)-
nicotinamide
(R)[5-(4-bromochlorotrifluoromethoxy-phenylcarbamoyl)-pyridinyl]-
3-methyl-piperazinecarboxylic acid tert-butyl ester (500 mg, 0.84 mmol) was treated
with 4 M HCl in 1,4-dioxane (4.2 mL) and HCl (1.3 mL) and stirred at RT for 1 h. The
reaction mixture was concentrated and dissolved in ethyl acetate and coevaporated (2 x)
to produce the di-HCl salt of the title intermediate as a yellow solid. (m/z): [M+H] calcd
for C H BrClF N O 493.02, 495.02 found 494.9.
18 17 3 4 2
(b) N-(4-Bromochlorotrifluoromethoxy-phenyl)[(R)(3-hydroxy-2,2-dimethyl-
propionyl)methyl-piperazinyl]-nicotinamide
To a solution of 2,2-dimethylhydroxypropionic acid (119 mg, 1.01 mmol) in
DMF (4.6 mL, 58.9 mmol) was added HATU (384 mg, 1.0 mmol). The reaction mixture
was stirred at RT for 15 min, the product of the previous step (534 mg) was added
followed by DIPEA (0.73 mL, 4.2 mmol) and the mixture was stirred at RT for 3 h, and
concentrated by rotary evaoporation to produce a yellow/orange oil which was dissolved
in a small amount of DCM and purified by silica chromatography 2(4g column, 0-80%
ethyl acetate:hexanes) to produce the title intermediate (495 mg) as a white solid.
(m/z): [M+H] calcd for C H BrClF N O 593.07, 595.07 found 595.4.
23 25 3 4 4
Preparation 34: N-{5-Chloro-4'-[2-((2S,4S)methoxy-pyrrolidinyl)-1H-
imidazolyl]trifluoromethoxy-biphenylyl}[(R)(3-hydroxy-2,2-dimethyl-
propionyl) methyl-piperazinyl]-nicotinamide
(a) (2S,4S)Methoxy{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolanyl)-phenyl]-
1H-imidazolyl}-pyrrolidinecarboxylic acid tert-butyl ester
To a solution of (2S,4S)[5-(4-Bromo-phenyl)-1H-imidazolyl]methoxy-
pyrrolidinecarboxylic acid tert-butyl ester (335 mg, 0.79 mmol),
bis(pinacolato)diboron (212 mg, 0.83 mmol) and potassium acetate (117 mg, 1.19 mmol)
was added degassed toluene (1.86 mL). The resulting mixture was sparged with nitrogen
for 15 min, Pd(dppf)Cl CH Cl (19.4 mg, 0.024 mmol) was added, and the reaction
2 2 2
mixture was stirred, purged with nitrogen, and heated to 90 °C for 4 h to provide the title
intermediate. (m/z): [M+H] calcd for C H BN O 470.27 found 470.1.
36 3 5
(b) (2S,4S){4-[5'-Chloro-4'-({6-[(R) (3-hydroxy-2,2-dimethyl-propionyl)methyl-
piperazinyl]-pyridinecarbonyl}-amino)-2'-trifluoromethoxy-biphenylyl]-1H-
imidazolyl}methoxy-pyrrolidinecarboxylic acid tert-butyl ester
To the reaction mixture of the previous step was added degassed water (0.89 mL),
potassium carbonate (603 mg, 4.36 mmol), and N-(4-bromochlorotrifluoromethoxy-
phenyl)[(R)(3-hydroxy-2,2-dimethyl-propionyl)methyl-piperazinyl]-
nicotinamide (495 mg, 0.84 mmol; Preparation 33). The reaction mixture was purged
with nitrogen, Pd(dppf)Cl CH Cl (9.72 mg, 0.012 mmol) was added; the mixture was
2 2 2
purged again and heated to 95 °C overnight, cooled to RT, diluted with EtOAc, filtered
through a combined pad of Celite® and silica gel, flushed several times with EtOAc, and
washed with water and brine to produce a dark colored oil. The residue was purified by
silica gel chromatography (24 g silica gel, 40% to 100% EtOAc/hexane, 5-25 min then 0-
10% methanol:EtOAc 10-30 min) to produce the title intermediate (211 mg, 31 % yield)
as a yellow solid. (m/z): [M+H] calcd for C H ClF N O 856.33 found 856.2.
42 49 3 7 7
(c) N-{5-Chloro-4'-[2-((2S,4S)methoxy-pyrrolidinyl)-1H-imidazolyl]
trifluoromethoxy-biphenylyl}[(R)(3-hydroxy-2,2-dimethyl-propionyl)
methyl-piperazinyl]-nicotinamide
The solid from the previous step (211 mg) was treated with 4 M HCl in 1,4-
dioxane(4.0 mL) and HCl (1.2 mL) and the reaction mixture was stirred at RT for 1 h,
concentrated, and evaporated with ethyl acetate (2 x) to produce the tri-HCl salt of the
title intermediate (230 mg, 33 % yield). (m/z): [M+H] calcd for C H ClF N O
37 41 3 7 5
756.283 found 756.2.
Preparation 35: 4'-{2-[(2S,4S)Methanesulfinyl((S)
methoxycarbonylaminomethyl-butyryl)-pyrrolidinyl]-1H-imidazolyl}
trifluoromethoxy-biphenylcarboxylic acid
(a) 4'-{2-[(2S,4S)((S)Methoxycarbonylaminomethyl-butyryl)methylsulfanyl-
pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-biphenylcarboxylic acid
methyl ester
To a mixture of 4-bromotrifluoromethoxy-benzoic acid methyl ester (184 mg,
0.62 mmol), [(S)methyl((2S,4S)methylsulfanyl{4-[4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)- propyl]-
carbamic acid methyl ester (300 mg, 0.55 mmol) and potassium carbonate (344 mg, 2.49
mmol) at RT was added toluene (1.35 mL) followed by water (0.69 mL). The reaction
mixture was purged with nitrogen, Pd(dppf)Cl CH Cl (27.4 mg, 0.034 mmol) was added
2 2 2
under an atmosphere of nitrogen. The reaction vial was capped and heated at 100 °C
overnight, cooled to RT and partitioned between EtOAc (10 mL) and water (2 mL). The
organic layer was dried over sodium sulfate, filtered and concentrated to give a brownish
oil which was purified by silica gel chromatography (12 g silica gel, 0-100%
EtOAc/Hexanes). Desired fractions were combined and concentrated to give the title
intermediate as an orange oil. (m/z): [M+H] calcd for C H F N O S 635.21 found
33 3 4 6
635.
(b) 4'-{2-[(2S,4S)Methanesulfinyl((S)methoxycarbonylaminomethyl-butyryl)-
pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-biphenylcarboxylic acid
The oily residue from the previous step was dissolved in a mixture of ACN (0.29
mL) and DMA (0.03 mL) and treated with N-chlorosuccinimide (74 mg, 0.55 mmol) at
65 °C for 1 h. The reaction mixture was cooled to RT and treated with saturated sodium
bicarbonate (3 mL), and extracted with EtOAc (5 mL). The organic layer was
concentrated, dissolved in a mixture of methanol (2 mL) and water (0.5 mL) and treated
with lithium hydroxide monohydrate (139 mg, 3.32 mmol) at 65 °C for 1 h, cooled to RT,
concentrated, dissolved in 1:1 acetic acid:water (6 mL) and purified by reverse phase
HPLC. Desired fractions were combined and freeze dried to provide the TFA salt of the
title intermediate (117 mg, 28 % yield) as a white solid. (m/z): [M+H] calcd for
C H F N O S 637.19 found 637.
29 31 3 4 7
Preparation 36: 4'-{2-[(2S,4S)Methanesulfonyl((S)
methoxycarbonylaminomethyl-butyryl)-pyrrolidinyl]-1H-imidazolyl}
trifluoromethoxy-biphenylcarboxylic acid
Potassium peroxymonosulfate sulfate (66 mg, 0.11 mmol) was added to a solution
of 4'-{2-[(2S,4S)methanesulfinyl((S)methoxycarbonylaminomethyl-butyryl)-
pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-biphenylcarboxylic acid TFA
(67 mg, 0.09 mmol; Preparation 35) in methanol (5 mL) and water (1 mL). The reaction
mixture was stirred at RT for 2 h, filtered, concentrated, dissolved in 1:1 acetic acid:water
(5 mL), filtered, and purified by reverse phase HPLC. Desired fractions were combined
and freeze dried to provide the TFA salt of the title intermediate (55 mg, 80 % yield).
(m/z): [M+H] calcd for C H F N O S 653.18 found 653.2.
29 31 3 4 8
Preparation 37: ((S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]
morpholinyl-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl
ester
(a) (2S,4R)(Toluenesulfonyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl
ester 2-methyl ester
To a solution of methyl (2S,4R)-N-tert-butoxycarbonylhydroxy
pyrrolidinecarboxylate (4.68 g, 19.1 mmol) in DCM (47 mL) at RT was added DIPEA
(3.66 mL, 21.0 mmol) and 4-dimethylaminopyridine (233 mg, 1.91 mmol) followed by p-
toluenesulfonyl chloride (3.82 g, 20.1 mmol). The reaction mixture was stirred at RT
overnight, washed with 1 N HCl (2 mL), saturated sodium bicarbonate (2 mL), and brine
(2 mL), dried over sodium sulfate, filtered and concentrated to give a yellowish oil, which
was purified by silica gel chromatography (80 g silica, 0-100% EtOAc/Hexanes). Desired
fractions were combined and concentrated to give the title intermediate (1.74 g, 23 %
yield) as a colorless oil.
(b) (2S,4S)Morpholinyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-
methyl ester
A mixture of the product of the previous step (908 mg, 2.27 mmol) and
morpholine (3.96 mL, 45.46 mmol) was heated at 70 °C overnight, concentrated by rotary
evaporation, dissolved in water (3 mL) and extracted with EtOAc (3 x 2 mL). The
aqueous layer was saturated with brine and 1 N aq NaOH (1 mL) was added. The aqueous
mixture was extracted with EtOAc (3 mL). Combined organic layers were dried over
sodium sulfate, filtered, and concentrated to give the title intermediate as a colorless oil.
(m/z): [M+H] calcd for C H N O 315.18 found 315.
26 2 5
(c) (2S,4S)Morpholinyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester
The product of the previous step was dissolved in methanol (3 mL) and water (1
mL) at RT and treated with lithium hydroxide monohydrate (191 mg, 4.55 mmol) for 30
min. The reaction mixture was concentrated, treated with EtOAc (3 mL) and acidified to
pH~6 with 2 N HCl. The aqueous layer was freeze dried to give the title intermediate as a
light brownish foam. (m/z): [M+H] calcd for C H N O 301.17 found 301.
14 24 2 5
(d) (2S,4S)Morpholinyl-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)
oxo-ethyl] ester 1-tert-butyl ester
The foam from the previous step was treated with DCM (11.7 mL, 181.8 mmol)
and DIPEA (0.32 mL, 1.82 mmol) and then p-bromophenacyl bromide (505 mg, 1.82
mmol) was added. The resulting mixture was heated at 35 °C for 1 h and concentrated to
give the title compound as a yellowish solid. (m/z): [M+H] calcd for C H BrN O
22 29 2 6
497.12. 499.12 found 499.
(e) (2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]morpholinyl-pyrrolidine
carboxylic acid tert-butyl ester
The solid from the previous step was mixed with ammonium acetate (2.80 g,
36.36 mmol) and DIPEA (0.48 mL, 2.73 mmol) in toluene (55 mL) and the reaction
mixture was heated at 110 °C overnight, cooled to RT, and concentrated. The resulting
residue was purified by silica gel chromatography (12 g silica gel, 0-100%
EtOAc/Hexanes). Desired fractions were combined and concentated to give the title
intermediate (133 mg, 15 % yield over steps (b) through (e)) as a brownish foam.
(m/z): [M+H] calcd for C H BrN O 477.14, 479.14 found 477.
22 29 4 3
(f) ((S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]morpholinyl-
pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
The product of the previous step (133 mg, 0.28 mmol) was treated with 4 M HCl
in 1,4-dioxane(2 mL) at RT for 30 min. The reaction mixture was concentrated, and
evaporated with EtOAc (3 x 2 mL) to give a brownish foam. The foam was dissolved in
DMF (2.5 mL) and treated with (S)methoxycarbonylaminomethyl-butyric acid (49
mg, 0.28 mmol) and HATU (106 mg, 0.28 mmol) at RT over the weekend. The reaction
mixture was diluted with EtOAc (5 mL) and washed with water (2 mL). The organic layer
was dried over sodium sulfate, filtered and concentrated to give a brownish oil, which
was purified by silica gel chromatography (4 g silica gel, 0-100% EtOAc/Hexanes then
10% MeOH/EtOAc, (3% Et N in MeOH)). Desired fractions were combined and
concentrated to give the title intermediate (57 mg, 38 % yield) as a yellowish oil.
(m/z): [M+H] calcd for C H BrN O 534.16, 536.16 found 534.
24 32 5 4
Preparation 38: (2S,4S)Cyano-pyrrolidine-1,2-dicarboxylic acid 1-tert-
butyl ester
(a) (2S,4R)Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
To a solution of (2S,4R)hydroxy-pyrrolidinecarboxylic acid methyl ester
HCl(10 g, 55.1 mmol ) in DCM ( 100 mL ) was added triethylamine (16.73 g,
165.3 mmol ) and di-tert-butyl dicarbonate (14.41 g, 66.1 mmol ). The reaction mixture
was stirred at RT overnight, concentrated, and purified by column chromatography (3:1
petroleum ether: EtOAc) to give the title intermediate (12 g, 89 % yield) H NMR (400
MHz, CDCl ): δ(ppm) 4.48 (m, 1H), 4.38 (m, 1H), 3.72 (s, 3H), 3.63 (m, 1 H), 3.45 (m,
1H), 2.29 (m, 1 H), 2.06 (m, 2 H), 1.39 (s, 9H).
(b) (2S,4R)Methanesulfonyloxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-
methyl ester
To the product of the previous step (12 g, 48.9 mmol) dissolved in dry DCM
(100 mL) was added triethylamine (14.87 g, 147 mmol) in an ice bath and then
methanesulfonyl chloride (6.72 g, 58.7 mmol) was added dropwise. The reaction mixture
was stirred at 0 ℃ for 1 h, poured into ice water, and extracted with DCM (3 x). The
combined organic layers were washed with NaHCO , water and brine, dried over Na SO ,
3 2 4
and concentrated to give the title intermediate (15 g). (m/z): [M+H-100] calcd for
C12H21NO7S 224.10 found 224.
(c) (2S,4S)Cyano-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester
A mixture of the product of the previous step (15 g, 46.4 mmol) and sodium
cyanide (22.74 g, 464 mmol) was stirred in DMSO (200 mL), heated at 55 °C for 3 days
under nitrogen, cooled to RT, and poured into ice water. The mixture was extracted with
EtOAc (3 x) and the combined organic extracts were washed three times with water and
brine, dried over Na SO , and concentrated. The residue was purified by column
chromatography (3:1 petroleum ether:EtOAc)to give the title intermediate (3 g, 25 %
yield). H NMR (400 MHz, CDCl ): δ(ppm) 4.38 (m, 1H), 3.93 (m, 1H), 3.73 (s, 3H),
3.65 (m, 1H), 3.08 (m, 1H), 2.24-2.70 (m, 2 H), 1.45 (m, 9H).
(d) (2S,4S)Cyano-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester
To a solution of the product of the previous step (3 g, 11.8 mmol) in methanol
(50 mL) was added an aqueous solution of 4 M NaOH (5.9 mL). The mixture was stirred
at RT overnight under nitrogen and concentrated. The residue was adjusted to pH 2 with
1 M HCl and the aqueous solution was extracted with DCM (3 x 50 mL). The combined
organic phase was washed with brine, dried over Na SO , filtered and concentrated to
give the title intermediate (2 g). H NMR (400 MHz, CDCl ): δ(ppm) 9.45 (br, 1H),
4.33-4.52 (m, 1H), 3.59-3.98 (m, 2H), 3.13-3.30 (m, 1H), 2.36-2.74 (m, 2H), 1.49
(m, 9H).
Preparation 39: (3S,5S)[4-(4-Bromo-phenyl)-1H-imidazolyl]-
pyrrolidinecarbonitrile
(a) (2S,4S)Cyano-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)oxo-
ethyl] ester 1-tert-butyl ester
To a solution of the product of Preparation 38 (2 g, 8.3 mmol) in acetonitrile
(50 mL) was added DIPEA (3.22 g, 25.0 mmol) and 2-bromo(4-bromo-phenyl)-
ethanone (2.31 g, 8.3 mmol). The reaction mixture was stirred at RT overnight under
nitrogen. The reaction mixture was concentrated and the residue was dissolved in EtOAc
(30 mL) and water (30 mL). The aqueous layer was extracted with EtOAc (2 x 30 mL).
The combined organic layers were washed with water and brine, dried over Na SO ,
filtered, concentrated, and purified by column chromatography (10- 30% EtOAc in
petroleum ether) to give the title intermediate (900 mg, 25 % yield). (m/z): [M+H-100]
calcd for C H BrN O 337.06, 339.06 found 339.
19 21 2 6
(b) (2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]cyano-pyrrolidinecarboxylic
acid tert-butyl ester
To a solution of the product of the previous step (900 mg, 2.1 mmol) in toluene
(30 mL) was added ammonium acetate (3.21g, 41.2 mmol). The reaction mixture was
heated at reflux for 1.5 h under nitrogen. The mixture was concentrated and the residue
was dissolved in EtOAc (50 mL) and water (50 mL). The aqueous layer was extracted
with EtOAc (2 x 50 mL). The combined organic layers were dried over Na SO , filtered,
concentrated, and purified by column chromatography (10- 50% EtOAc in petroleum
ether) to give the title intermediate (400 mg, 46 % yield). (m/z): [M+H] calcd for
C H BrN O 417.09, 419.09 found 417.
19 21 4 2
(c) (3S,5S)[4-(4-Bromo-phenyl)-1H-imidazolyl]-pyrrolidinecarbonitrile
The product of the previous step (400 mg, 0.96 mmol) was dissolved in
HCl/dioxane (10 mL) and the mixture was stirred at RT for 1 h. The reaction mixture was
concentrated to give the HCl salt of the title intermediate (340 mg). (m/z): [M+H] calcd
for C H BrN O 317.03, 319.03 found 317, 319.
19 21 4 2
Preparation 40: [(S)((2S,4S)Cyano{4-[4-(4, 4,5,5-tetramethyl-
[1,3,2]dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)
methyl-propyl]-carbamic acid methyl ester
(a) ((S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]cyano-pyrrolidine
carbonyl}methyl-propyl)- carbamic acid methyl ester
The product of Preparation 39 (340 mg, 0.96 mmol) was dissolved in DCM
(20 mL) and DIPEA (620 mg, 4.80 mmol) was added followed by 2-
methoxycarbonylaminomethyl-butyric acid (168 mg, 0.96 mmol) and HATU (365 mg,
0.96 mmol). The reaction mixture was stirred at RT for 1 h under nitrogen, diluted with
DCM, and washed with aqueous bicarbonate solution, water (30 mL), and brine (30 mL),
dried over Na SO , filtered, concentrated and purified by column chromatography (30-
100 % EtOAc in petroleum ether) to give the title intermediate (350 mg, 77 % yield).
(m/z): [M+H] calcd for C H BrN O 474.11, 476.11 found 474, 476.
21 24 5 3
(b) [(S)((2S,4S)Cyano{4-[4-(4, 4,5,5-tetramethyl-[1,3,2]dioxaborolanyl)-
phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)methyl-propyl]-carbamic acid
methyl ester
To a solution of ((S){(2S,4S)[4-(4-bromo-phenyl)-1H-imidazolyl]
cyano-pyrrolidinecarbonyl}methyl-propyl)- carbamic acid methyl ester (450 mg,
0.95 mmol), bis(pinacolato)diboron (362 mg, 1.42 mmol), and potassium acetate
(186 mg, 1.90 mmol) in dioxane (20 mL) was added Pd(dppf)Cl -CH Cl (78 mg,
2 2 2
0.095 mmol) and the mixture was degassed with nitrogen and heated at reflux overnight
under nitrogen. The cooled mixture was filtered through Celite® and washed with
EtOAc. The filtrate was washed with water and brine, dried over Na SO , filtered,
concentrated, and purified by column chromatography (20-100 % EtOAc in petroleum
ether) to give the title intermediate (320 mg, 65 % yield). (m/z): [M+H] calcd for
C H BN O 522.28 found 522. H NMR (400 MHz, MeOD): δ(ppm) 7.72 (m, 2H), 7.64
27 36 5 5
(m, 2H), 7.36 (s, 1H), 5.14 (m, 1H), 4.60 (m, 1H), 4.11 (m, 1H), 3.99 (m, 1H), 3.63 (s,
3H), 3.45 (m, 1H), 2.85 (m, 1H), 2.52 (m, 1H), 2.00 (m, 1H), 1.34 (s, 12H), 0.84 (m, 6H).
Preparation 41: (2S,5S)Methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-
butyl ester
N OH
(a) (S)tert-Butoxycarbonylaminooxo-hexanoic acid ethyl ester
A solution of (S)oxo-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl
ester (20 g, 10 mmol) in dry THF (150 mL) was cooled to -50 °C, and then
methylmagnesium bromide (31 mL, 93.28 mmol) was added dropwise at a temperature
between -50 and -44 °C in 30 min. The reaction mixture was stirred at -43 °C for 2 h and
placed in a freezer (ca. -20 °C) overnight. The mixture was quenched with sat. NH Cl
solution and extracted with EtOAc. The combined organic layers were dried over
Na SO , filtered and concentrated under reduced pressure to give the crude product,
which was purified by column chromatography (8:1-3:1 petroleum ether:EtOAc) to give
the title intermediate (38 g) as light yellow oil. H NMR (400 MHz, CDCl ): δ(ppm)
.11-5.09 (m, 1H), 4.25-4.24 (m, 1H), 4.19 (q, J = 7.2 Hz, 2H), 2.63-2.52 (m, 2H), 2.15
(s, 3H), 2.12-2.08 (m, 1H), 1.92-1.82 (m, 1H), 1.44 (s, 9H), 1.28 (t, J = 7.2 Hz, 3H).
(b) (S)Methyl-3,4-dihydro-2H-pyrrolecarboxylic acid ethyl ester
To a solution of the product of the previous step (5 g, 18.29 mmol) in dry DCM
(10 mL) was added TFA (7.5 mL) and the reaction mixture was stirred at ambient
temperature for 3 h. The mixture was concentrated to give the title intermediate (7 g). H
NMR (400 MHz, CDCl ): δ(ppm) 5.14-5.09 (m, 1H), 4.29-4.25 (m, 2H), 3.21-3.17 (m,
2H), 2.77-2.69 (m, 1H), 2.62 (s, 3H), 2.49-2.41 (m, 1H), 1.32-1.29 (m, 3H).
(c) (2S,5S)Methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester
The product of the previous step (4 g) was dissolved in ethanol (40 mL) and 10 %
Pd/C (400 mg) was added. The reaction mixture was stirred at 35 °C under 55 psi of
hydrogen overnight. After filtration, the filtrate was concentrated under reduced pressure
to give 2.62 g of crude product, which was added to a mixture of triethylamine (4.6 mL)
and 4-dimethylaminopyridine (DMAP) (102 mg, 0.83 mmol) in dry DCM (10 mL).
Then, di-tert-butyl dicarbonate (4 g, 18.33 mmol) was added and the reaction mixture was
stirred at RT overnight. The reaction mixture was washed with 1 N HCl solution and
brine. The organic layer was dried over Na SO , filtered and concentrated under reduced
pressure to give the residue, which was purified by column chromatography (8:1-3:1
petroleum ether:EtOAc) to give the title intermediate (2 g) as a colorless oil. H NMR
(400 MHz, CDCl ): δ(ppm) 4.53-4.50 (m, 1H), 4.30 (q, J = 7.2 Hz, 1H), 3.93-3.87 (m,
1H), 2.52-2.42 (m, 1H), 2.31-2.19 (m, 2H), 1.71-1.60 (m, 1H), 1.52-1.50 (m, 3H), 1.32 (t,
J = 7.2 Hz, 3H).
(d) (2S,5S)Methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester
A mixture of the product of the previous step (2 g, 7.77 mmol) and lithium
hydroxide (466 mg, 23.3 mmol) in 3:1 methanol:water (24 mL) was stirred at RT
overnight, and concentrated. The residue was dissolved in water and extracted with
EtOAc (2 x 20 mL). The aqueous layer was adjusted to pH 2 with 1 N HCl and extracted
with 3:1 DCM:methanol (3 x 24 mL) to give the title intermediate (1.7 g) as a white
crystal.
Preparation 42: 4-(4-Bromo-phenyl)((2S,5S)methyl-pyrrolidinyl)-1H-
imidazole
(a) (2S,5S)Methyl-pyrrolidine-1,2-dicarboxylic acid 2-[2-(4-bromo-phenyl)oxo-
ethyl] ester 1-tert-butyl ester
A mixture of the product of Preparation 41 (1.7 g, 7.41 mmol), 2-bromo(4-
bromo-phenyl)-ethanone (2.08 g, 7.49 mmol) and DIPEA (2.87 g, 22.23 mmol) in ACN
(50 mL) was stirred under nitrogen at RT for 2 h. The reaction mixture was concentrated
under reduced pressure to give the title intermediate (3.16 g).
(b) (2S,5S)[4-(4-Bromo-phenyl)-1H-imidazolyl]methyl-pyrrolidinecarboxylic
acid tert-butyl ester
A mixture of the product of the previous step (3.16 g, 7.41 mmol) and ammonium
acetate (17 g, 222.3 mmol) in toluene (50 mL) was refluxed under nitrogen overnight.
The reaction mixture was washed with water and extracted with EtOAc. The combined
organic layers were dried over Na SO , filtered and concentrated under reduced pressure
to give the residue, which was purified by column chromatography (10:1-5:1 petroleum
ether:EtOAc) to give the title intermediate (3.06 g) as a solid.
(c) 4-(4-Bromo-phenyl)((2S,5S)methyl-pyrrolidinyl)-1H-imidazole
The product of the previous step (3.06 g, 7.53 mmol) was dissolved in EtOAc (10
mL) and HCl/dioxane solution (20 mL) was added slowly. The reaction mixture was
stirred at RT for 3 h, and concentrated under reduced pressure to give the residue, which
was partitioned between sat. NaHCO and DCM. The combined organic layers were dried
over Na SO , filtered and concentrated under reduced pressure to give the title
intermediate (2.5 g) as a solid.
Preparation 43: [(S)Methyl((2S,5S)methyl{4-[4-(4,4,5,5-
H-imidazolyl}-pyrrolidine
tetramethyl-[1,3,2] dioxaborolanyl)-phenyl]-1
carbonyl)-propyl]-carbamic acid methyl ester
(a) ((S){(2S,5S)[4-(4-Bromo-phenyl)-1H-imidazolyl]methyl-pyrrolidine
carbonyl}methyl-propyl) -carbamic acid methyl ester
A mixture of the product of Preparation 42 (2.5 g, 8.16 mmol), 2-
methoxycarbonyl-aminomethyl-butyric acid (1.72 g, 9.79 mmol), HATU (3.72 g, 9.79
mmol) and DIPEA (3.16 g, 24.48 mmol) in DCM (50 mL) was stirred at RT overnight.
The reaction mixture was washed with water and brine and extracted with EtOAc. The
combined organic layers were dried over Na SO , filtered, and concentrated under
reduced pressure to give the residue, which was purified by column chromatography (3:1-
1:1 petroleum ether:EtOAc) to give the title intermediate (1.5 g, 85 % purity) as a solid.
H NMR (400 MHz, CD OD): δ(ppm) 7.73-7.33 (m, 5H), 5.36 (m, 0.5H), 5.10-5.05 (m,
0.5H), 4.75-4.71 (m, 0.5H), 4.23-4.08 (m, 1H), 3.69-3.67 (m, 3H), 2.82-2.80 (m, 0.5H),
2.35-2.33 (m, 0.5H), 2.17-1.91 (m, 4H), 1.5-1.48 (m, 0.5H), 1.27-0.84 (m, 9H).
(b) [(S)Methyl((2S,5S)methyl{4-[4-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-
2-yl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)-propyl]-carbamic acid
methyl ester
A mixture of the product of the previous step (1.5 g, 3.24 mmol),
bis(pinacolato)diboron (988 mg, 3.89 mmol), potassium acetate (954 mg, 9.72 mmol) and
Pd(dppf)Cl (150 mg) in dioxane (50 mL) was refluxed under nitrogen for 3 h. The
reaction mixture was concentrated under reduced pressure to give the residue, which was
partitioned between water and EtOAc. The combined organic layers were washed with
brine, dried over Na SO , filtered, and concentrated under reduced pressure to give the
residue, which was purified by column chromatography to give the title intermediate
(1.1 g). (m/z): [M+H] calcd for C H BN O 511.3 found 511.3. H NMR (400 MHz,
27 39 4 5
CDCl ): δ(ppm) 7.78 (s, 4H), 7.44-7.38 (m, 1H), 5.52-5.45 (m, 1H), 5.3-5.18 (m, 1H),
4.23-4.20 (m, 1H), 3.79-3.68 (m, 3H), 2.39-1.50 (m, 5H), 1.35-1.29 (m, 12H), 1.27-0.78
(m, 9H).
Preparation 44: (R)chloro(6-(2-methylpivaloylpiperazin
yl)nicotinamido)(trifluoromethoxy)phenylboronic acid
Under an atmosphere of nitrogen, a mixture of N-(4-bromochloro
trifluoromethoxy-phenyl)[(R)(2,2-dimethyl-propionyl)methyl-piperazinyl]-
nicotinamide (20.0 g, 34.6 mmol) and tetrahydrofuran (200 mL) was cooled to 0 °C and
then 1.3 M isopropylmagnesium chloride lithium chloride complex in tetrahydrofuran
(79.9 mL, 104 mmol) was added dropwise at 0-10 °C. After 2.5 h, boric acid, trimethyl
ester (12.0 mL, 106 mmol) was added dropwise, and then 1 N HCl (105 mL) was added
and the reaction mixture was stirred overnight. The reaction mixture was extracted with
EtOAc (250 mL); the organic layer was washed with water, sat. aq. NaHCO , dried over
MgSO , and evaporated to give crude product (22.8 g). To the crude product was added
ethanol (230 mL) and then slowly water (57.5 mL). The resulting mixture was stirred for
days and filtered to give the title intermediate as a crystalline solid (10.7 g, 57 %
yield).
A powder x-ray diffraction pattern of a crystalline sample of (R)chloro(6-(2-
methylpivaloylpiperazinyl)nicotinamido)(trifluoromethoxy)phenylboronic acid
prepared by the above process is shown in the Figure. The pattern was obtained with a
Thermo ARL X’Tra X-ray diffractometer using Cu-K α radiation ( λ = 1.54051 Å) with
output voltage of 45 kV and current of 40 mA. The sample was scanned in 2 θ-2 θ mode
from 2° to 40° in 2 θ with a step size of 0.03° and a scan speed of 2.0° per minute.
Observed PXRD two-theta peak positions and d-spacings are given in the following table
(only peaks having a relative peak height (H%) of about 8 % or greater are listed).
2-Theta d(Å) Height H%
4.77 18.51 1579 100.0
6.66 13.26 513 32.5
13.24 6.68 323 20.5
14.23 6.22 140 8.8
14.92 5.93 314 19.9
.58 5.68 419 26.5
16.93 5.23 617 39.1
18.57 4.77 291 18.4
19.47 4.56 183 11.6
.21 4.39 137 8.7
23.63 3.76 191 12.1
24.06 3.70 126 8.0
24.91 3.57 147 9.3
.76 3.46 529 33.5
27.84 3.20 165 10.5
31.36 2.85 137 8.7
Preparation 45: [(S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]
methyl-pyrrolidinyl}oxo(tetrahydropyranyl)-ethyl]-carbamic acid methyl
ester
(a) 4-(4-Bromo-phenyl)((2S,4S)methyl-pyrrolidinyl)-1H-imidazole
(2S,4S)[4-(4-bromo-phenyl)- 1H-imidazolyl]methyl-pyrrolidine
carboxylic acid tert-butyl ester (0.65 g, 1.6 mmol) was treated with 4 M HCl in 1,4-
dioxane (4 mL, 20 mmol) at 50 C for 1 h. The reaction mixture was concentrated and
dissolved in ethyl acetate and evaporated with ethyl acetate (2 x) to produce the HCl salt
of the title intermediate as a yellow solid.
(b) [(S){(2S,4S)[4-(4-Bromo-phenyl)-1H-imidazolyl]methyl-pyrrolidinyl}-
2-oxo(tetrahydropyranyl)-ethyl]-carbamic acid methyl ester
The yellow solid from the previous step was dissolved in DMA (3 mL) and
DIPEA (1.4 mL, 8.0 mmol) was added. A solution of 0.5 M (S)-methoxycarbonylamino-
(tetrahydro-pyranyl)-acetic acid in DMA (4.0 mL, 2.0 mmol) and HATU (760 mg, 2.0
mmol) were added. The reaction mixture was stirred at RT for 1 h, dissolved in ethyl
acetate (100 mL) and washed with water (300 mL). The aqueous layer was extracted with
ethyl acetate (100 mL). The combined organic layer was washed with brine, dried over
sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (0-100%
ethyl acetate:hexanes) to produce the title intermediate as a light colored solid. (760 mg,
94 % yield). (m/z): [M+H] calcd for C H BrN O 505.14, 507.14 found 506.95.
23 29 4 4
Preparation 46: [(S)((2S,4S)Methyl{4-[4-(4,4,5,5-tetramethyl-1,3,2-
H-imidazolyl}-pyrrolidinyl)oxo(tetrahydro-
dioxaborolanyl)-phenyl]-1
pyranyl)-ethyl]-carbamic acid methyl ester
The product of Preparation 45 (760 mg, 1.5 mmol), bis(pinacolato)diboron (570
mg, 2.2 mmol) and potassium acetate (220 mg, 2.2 mmol) were mixed with 1,4-dioxane
(5 mL). The resulting suspension was sparged under nitrogen and then
Pd(dppf)Cl CH Cl (61 mg, 0.075 mmol) was added. The reaction mixture was heated at
2 2 2
100 C overnight, cooled to RT and filtered through a stacked pad of silica gel and
Celite®. The pad was washed with EtOAc (180 mL). The filtrate was concentrated to
give a black oil which was purified by silica gel chromatography (24 g silica gel
disposable column, eluted with 0-100% EtOAc:hexanes). Desired fractions were
combined and concentrated to give the title intermediate (544 mg, 65 % yield) as a
yellowish foam. (m/z): [M+H] calcd for corresponding boronic acid C H BN O
23 31 4 6
471.23 found 471.05.
Preparation 47: (R)(5-Amino-pyridinyl)methyl-piperazine
carboxylic acid tert-butyl ester
H N N
(a) (R)Methyl(5-nitropyridinyl)-piperazinecarboxylic acid tert-butyl ester
A mixture of 2-chloronitropyridine (1.0 g, 6.3 mmol), (R)methyl-piperazine-
1-carboxylic acid tert-butyl ester (1.26 g, 6.31 mmol), and potassium carbonate (2.18 g,
.77 mmol) was stirred in DMSO (5 mL) at 120 C overnight. The reaction mixture was
concentrated under rotary evaporation and mixed with water (50 mL). The resulting
precipitate was filtered, washed with water (3 x 10 mL) and air-dried to provide the title
intermediate.
(b) (R)(5-Amino-pyridinyl)methyl-piperazinecarboxylic acid tert-butyl ester
A solution of the product of the previous step in methanol (150 mL) was degassed
several times, then palladium hydroxide on carbon (20 weight %, 200 mg, 0.29 mmol)
was added, and resulting mixture was degassed, hydrogenated overnight under a balloon
of hydrogen, degassed again, and filtered thru Celite®. The filter pad was washed with
methanol (3 x 5 mL). The filtrate was concentrated and purified by silica gel
chromatography (20-80 % EtOAc:hexanes) to provide the title intermediate (1514 mg; 82
% yield). (m/z): [M+H] calcd for C15H24N4O2 293.19 found 293.1.
Preparation 48: 4-Bromochlorotrifluoromethoxy-benzoic acid methyl
ester
(a) 2-Chlorotrifluoromethoxy-benzoic acid methyl ester
A mixture of 2-bromochlorotrifluoromethoxy-benzene (5 g, 18.2 mmol),
triethylamine (5.51 g, 54.5 mmol), and Pd(dppf)Cl (1.33 g, 1.82 mmol) in methanol (200
mL) was stirred at 80 °C under carbon monoxide (50 Psi) overnight, filtered, and
concentrated under vacuum. The residue was purified by silica gel chromatography (5 %
EtOAc in petroleum ether) to give the title intermediate as a colorless liquid (3.4 g, 74 %
yield).
(b) (2-Chlorotrifluoromethoxy-phenyl)-methanol
To a solution of the product of the previous step (2.9 g, 11.4 mmol) in THF (30
mL) was added NaBH (2.59 g, 68.3 mmol). The resulting mixture was stirred for 15 min
at 70 C, methanol (10 mL) was then added dropwise during 0.5h and the mixture was
stirred for 2 h at 70 C. The reaction mixture was cooled to RT, and quenched with sat.
NH Cl. The organic layer was separated and the aqueous layer was extracted with EtOAc.
The combined organics were dried over sodium sulfate, filtered, and concentrated to give
the title intermediate. (2.3 g, 98 % yield). (m/z): [M-OH] calcd for C H ClF O 209.0
8 6 3 2
found 209.0
(c) (4-Bromochlorotrifluoromethoxy-phenyl)-methanol
To a solution of (2-chlorotrifluoromethoxy-phenyl)-methanol (16.3 g, 71.94
mmol) in sulfuric acid (200 mL) and water (60 mL) was added bromine (12.65 g, 79.13
mmol), followed by silver sulfate (12.34 g, 39.57 mmol). The reaction mixture was stirred
at RT for 1 h, poured onto ice, and then extracted with EtOAc (3 x 100 mL). The organic
layers were combined, dried over Na SO and concentrated to afford crude product,
which was purified by flash chromatography (0-10% EtOAc in petroleum ether) to give
the title intermediate (6.0 g, 27 % yield). (m/z): [M-OH] calcd for C H BrClF O
8 5 3 2
286.91, 288.91 found 289.0.
(d) 4-Bromochlorotrifluoromethoxy-benzoic acid methyl ester
To a solution of (4-bromochlorotrifluoromethoxy-phenyl)-methanol (6.6 g,
21.61 mmol) in methanol (70 mL) was added 2-methyl-propyl-hydroperoxide (14.4
mL, 86.42 mmol), and potassium iodide (0.72 g, 4.32 mmol), The reaction mixture was
stirred under reflux for 48 h and sat. sodium thiosulfate (20 mL) was added. The reaction
mixture was concentrated and extracted with EtOAc (3 x 100 mL). The organic layers
were combined, washed with brine, dried over sodium sulfate, concentrated , and purified
by HPLC to provide the title intermediate (2.86 g, 39 % yield). (m/z): [M+H] calcd for
C H BrClF O 332.91, 334.91 found 332.9, 334.9. H NMR (400 MHz, CDCl ): δ(ppm)
9 5 3 3 3
7.79 (s, 1H), 7.77 (s, 1H), 3.94 (s, 3H).
Preparation 49: (R)[5-(4-Bromochlorotrifluoromethoxy-
benzoylamino)-pyridinyl]methyl-piperazinecarboxylic acid tert-butyl ester
(a) 4-Bromochlorotrifluoromethoxy-benzoic acid
To a mixture of 4-bromochlorotrifluoromethoxy-benzoic acid methyl ester
(1.0 g, 3.0 mmol, Preparation 48) dissolved in methanol (4 mL) and water (4 mL) was
added lithium hydroxide (360 mg, 15 mmol). The reaction mixture was stirred at at 60 C
for 1 h and concentrated. The reaction mixture was adjusted to acidic pH with 1 N HCl,
dissolved in EtOAc (60 mL) and washed with water (60 mL). The aqueous layer was
extracted with EtOAc (60 mL). The combined organic layers were washed with brine,
dried over sodium sulfate, filtered, and concentrated to produce the title intermediate (966
mg, 100 % yield) as a white powder.
(b) (R)[5-(4-Bromochlorotrifluoromethoxy-benzoylamino)-pyridinyl]
methyl-piperazinecarboxylic acid tert-butyl ester
The white powder from the previous step (300 mg) was dissolved in DMF (2.5
mL) and HATU (480 mg, 1.3 mmol) was added, followed by DIPEA (550 µL, 3.2 mmol)
and 0.5 M (R)(5-amino-pyridinyl)methyl-piperazinecarboxylic acid tert-butyl
ester in DMA (2.1 mL, 1.0 mmol; Preparation 47) The reaction mixture was stirred at
room temperature overnight, dissolved in EtOAc (60 mL) and washed with water
(120 mL). The aqueous layer was extracted with EtOAc (60 mL). The combined organic
layer was washed with brine (60 mL), isolated and dried over sodium sulfate, filtered,
concentrated, and purified by silica gel chromatography (40 g silica, 0-40% ethyl
acetate:hexanes) to produce the title intermediate (491mg, 80% yield) as a colored solid.
(m/z): [M+H] calcd for C H BrClF N O 593.07, 595.07 found 595.0.
23 25 3 4 4
Preparation 50: 4-bromochloro(trifluoromethoxy) benzoic acid
(a) 4-Aminotrifluoromethoxybenzoic acid methyl ester
A mixture of 4-amino(trifluoromethoxy)benzoic acid (5.0 g, 22.61 mmol),
methanol (75 mL) and 4.0 M HCl in 1,4-dioxane(56.53 mL, 226.1 mmol) was stirred at
RT for 2 days. The reaction mixture was concentrated and the resulting residue was
coevaporated with EtOAc (3 x 20 mL), and further dried under vacuum to give the HCl
salt of the title intermediate as an off-white solid (6.9 g). Structure confirmed by NMR.
(b) 4-Aminochlorotrifluoromethoxy-benzoic acidmethyl ester
The product of the previous step (200.0 mg, 0.74 mmol) was dissolved in a
mixture of ACN (9.44 mL) and DMA (0.944 mL) at RT. To this stirred solution was
added N-chlorosuccinimide (108.2 mg, 0.81 mmol). The resulting mixture was heated at
60 °C for 1 h, cooled to RT and partitioned between EtOAc (20 mL) and saturated
sodium bicarbonate (4 mL). The organic layer was washed with saturated sodium
bicarbonate (4 mL) and brine (4 mL), dried over sodium sulfate, filtered, and
concentrated to give a yellowish oil, which was purified by silica gel chromatography (12
g silica gel, 0-40% EtOAc/hexanes) to give the title intermediate as a white solid
(173.8 mg, 88 % yield). Structure confirmed by NMR.
(c) 4-Bromochlorotrifluoromethoxy-benzoic acidmethyl ester
To a solution of the product of the previou step (173.8 mg, 0.65 mmol) in a
mixture of ACN (7.74 mL) and water (0.80 mL) at RT was added copper(II) bromide
(198.7 mg, 0.89 mmol) followed by tert-butyl nitrite (0.13 mL, 1.11 mmol) dropwise. The
resulting mixture was heated at 60 C for 1 h. The reaction mixture was cooled to RT and
partitioned between EtOAc (10 mL) and water (2 mL). The organic layer was washed
with water (4 mL), brine (4 mL), dried over sodium sulfate, filtered, and concentrated to
give a brownish oil which was purified by silica gel chromatography (12 g silica gel, 0-
% EtOAc/hexanes) to give the title intermediate as a white solid (163.7 mg, 76 %
yield). Structure confirmed by NMR.
(d) 4-bromochloro(trifluoromethoxy) benzoic acid
The product of the previous step (75.6 mg, 0.23 mmol) was dissolved in a mixture
of methanol (0.7 mL) and water (0.2 mL) and treated with lithium hydroxide (21.7 mg,
0.91 mmol) at 75 °C for 30min. The reaction mixture was concentrated, diluted with
water (3 mL), then acidified to pH~1 with 1 N HCl, and extracted with EtOAc (5 mL).
The organic layer was washed with water (2 mL) and brine (2 mL), dried over sodium
sulfate, filtered and concentrated to give a white solid, which was used directly in
Preparation 51.
Preparation 51: (R)bromochloro-N-(6-(2-methylpivaloylpiperazin
yl)pyridinyl)(trifluoromethoxy)benzamide
(a) (R)-tert-butyl 4-(5-(4-bromochloro (trifluoromethoxy)benzamido)pyridinyl)-
3-methylpiperazinecarboxylate
To a mixture of (R)-tert-butyl 4-(5-aminopyridinyl)methylpiperazine
carboxylate (59.9 mg, 0.21 mmol) and 4-bromochloro(trifluoromethoxy)benzoic
acid (65.5 mg, 0.21 mmol; Preparation 50) in DMA (0.5 mL) at RT was added HATU
(86 mg, 0.23 mmol) followed by DIPEA (0.11 mL, 0.62 mmol). The reaction mixture
was stirred at RT for 1 h, partitioned between EtOAc (10 mL) and water (2 mL). The
organic layer was washed with water (2 mL), dried over sodium sulfate, filtered and
concentrated to give the title intermediate as a dark purplish oil. (m/z): [M+H] calcd for
C H BrClF N O 593.07, 595.07 found 595.
23 25 3 4 4
(b) (R)bromochloro-N-(6-(2-methylpiperazinyl)pyridinyl)
(trifluoromethoxy)-benzamide
To the oily residue from the previous step (122 mg, 0.21 mmol) was added 4 N
HCl in dioxane (0.51 mL, 2.05 mmol). The reaction mixture was held at RT overnight,
concentrated, evaporated with EtOAc (3 x 2.0 mL), and dried under vacuum to give the
di-HCl salt of the title intermediate as a purplish solid. (m/z): [M+H] calcd for
C H BrClF N O 493.02, 495.02 found 495.
18 17 3 4 2
(c) (R)bromochloro-N-(6-(2-methylpivaloylpiperazinyl)pyridinyl)
(trifluoromethoxy)benzamide
The product of the previous step (116 mg, 0.21 mmol) was dissolved in a mixture
of DCM (2 mL) and DIPEA (0.14 mL, 0.82 mmol) at RT. Pivaloyl chloride (24.7 mg,
0.21 mmol) was added. The reaction mixture was stirred at RT for 10 min and then
purified by silica gel chromatography (12 g silica gel, 0-40% EtOAc/hexanes) to give the
title intermediate (80.3 mg, 68 % yield) as a light yellowish solid. (m/z): [M+H] calcd
for C H BrClF N O 577.08, 579.07 found 579.
18 17 3 4 2
Preparation 52: 4-bromofluoro(trifluoromethoxy)benzoic acid
(a) 4-bromofluoro(trifluoromethoxy)aniline
To a solution of 2-fluoro(trifluoromethoxy)aniline (1.0 g, 5.13 mmol)
dissolved in DMF (2 mL) at 0°C was slowly added a solution of cold N-
bromosuccinimide (0.91 g, 5.13 mmol) dissolved in DMF (6 mL) over 5 min. The
reaction mixure was stirred at 0 °C for 1 h, extracted with EtOAc (125 mL) and washed
with water (3 x 25 mL). The combined aqueous layers were extracted with EtOAc (75
mL). The combined organic layers were washed with brine (25 mL), dried over sodium
sulfate, filtered, and concentrated to produce the title compound as a dark colored liquid
(1.27 g, 90 % yield). (m/z): [M+H] calcd for C H BrF NO 273.94 found 273.8.
7 4 4
(b) 4-bromofluoro(trifluoromethoxy)benzonitrile
A mixture of water (3 mL) and sulfuric acid (0.59 mL) was cooled to 10 °C and
the product of the previous step (1.27 g, 4.62 mmol) was added and stirred for 30 min at
less than 15 °C. The mixture was cooled to below 3 °C, a solution of sodium nitrite (0.36
g, 5.22 mmol) in water (0.75 mL) was added, keeping the temperature below 3°C and the
reaction mixture was stirred for 45 min. The reaction mixture was added to a hot slurry
(80°C) of sodium carbonate (1.35 g, 12.75 mmol), copper(I) cyanide (0.42 g, 4.71 mmol)
and sodium cyanide (0.36 g, 7.39 mmol) in water (3.27 mL) and the reaction mixture was
heated at 65 °C for 2 h. Hexanes (80 mL) was added and the aqueous phase was extracted
with hexanes (2 x 60 mL). The combined organic layer was washed with brine, dried over
sodium sulfate, filtered, concentrated, and purified by silica gel chromatography (0-5%
EtOAc:hexanes over 40 min). Fractions 33-39 were combined and concentrated to
provide the title compound (258.6 mg, 20 % yield) .
(c) 4-bromofluoro(trifluoromethoxy)benzoic acid
To a solution of the product of the previous step (258.6 mg, 0.91 mmol) in
dioxane (2 mL) was added water (0.8 mL) and sulfuric acid (1.2 mL). The reaction
mixture was heated at 110 °C overnight, and extracted with DCM (80 mL) and water (20
mL). The aqueous layer was extracted with DCM (2 x 30 mL). The combined organic
layer was washed with water (2 x 30 mL), then with brine (30 mL), dried over sodium
sulfate, and filtered, and concentrated to provide the title intermediate (275 mg) as a
colored solid. (m/z): [M+H] calcd for C H BrF O 302.92 found 302.8.
8 3 4 3
Preparation 53: (R)bromofluoro-N-(6-(2-methylpivaloylpiperazin
yl)pyridinyl)(trifluoromethoxy)benzamide
O F O
HN N
(a) (R)-tert-butyl 4-(5-(4-bromofluoro(trifluoromethoxy)benzamido)pyridinyl)-
3-methylpiperazinecarboxylate
To a solution of 4-bromofluoro(trifluoromethoxy)benzoic acid (150 mg,
0.50 mmol, Preparation 52), (R)-tert-butyl 4-(5-aminopyridinyl)methylpiperazine
carboxylate (145 mg, 0.50 mmol), and HATU (235 mg, 0.62 mmol) dissolved in DMF (1
mL) was added DIPEA (0.43 mL, 2.48 mmol). The reaction mixture was stirred at RT for
1 h, extracted with EtOAc (80 mL) washed with water (3 x 20 mL) and brine (20 mL),
dried over sodium sulfate, filtered, concentrated, and purified by silica gel
chromatography (12 g silica gel, 0-40% EtOAc:hexanes over 20 min), to provide the title
intermediate (203 mg, 71 % yield) as a yellow solid. (m/z): [M+H] calcd for
C H BrF N O 577.10, 579.10 found 579.0.
23 25 4 4 4
(b) (R)bromofluoro-N-(6-(2-methylpiperazinyl)pyridinyl)
(trifluoromethoxy)-benzamide
To the product of the previous step (203 mg, 0.35 mmol) was added 4.0 M HCl in
dioxane (3 mL) and the reaction mixture was stirred at RT for 1 h, concentrated and
evaporated with EtOAc (2 x) to produce the di-HCl salt of the title intermediate (189.3
mg, 98 % yield) as a yellow solid. (m/z): [M+H] calcd for C H BrF N O 477.05,
18 17 4 4 2
479.05 found 476.9.
(c) (R)bromofluoro-N-(6-(2-methylpivaloylpiperazinyl)pyridinyl)
(trifluoromethoxy)benzamide
To a solution of the product of the previous step (189.3 mg, 0.34 mmol) and
DIPEA (0.18 mL, 1.03 mmol) dissolved in DMF (1 mL) was added pivaloyl chloride
(0.042 mL 0.34 mmol) and the reaction mixture was stirred at RT overnight,
concentrated, and purified by silica gel chromatography (0-40% EtOAc:hexanes over 25
min), to provide the title intermediate (128.6 mg, 67 % yield) as a white solid.
(m/z): [M+H] calcd for C H BrF N O 561.10, 563.10 found 563.0.
23 25 4 4 3
Preparation 54: (2S,4S)-tert-butyl 2-(4-(4-bromophenyl)-1H-imidazolyl)
(methoxymethyl)pyrrolidinecarboxylate
(a) (S)tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate
To a solution of (2S,4R)tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-
dicarboxylate (40 g, 157 mmol) in DCM (500 mL) was added DMP (80 g, 189 mmol) at
0 °C and the reaction mixture was stirred at RT for 4 h, quenched with NaHSO , extracted
with DCM and washed with NaHCO . The organic phase was concentrated to provide
the title intermediate (33 g, 89 % yield) as a colorless oil. H NMR (400 MHz, CDCl ):
δ(ppm) 1.51 (s, 9H), 2.550-2.597 (d, 1H, J=18.8 Hz), 2.876-2.944 (t, 1H, J=13.6 Hz),
3.895 (s, 3H), 3.766-3.895 (m,1H), 4.696-4.814 (m, 1H).
(b) (S,E)tert-butyl 2-methyl 4-(methoxymethylene)pyrrolidine-1,2-dicarboxylate
Potassium carbonate (200 g, 2.17 mmol) was added to a solution of (S)tert-
butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate (88 g, 362 mmol) and dimethyl 1-
diazooxopropylphosphonate (200 g, 1.04 mol) in methanol (1 L) at 0 °C and the
reaction mixture was stirred at RT overnight, quenched, concentrated, poured into water,
extracted with DCM, and purified by column chromatography to provide the title
intermediate (18 g, 17 % yield) as a yellow oil. H NMR (400 MHz, CDCl ): δ(ppm)
1.406-1.457 (d, 9H, J=20.4 Hz), 2.502-2.520 (m, 1H), 2.601-2.631 (m, 1H), 2.720-2.782
(m, 1H), 3.578 (s, 3H), 3.707 (s, 3H), 3.952-3.983 (m, 1H), 4.302-4.375 (m, 1H), 4.471-
4.490(m, 1H), 5.810-5.968 (m, 1H).
(c) (2S,4S)tert-butyl 2-methyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate
A solution of (S,E)tert-butyl 2-methyl 4-(methoxymethylene)pyrrolidine-1,2-
dicarboxylate (9 g, 33.21 mmol), magnesium oxide (12 g, 33.21 mmol) and palladium on
carbon (3 g) in methanol (100 mL) was held under a steady flow of hydrogen at RT for 2
h, and filtered. The organic phase was concentrated to provide the title intermediate (9 g,
100 % yield) as a colorless oil. H NMR (400 MHz, (CD ) S=O): δ(ppm) 1.367 (s, 9H),
1.620-1.670 (m, 1H), 1.904-1.953 (m, 1H), 3.110-3.140 (s, 3H, J=12Hz), 3.255-3.360 (m,
2H), 3.523-3.561 (m, 1H), 3.653 (s, 3H), 4.241-4.283 (m, 1H).
(d) (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidinecarboxylic acid
A solution of (2S,4S)tert-butyl 2-methyl 4-(methoxymethyl)pyrrolidine-1,2-
dicarboxylate (18 g, 66.91 mmol) and lithium hydroxide (3.37 g, 80.3 mmol) in THF (50
mL), methanol (50 mL), and water (50 mL) was stirred at RT for 2 h. The reaction
mixture was adjusted to ph 6 and extracted with 10:1 DCM:methanol. The organic phase
was dried over sodium sulfate and concentrated to provide the title intermediate (17 g, 84
% yield) as a colorless oil). H NMR (400 MHz, CDCl ): δ(ppm) 1.398-1.451 (d, 9H,
J=21.2 Hz), 1.625-1.754 (m, 1H), 2.226-2.652 (m, 3H), 3.251-3.458 (m, 1H), 3.316 (s,
3H), 3.316-3.462 (m, 2H), 3.556-3.750 (m, 2H), 4.405-4.445 (m, 1H), 7.652(s, 1H).
(e) (2S,4S)(2-(4-bromophenyl)oxoethyl) 1-tert-butyl 4-
(methoxymethyl)pyrrolidine-1,2-dicarboxylate
To a solution of (2S,4S)(tert-butoxycarbonyl)(methoxymethyl)pyrrolidine
carboxylic acid (10 g, 38.61 mmol) in DCM (100 mL) was added (2-bromo(4-
bromophenyl)-ethanone (11.8 g, 42.47 mmol) and triethylamine (7.8 g, 77.22 mmol).
The reaction mixture was stirred at RT for 3 h. Water was added and the mixture was
extracted with EtOAc. The organic phase was dried over sodium sulfate, concentrated,
and purified by column chromatography to provide the title intermediate (12 g, 56 %
yield) as a colorless oil. H NMR (400 MHz, CDCl ): δ(ppm) 1.438-1.466 (d, 9H, J=11.2
Hz), 2.024-2.056 (t, 1H, J=12.8 Hz), 2.553 (s, 2H), 3.214-3.776 (m, 6H), 4.410-4.850 (t,
1H, J=15 Hz), 5.155-5.549 (m, 1H), 7.270-7.278 (t, 1H, J=1.6 Hz), 7.636-7.654 (d, 1H,
J=7.2 Hz), 7.765-7.774(d, 1H, J=3.6 Hz).
(f) (2S,4S)-tert-butyl 2-(4-(4-bromophenyl)-1H-imidazolyl)
(methoxymethyl)pyrrolidinecarboxylate
Ammonium acetate (77 g, 1 mol) was added to a solution of (2S,4S)(2-(4-
bromophenyl)oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate
(11 g, 25.11 mmol) in toluene (150 mL) and the reaction mixture was refluxed overnight
and concentrated. Water (50 mL) was added, the reaction mixture was adjusted to pH 8,
and extracted with EtOAc. The organic phase was dried over sodium sulfate,
concentrated, and purified by column chromatography to provide the title intermediate
(3 g, 31 % yield) as a white solid. H NMR (400 MHz, CDCl ) δ(ppm) 1.316-1.535 (m,
9H), 2.457-2.630 (m, 4H), 2.808 (d, 1H), 3.202-3.223 (d, 1H, J=8.4 Hz), 3.404-3.565 (m,
6H), 3.832-3.877(m, 1H), 5.019-5.054 (t, 1H, J=14 Hz), 7.056-7.592 (m, 6H).
Example 1: ((S){(2S,4S)[4-(5'-Chloro-4'-{[6-((2R,5S)-2,5-dimethyl
methylcarbamoyl-piperazinyl)-pyridinecarbonyl]-amino}-2'-trifluoromethoxy-
biphenylyl)-1H-imidazolyl]methyl-pyrrolidinecarbonyl}methyl-
propyl)-carbamic acid methyl ester
(a) ((S){(2S,4S)- 2-[4-(5'-Chloro-4'-{[6-((2R,5S)-2,5-dimethyl-piperazinyl)-
pyridinecarbonyl]-amino}-2'-trifluoromethoxy-biphenylyl)-1H-imidazolyl]-
4-methyl-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
To a solution of [(S)Methyl((2S,4S)methyl{4-[4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)-propyl]-
carbamic acid methyl ester (168 mg, 0.33 mmol) and (2S,5R)[5-(4-bromochloro
trifluoromethoxy-phenylcarbamoyl)-pyridinyl]-2,5-dimethyl-piperazinecarboxylic
acid tert-butyl ester (200 mg, 0.33 mmol) dissolved in toluene (2.1 mL) and water (0.36
mL) was added potassium carbonate (227 mg, 1.65 mmol). The reaction mixture was
sparged under nitrogen for 15 min. Tetrakis(triphenylphosphine)palladium(0) (45.6 mg,
0.039 mmol) was added and the reaction mixture was sparged with nitrogen and heated at
100 °C overnight. The reaction mixture was diluted with ethyl acetate and washed with
water and brine. The organic layer was dried over sodium sulfate, filtered and
concentrated to produce a brownish solid.
The solid from the previous step was treated with 4 M HCl in 1,4-dioxane
(2.5mL) and HCl (0.6 mL) and stirred at RT for 1 h. The reaction mixture was
concentrated, dissolved in 1:1 acetic acid:water (6 mL) and purified by reverse phase
HPLC. Fractions containing desired compound were combined and lyophilized to
produce the tri-TFA salt of the title intermediate (99 mg, 26 % yield) as a white powder.
(m/z): [M+H] calcd for C H ClF N O 811.32 found 811.0.
40 46 3 8 5
(b) ((S){(2S,4S)[4-(5'-Chloro-4'-{[6-((2R,5S)-2,5-dimethylmethylcarbamoyl-
piperazinyl)-pyridinecarbonyl]-amino}-2'-trifluoromethoxy-biphenylyl)-1H-
imidazolyl]methyl-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid
methyl ester
The product of the previous step was dissolved in DMA and 0.5 M
methylaminoformyl chloride in DMA (34.7 µL, 0.017 mmol) was added followed by
N,N-diisopropylethylamine (0.015 mL, 0.087 mmol) and the reaction mixture was stirred
at RT overnight, concetnrated by rotary evaporation, dissolved in 1:1 acetic acid:water
(1.5 mL) and purified by reverse phase HPLC to provide the di-TFA salt of the title
compound (15 mg, 79 % yield). (m/z): [M+H] calcd for C H ClF N O 868.35 found
42 49 3 9 6
868.6.
Example 2: [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(R)((S)-2,2-dimethyl-
cyclopropanecarbonyl)methyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-
trifluoromethoxy-biphenylyl]-1H-imidazolyl}methyl-pyrrolidine
carbonyl)methyl-propyl]-carbamic acid methyl ester
(a) ((S){(2S,4S)- 2-[4-(5'-Chloro-4'-{[6-((R)methyl-piperazinyl)-pyridine
carbonyl]-amino}-2'-trifluoromethoxy-biphenylyl)-1H-imidazolyl]methyl-
pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
Following the general procedure of Example 1(a) at the 0.30 mmol scale,
substituting (R)[5-(4-bromochlorotrifluoromethoxy-phenylcarbamoyl)-pyridin
yl]methyl-piperazinecarboxylic acid tert-butyl ester for (2S,5R)[5-(4-bromo
chlorotrifluoromethoxy-phenylcarbamoyl)-pyridinyl]-2,5-dimethyl-piperazine
carboxylic acid tert-butyl ester, with, alternative purification by evaporation with ethyl
acetate (2 x) the tri-HCl salt of the title intermediate was prepared (101 mg, 29 % yield).
(m/z): [M+H] calcd for C H ClF N O 797.31 found 797.
39 44 3 8 5
(b) [(S)((2S,4S){4-[5'-Chloro-4'- ({6-[(R)((S)-2,2-dimethyl-
cyclopropanecarbonyl)methyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-
methoxy-biphenylyl]-1H-imidazolyl}methyl-pyrrolidinecarbonyl)
methyl-propyl]-carbamic acid methyl ester
To a solution of 0.5 M (S)-(+)-2,2-dimethylcyclopropane carboxylic acid in DMA
(41.6 µL, 0.02 mmol) was added HATU (7.9 mg, 0.02). The reaction mixture was stirred
for 15 min and then the product of the previous step (20 mg, 0.02 mmol) was added
followed by N,N-diisopropylethylamine (0.015 mL, 0.09 mmol) and the reaction mixture
was stirred at 55 °C overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL)
and purified by reverse phase HPLC to provide the di-TFA salt of the title compound (16
mg, 78 % yield). (m/z): [M+H] calcd for C H ClF N O 893.37 found 893.6
45 52 3 8 6
Example 3: [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(2R,5S)(1H-imidazole
carbonyl)-2,5-dimethyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-
trifluoromethyl-biphenylyl]-1H-imidazolyl}methyl-pyrrolidinecarbonyl)-
2-methyl-propyl]-carbamic acid methyl ester
(a) ((S){(2S,4S)[4-(5'-Chloro-4'-{[6-((2R,5S)-2,5-dimethyl-piperazinyl)-
pyridinecarbonyl]-amino}-2'-trifluoromethyl-biphenylyl)-1H-imidazolyl]
methyl-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
Following the procedure of Example 1 at the 0.24 mmol scale, substituting
(2S,5R)[5-(4-Bromochlorotrifluoromethyl-phenylcarbamoyl)-pyridinyl]-2,5-
dimethyl-piperazinecarboxylic acid tert-butyl ester for (2S,5R)[5-(4-bromo
chlorotrifluoromethoxy-phenylcarbamoyl)-pyridinyl]-2,5-dimethyl-piperazine
carboxylic acid tert-butyl ester, the tri-TFA salt of the title intermediate was prepared
(116 mg, 54 % yield). (m/z): [M+H] calcd for C H ClF N O 795.33 found 795.4.
40 46 3 8 4
(b) [(S)((2S,4S){4-[5'-Chloro-4'- ({6-[(2R,5S)(1H-imidazolecarbonyl)-2,5-
dimethyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-trifluoromethyl-biphenyl
yl]-1H-imidazolyl}methyl-pyrrolidinecarbonyl)methyl-propyl]-carbamic
acid methyl ester
To a solution of the product of the previous step (12 mg, 0.013 mmol) and N,N-
diisopropylethylamine (23 µL, 0.13 mmol) dissolved in DMA (0.5 mL) was added
imidazolcarboxylic acid (1.5 mg, 0.013 mmol) and HATU (7.6 mg, 0.02 mmol) and
the reaction mixture was stirred at 50 °C for 2 hours, concentrated and dissolved in 1:1
acetic acid:water (1.5 mL) and purified by reverse phase HPLC to provide the tri-TFA
salt of the title compound (5 mg). (m/z): [M+H] calcd for C H ClF N O 889.35 found
44 48 3 10 5
889.6.
Example 4: Methyl (S)((S)(4-(4'-(6-((R)((S)-2,2-
dimethylcyclopropanecarbonyl)methylpiperazinyl)nicotinamido)-2'-
(trifluoromethoxy)biphenylyl)-1H-imidazolyl)-1,4-dioxaazaspiro[4.4]nonan-
7-yl)methyloxobutanylcarbamate
To a solution of ((S){(S)[4-(4'-Amino-2'-trifluoromethoxy-biphenylyl)-
1H-imidazolyl]-1,4-dioxaaza-spiro[4.4]nonanecarbonyl}methyl-propyl)-
carbamic acid methyl ester 2 HCl (92.0 mg, 0.136 mmol; Preparation 9) in DCM
(1.36 mL) and DMA (0.14 mL) at RT was added N,N-diisopropylethylamine (94.7 µL,
0.54 mmol) and 2-fluoropyridinecarbonyl chloride (228 mg, 0.143 mmol), The
reaction mixture was stirred for 30 min at RT and concentrated.
The residue from the previous step was dissolved in DMSO (2.0 mL) and treated
with (R)methyl-piperazinecarboxylic acid tert-butyl ester (136 mg, 0.680 mmol)
and N,N-diisopropylethylamine (0.237 mL, 1.36 mmol) at 120 °C overnight.
The reaction mixture was concentrated and treated with 4 M HCl in 1,4-Dioxane
(1.0 mL, 4.0 mmol) at RT for 30 min . The reaction mixture was concentrated, dissolved
in 1:1 acetic acid:water (6 mL), filtered and purified by reverse phase HPLC. Desired
fractions were combined and freeze dried to give a white solid (48 mg, 30 % yield).
To a mixture of (S)-(+)-2,2-dimethylcyclopropane carboxylic acid (1.75 mg,
0.015 mmol) in DMA (0.5 mL) at RT was added the product of the previous step (3-TFA
salt form) (16 mg, 0.014 mmol) and N,N-diisopropylethylamine (12.1 µL, 0.070 mmol)
and the reaction mixture was stirred at RT overnight, dissolved in 1:1 acetic acid:water
(1.5 mL), filtered and purified by reverse phase HPLC to provide the di-TFA salt of the
title compound (6 mg). (m/z): [M+H] calcd for C H F N O 903.39 found 904.0.
46 53 3 8 8
Example 5: (S){(R)[5-(4'-{2-[(2S,4S)Hydroxy((S)
methoxycarbonyl-aminomethyl-butyryl)-pyrrolidinyl]-1H-imidazolyl}-
biphenylylcarbamoyl)-pyridinyl]methyl-piperazinecarbonyl}methyl-
pyrrolidinecarboxylic acid methyl ester
(a) (S){(2S,4S)Hydroxy[4-(4'-{[6-((R)methyl-piperazinyl)-pyridine
carbonyl]-amino}-biphenylyl)-1H-imidazolyl]-pyrrolidinecarbonyl}
methyl-propyl)-carbamic acid methyl ester
A solution of (R)(5-carboxy-pyridinyl)methyl-piperazinecarboxylic
acid tert-butyl ester (130 mg, 0.42 mmol), EDC (120 mg, 0.63 mmol) and HOAt (86 mg,
0.63 mmol) dissolved in DMA (3.9 mL) was stirred at room temperature for 30 min and
then ((S){(2S,4S)[4-(4'-Amino-biphenylyl)-1H-imidazolyl]hydroxy-
pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester (200 mg,
0.40 mmol; Preparation 10) was added followed by N,N-diisopropylethylamine (0.18 mL,
1.0 mmol). The reaction mixture was stirred at RT over the weekend, and extracted with
EtOAc and water. The organic layer was dried over sodium sulfate, filtered and
evaporated under vacuum.
The brown oil from the previous step was treated with 4 M HCl in 1,4-dioxane
(3.1 mL) and HCl (1.15 mL) and stirred at room temperature for 1 h. The reaction
mixture was concentrated and evaporated with ethyl acetate (2 x) to produce a brown oil.
The oil was dissolved in 1:1 acetic acid:water (4 mL),filtered, and purified by reverse
phase HPLC to produce the tri-TFA salt of the desired product (276 mg). (m/z): [M+H]
calcd for C H N O 681.34 found 681.4.
37 44 8 5
(b) (S){(R)[5-(4'-{2-[(2S,4S)Hydroxy((S)methoxycarbonyl-amino
methyl-butyryl)-pyrrolidinyl]-1H-imidazolyl}-biphenylylcarbamoyl)-
pyridinyl]methyl-piperazinecarbonyl}methyl-pyrrolidinecarboxylic
acid methyl ester
The product of the previous step (20.0 mg, 0.029 mmol) was dissolved in DMA (1
mL) and N,N-diisopropylethylamine (0.015 mL, 0.088 mmol) was added. To the reaction
mixture was added 0.5 M (S)methyl-pyrrolidine-1,2-dicarboxylic acid 1-methyl ester
in DMA (70.5 µL, 0.035 mmol) followed by HATU (13 mg, 0.035 mmol). The reaction
mixture stirred at RT overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL)
and purified by reverse phase HPLC to provide the di-TFA salt of the title compound
(16.8 mg, 56 % yield). (m/z): [M+H] calcd for C H N O 850.42 found 850.4.
45 55 9 8
Example 6: ((S){(2S,4S)[4-(4'-{[6-((R)Cyclopropanecarbonyl
methyl-piperazinyl)-pyridinecarbonyl]-amino}-biphenylyl)-1H-imidazol
yl]dimethylamino-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid
methyl ester
(a) ((S){(2S,4S)Dimethylamino[4-(4'-{[6-((R)methyl-piperazinyl)-
pyridinecarbonyl]-amino}-biphenylyl)-1H-imidazolyl]-pyrrolidine
carbonyl}methyl-propyl)-carbamic acid methyl ester
A solution of ((S){(2S,4S)[4-(4-bromo-phenyl)-1H-imidazolyl]
dimethylamino-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
(135 mg, 0.27 mmol; Preparation 12) and (R)methyl{5-[4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolanyl)-phenylcarbamoyl]-pyridinyl}-piperazinecarboxylic acid
tert-butyl ester (140 mg, 0.27 mmol; Preparation 13) dissolved in 1,2-dimethoxyethane
(2.85 mL) and water (0.99 mL) was sparged under nitrogen. Sodium bicarbonate (86.4
mg, 1.03 mmol) was added, followed by tetrakis(triphenylphosphine)palladium(0) (48
mg, 0.041 mmol) and the reaction mixture was sealed under nitrogen and heated at 90 °C
overnight and extracted with ethyl acetate/water. The organic layer was dried over
sodium sulfate, filtered, and concentrated to produce a yellow oil.
The yellow oil from the previous step was treated with 4 M HCl in 1,4-dioxane
(3 mL) and stirred at RT for 1 h, concentrated, dissolved in 1:1 acetic acid:water (4 mL)
and purified by reverse phase HPLC to produce the tri-TFA salt of the title intermediate
(100 mg, 30 % yield). (m/z): [M+H] calcd for C H N O 708.39 found 708.9.
39 49 9 4
(b) ((S){(2S,4S)[4-(4'-{[6-((R)Cyclopropanecarbonylmethyl-piperazinyl)-
pyridinecarbonyl]-amino}-biphenylyl)-1H-imidazolyl]dimethylamino-
pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
To a solution of the product of the previous step (10 mg, 0.01 mmol) and N,N-
diisopropylethylamine (8.3 µL, 0.048 mmol) dissolved in DMA (0.3 mL) was added
cyclopropanecarbonyl chloride (0.86 µL, 0.0095 mmol) and the reaction mixture was
stirred at RT overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and
purified by reverse phase HPLC to provide the tri-TFA salt of the title compound
(6.9 mg). (m/z): [M+H] calcd for C H N O 776.42 found 776.4.
43 53 9 5
Example 7: ((S){(2S,4S)[4-(4'-{6-[(2R,5S)((S)-2,2-Dimethyl-
cyclopropanecarbonyl)-2,5-dimethyl-piperazinyl]-pyridinylcarbamoyl}-2'-
H-imidazolyl]methyl-pyrrolidine
trifluoromethoxy-biphenylyl)-1
carbonyl}methyl-propyl)-carbamic acid methyl ester
(a) {(S)[(2S,4S)(4-{4'-[6-((2R,5S)-2,5-Dimethyl-piperazinyl)-pyridin
ylcarbamoyl]- 2'-trifluoromethoxy-biphenylyl}-1H-imidazolyl)methyl-
pyrrolidinecarbonyl]methyl-propyl}-carbamicacid methyl ester
To a mixture of 4'-{2-[(2S,4S)((S)methoxycarbonylaminomethyl-
butyryl)methyl-pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-biphenyl
carboxylic acid TFA (80 mg, 0.11 mmol; Preparation 15) and (2S,5R)(5-amino-
pyridinyl)-2,5-dimethyl-piperazinecarboxylic acid tert-butyl ester (416 mg,
0.14 mmol; Preparation 16) in DMF (1 mL) at RT was added HATU (56.8 mg, 0.15
mmol) followed by N,N-diisopropylethylamine (0.12 mL, 0.68 mmol). The reaction
mixture was stirred at RT overnight, and partitioned between EtOAc (10 mL) and water
(3 mL). The organic layer was washed with water (3 mL), dried over sodium sulfate,
filtered and concentrated to give a brownish red oil.
The oily residue from previous step was treated with 4 M HCl in 1,4-dioxane
(1.0 mL) at RT for 30 min. The reaction mixture was concentrated, evaporated with
EtOAc (3 x 3 mL) dissolved in a mixture of ACN and water and freeze dried to give the
tri-HCl salt of the title intermediate (124 mg) as a reddish solid. (m/z): [M+H] calcd for
C H F N O 777.36 found 777.
40 47 3 8 5
(b) ((S){(2S,4S)[4-(4'-{6-[(2R,5S)((S)-2,2-Dimethyl-cyclopropanecarbonyl)-2,5-
dimethyl-piperazinyl]-pyridinylcarbamoyl}-2'-trifluoromethoxy-biphenylyl)-
1H-imidazolyl]methyl-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid
methyl ester
To a mixture of (S)-(+)-2,2-dimethylcyclopropane carboxylic acid (2.6 mg,
0.023 mmol) and HATU (8.58 mg, 0.023 mmol) in DMF (0.5 mL) at RT was added the
product of the previous step (20.0 mg, 0.023 mmol) followed by N,N-
diisopropylethylamine (31.4 µL, 0.180 mmol). The reaction mixture was stirred at RT
overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by
reverse phase HPLC to provide the di-TFA salt of the title compound (10 mg).
(m/z): [M+H] calcd for C H F N O 873.42 found 873.8.
46 55 3 8 6
Example 8: ((S){(2S,4S)[4-(4'-{6-[(R)((S)-2,2-Dimethyl-
cyclopropanecarbonyl)- 2-methyl-piperazinyl]-pyridinylcarbamoyl}-2'-
trifluoromethoxy-biphenylyl)-1H-imidazolyl]methyl-pyrrolidine
carbonyl}methyl-propyl)- carbamic acid methyl ester
To a mixture of 4'-{2-[(2S,4S)((S)methoxycarbonylaminomethyl-
butyryl)methyl-pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-biphenyl
carboxylic acid TFA (11.4 mg, 0.016 mmol) and HATU (6.8 mg, 0.018 mmol) in DMF
(0.5 mL) at RT was added [(R)(5-amino-pyridinyl)methyl-piperazin yl]-((S)-
2,2-dimethyl-cyclopropyl)-methanone (5.1 mg, 0.018 mmol, Preparation 17) followed by
N,N-diisopropylethylamine (14.07 µL, 0.081 mmol). The reaction mixture was stirred at
RT overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by
reverse phase HPLC to provide the di-TFA salt of the title compound (9 mg).
(m/z): [M+H] calcd for C H F N O 859.40 found 859.4.
45 53 3 8 6
Example 9: ((S){(2S,4S)[4-(4'-{6-[(R)((S)-2,2-Dimethyl-
cyclopropanecarbonyl)methyl-piperazinyl]-pyridinylcarbamoyl}-2'-
trifluoromethoxy-biphenylyl)-1H-imidazolyl]methylsulfanyl-pyrrolidine
carbonyl}methyl-propyl)-carbamic acid methyl ester
(a) {(S)Methyl[(2S,4S)(4-{4'-[6-((R)methyl-piperazinyl)-pyridin
ylcarbamoyl]-2'-trifluoromethoxy-biphenylyl}-1H-imidazolyl)
methylsulfanyl-pyrrolidinecarbonyl]-propyl}-carbamic acid methyl ester
To a mixture of 4'-{2-[(2S,4S)((S)methoxycarbonylaminomethyl-
butyryl)methylsulfanyl-pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-
biphenylcarboxylic acid TFA (37 mg, 0.05 mmol; Preparation 21) and (R)(5-amino-
pyridinyl)methyl-piperazinecarboxylic acid tert-butyl ester (16 mg, 0.06 mmol)
in DMF (0.5 mL) at RT was added HATU (21 mg, 0.06 mmol) followed by N,N-
Diisopropylethylamine (44.3 µL, 0.25 mmol). The resulting mixture was stirred at RT
overnight. The reaction mixture was partitioned between EtOAc (5 mL) and water
(2 mL). The organic layer was washed with water (2 mL), dried over sodium sulfate,
filtered and concentrated to give a brownish red oil.
The oily residue from previous step was treated with 4 M of HCl in 1,4-
dioxane(1.0 mL) at RT for 30 min. The reaction mixture was concentrated, evaporated
with EtOAc (3 x 2 mL), dissolved in a mixture of ACN and water, and freeze dried to
give the tri-HCl salt of the title intermediate (57 mg) as a brownish solid. (m/z): [M+H]
calcd for C H F N O S 891.38 found 891.
45 53 3 8 6
(b) ((S){(2S,4S)[4-(4'-{6-[(R)((S)-2,2-Dimethyl-cyclopropanecarbonyl)
methyl-piperazinyl]-pyridinylcarbamoyl}-2'-trifluoromethoxy-biphenylyl)-
1H-imidazolyl]methylsulfanyl-pyrrolidinecarbonyl}methyl-propyl)-
carbamic acid methyl ester
To a mixture of (S)-(+)-2,2-dimethylcyclopropane carboxylic acid (2.7 mg,
0.023 mmol) and HATU (8.8 mg, 0.023 mmol) in DMF (0.5 mL) at RT was added the
product of the previous step (19.1 mg, 0.021 mmol) followed by N,N-
diisopropylethylamine (18.4 µL, 0.11 mmol). The reaction mixture was stirred at RT
overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by
reverse phase HPLC to provide the di-TFA salt of the title compound (11 mg).
(m/z): [M+H] calcd for C H F N O S 891.38 found 891.
45 53 3 8 6
Example 10: [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(R)(2,2-dimethyl-
propionyl)methyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-
trifluoromethoxy-biphenylyl]-1H-imidazolyl}methyl-pyrrolidine
carbonyl)methyl-propyl]-carbamic acid methyl ester
(a) (R)[5-(5-Chloro-4'-{2-[(2S,4S)((S)methoxycarbonylaminomethyl-butyryl)-
4-methyl-pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-biphenyl
ylcarbamoyl)-pyridinyl]methyl-piperazinecarboxylic acid tert-butyl ester
To a solution of [(S)methyl((2S,4S)methyl{4-[4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)-propyl]-
carbamic acid methyl ester (155 mg, 0.30 mmol) and (R)[5-(4-bromochloro
trifluoromethoxy-phenylcarbamoyl)-pyridinyl]methyl-piperazinecarboxylic acid
tert-butyl ester (180 mg, 0.30 mmol, Preparation 1) dissolved in toluene (1.9 mL) and
water (0.33 mL) was added potassium carbonate (210 mg, 1.52 mmol). The reaction
mixture was sparged under nitrogen. Tetrakis(triphenylphosphine)palladium(0) (42 mg,
0.036 mmol) was added and the reaction mixture was sparged with nitrogen and heated at
100 °C overnight. The reaction mixture was diluted with ethyl acetate and washed with
water and brine. The organic layer was dried over sodium sulfate, filtered, and
concentrated to produce the title intermediate as a brownish solid. (m/z): [M+H] calcd
for C H ClF N O 897.36 found 897.
44 52 3 8 7
(b) ((S){(2S,4S)[4-(5'-Chloro-4'-{[6-((R)methyl-piperazinyl)-pyridine
carbonyl]- amino}-2'-trifluoromethoxy-biphenylyl)-1H-imidazolyl]methyl-
pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
The solid from the previous step (431 mg, 0.48 mmol) was treated with 4 M HCl
in 1,4-dioxane (2 mL) and the reaction mixture was stirred at 50 °C for 30 min,
concentrated, and evaporated with ethyl acetate (2 x) to produce the tri-HCl salt of the
title intermediate as a yellow solid (426 mg, 0.47 mmol). (m/z): [M+H] calcd for
C H ClF N O 797.31 found 797.8.
39 44 3 8 5
(c) [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(R)(2,2-dimethyl-propionyl)methyl-
piperazinyl]-pyridinecarbonyl}-amino)-2'-trifluoromethoxy-biphenylyl]-1H-
imidazolyl}methyl-pyrrolidinecarbonyl)methyl-propyl]-carbamic acid
methyl ester
To a solution of the product of the previous step (12 mg, 0.014 mmol) in
DMF (0.5 mL)was added N,N-diisopropylethylamine (0.024 mL, 0.14 mmol) followed by
2,2-dimethylpropanoyl chloride (1.7 µL, 0.014 mmol). The reaction mixture was stirred
at RT for 30 min, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified
by reverse phase HPLC to provide the di-TFA salt of the title compound (7 mg).
(m/z): [M+H] calcd for C H ClF N O 881.37 found 881.8.
44 52 3 8 6
Example 11: [(S)((2S,4S){4-[4'-({6-[(R)(2,2-Dimethyl-propionyl)
methyl-piperazinyl]-pyridinecarbonyl}-amino)-5'-fluoro-2'-trifluoromethoxy-
biphenylyl]-1H-imidazolyl}methyl-pyrrolidinecarbonyl)methyl-
propyl]-carbamic acid methyl ester
(a) (R)[5-(5-Fluoro-4'-{2-[(2S,4S)((S)methoxycarbonylaminomethyl-butyryl)-
4-methyl-pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-biphenyl
ylcarbamoyl)-pyridinyl]methyl-piperazinecarboxylic acid tert-butyl ester
To a solution of [(S)methyl((2S,4S)methyl{4-[4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)-propyl]-
carbamic acid methyl ester (170 mg, 0.33 mmol) and (R)[5-(4-bromofluoro
trifluoromethoxy-phenylcarbamoyl)-pyridinyl]methyl-piperazinecarboxylic acid
tert-butyl ester (192 mg, 0.33 mmol, Preparation 24) dissolved in toluene (2.1 mL) and
water (0.8 mL) was added potassium carbonate (230 mg, 1.67 mmol). The reaction
mixture was sparged with nitrogen, Pd(dppf)Cl CH Cl (25 mg, 0.03 mmol) was added
2 2 2
and the reaction mixture was sparged with nitrogen and heated at 90 °C overnight. The
reaction mixture was cooled to RT, filtered through a pad of Celite® and silica gel and
washed with EtOAc. The filtrate was washed with water and brine to produce a brownish
colored oil. The residue was purified by silica gel chromatography (24 g, 40% to 100%
EtOAc/hexanes) to produce the title intermediate as a yellowish solid (227 mg, 78 %
yield). (m/z): [M+H] calcd for C H F N O 881.39 found 881.4.
44 52 4 8 7
(b) ((S){(2S,4S)- 2-[4-(5'-Fluoro-4'-{[6-((R)methyl- piperazinyl)-pyridine
carbonyl]- amino}-2'-trifluoromethoxy-biphenylyl)-1H-imidazolyl]methyl-
pyrrolidinecarbonyl}methyl- propyl)-carbamic acid methyl ester
The solid from the previous step (227 mg) was treated with 4 M HCl in 1,4-
dioxane (1.67 mL) and HCl (0.51 mL) and the reaction mixture was stirred at RT for 1 h.
The reaction mixture was concentrated and evaporated with ethyl acetate (2 x) to produce
the tri-HCl salt of the title intermediate as a yellow solid. (237 mg, 80 % yield).
(m/z): [M+H] calcd for C H F N O 781.34 found 781.3.
39 44 4 8 5
(c) [(S)((2S,4S){4-[4'-({6-[(R)(2,2-Dimethyl-propionyl)methyl-piperazin
yl]-pyridinecarbonyl}-amino)-5'-fluoro-2'-trifluoromethoxy-biphenylyl]-1H-
imidazolyl}methyl-pyrrolidinecarbonyl)methyl-propyl]-carbamic acid
methyl ester
To the product of the previous step (15 mg, 0.017 mmol) dissolved in DMA
(1 mL) was added N,N-diisopropylethylamine (14.4 µL, 0.083 mmol) followed by 2,2-
dimethylpropanoyl chloride (24 mg, 0.020 mmol) and the reaction mixture was stirred at
RT overnight, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by
reverse phase HPLC to provide the di-TFA salt of the title compound (15 mg, 81 %
yield). (m/z): [M+H] calcd for C H F N O 865.39 found 865.8.
44 52 4 8 6
Example 12: ((S){(2S,4S)[5-Chloro(4'-{6-[(R)(2,2-dimethyl-
propionyl)methyl-piperazinyl]-pyridinylcarbamoyl}-2'-trifluoromethoxy-
biphenylyl)-1H-imidazolyl]methyl-pyrrolidinecarbonyl}methyl-
propyl)-carbamic acid methyl ester
(a) {(S)[(2S,4S)- 2-(5-Chloro{4'- [6-((R)methyl-piperazinyl) -pyridin
ylcarbamoyl]- 2'-trifluoromethoxy-biphenylyl}-1H-imidazolyl) methyl-
pyrrolidinecarbonyl]methyl-propyl}-carbamic acid methyl ester
To a mixture of 4'-{5-chloro[(2S,4S)((S)methoxycarbonylamino
methyl-butyryl)methyl-pyrrolidinyl]-1H-imidazolyl}trifluoromethoxy-
biphenylcarboxylic acid TFA (48 mg, 0.06 mmol; Preparation 25) and HATU (27 mg,
0.07 mmol) in DMF (1 mL) at RT was added 4-(5-amino-pyridinyl)methyl-
piperazinecarboxylic acid tert-butyl ester (21 mg, 0.07 mmol followed by N,N-
diisopropylethylamine (67.6 µL, 0.39 mmol). The reaction mixture was stirred for 1 h,
and partitioned between EtOAc (10 mL) and water (3 mL). The organic layer was washed
with water (2 mL), dried over sodium sulfate, filtered, and concentrated to give a a dark
oil, which was purified by silica gel chromatography (0-100% EtOAc/Hexanes). Desired
fractions were combined and concentrated to give a yellowish oil.
The oily residue from previous step was treated with 4 M HCl in 1,4-dioxane
(1.0 mL) at RT for 30 min. The reaction mixture was concentrated, evaporated with
EtOAc (2 x 2 mL) and dried under vacuum to give the tri-HCl salt of the title
intermediate (47 mg) as a light yellowish solid. (m/z): [M+H] calcd for C H ClF N O
39 44 3 8 5
797.31 found 797.
(b) ((S){(2S,4S)[5-Chloro(4'-{6-[(R)(2,2-dimethyl-propionyl)methyl-
piperazinyl]-pyridinylcarbamoyl}-2'-trifluoromethoxy-biphenylyl)-1H-
imidazolyl]methyl-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid
methyl ester
To a mixture of the product of the previous step (12 mg, 0.013 mmol) and N,N-
diisopropylethylamine (13.6 µL, 0.078 mmol)in DMF (0.5 mL) at RT was added 2,2-
dimethylpropanoyl chloride (1.92 µL, 0.016 mmol). The reaction mixture was stirred at
RT for 1 h, concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by
reverse phase HPLC to provide the di-TFA salt of the title compound (6 mg).
(m/z): [M+H] calcd for C H ClF N O 881.37 found 881.8.
44 52 3 8 6
Example 13: ((S){(2S,4S)[4-(4'-{[6-((R)tert-Butylmethyl-piperazin-
1-yl)-pyridinecarbonyl]-amino}-5'-chloro-2'-trifluoromethoxy-biphenylyl)-1H-
imidazolyl]methoxy-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid
methyl ester
To a solution of ((S){(2S,4S)[4-(5'-chloro-4'-{[6-((R)methyl-piperazin
yl)-pyridinecarbonyl]-amino}-2'-trifluoromethoxy-biphenylyl)-1H-imidazolyl]-
4-methoxy-pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester tri-HCl
(10 mg, 0.01 mmol; Preparation 28) in DMA (1 mL) was added N,N-
diisopropylethylamine (9.44 µL, 0.05 mmol) followed by 2,2-dimethylpropanoyl chloride
(1.31 mg, 0.01 mmol). The reaction mixture was stirred at RT overnight, concentrated by
rotary evaporation, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by reverse
phase HPLC to provide the di-TFA salt of the title compound (7 mg, 51 % yield)
(m/z): [M+H] calcd for C H ClF N O 897.36 found 897.8.
44 52 3 8 7
Example 14A: [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(R)(2,2-dimethyl-
propionyl)methyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-
trifluoromethoxy-biphenylyl]-1H-imidazolyl}methyl-pyrrolidinyl)-
oxo—1-(tetrahydro-pyranyl)-ethyl]-carbamic acid methyl ester
To a solution of (S)-methoxycarbonylamino-(tetrahydro-pyranyl)-acetic acid
(9.4 mg, 0.046 mmol; Preparation 29) in DMA (5 mL) was added HATU (45.3 mg,
0.12 mmol). The reaction mixture was stirred at RT for 15 min, and N-{5-chloro-4'-[2-
((2S,4S)methyl-pyrrolidinyl)-1H-imidazolyl]trifluoromethoxy-biphenyl
yl}[(R)(2,2-dimethyl-propionyl)methyl-piperazinyl]-nicotinamide tri-HCl
(30.0 mg, 0.036 mmol; Preparation 31 was added followed by DIPEA (86.4 µL, 0.50
mmol). The reaction mixture was stirred at RT overnight, concentrated by rotary
evaporation, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by reverse phase
HPLC to provide the di-TFA salt of the title compound (14 mg, 37 % yield).
(m/z): [M+H] calcd for C H ClF N O 923.38 found 923.8.
46 54 3 8 7
Example 14B: [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(R)(2,2-dimethyl-
propionyl)methyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-
trifluoromethoxy-biphenylyl]-1H-imidazolyl}methoxy-pyrrolidinyl)-
oxo(tetrahydro-pyranyl)-ethyl]-carbamic acid methyl ester
(a) (2S,4S)-tert-butyl 2-(4-(5'-chloro-4'-(6-((R)methylpivaloylpiperazin
yl)nicotinamido)-2'-(trifluoromethoxy)-[1,1'-biphenyl]yl)-1H-imidazolyl)
methylpyrrolidinecarboxylate
To a round bottom flask was added (2S,4S)-tert-butyl 2-(4-(4-bromophenyl)-1H-
imidazolyl)methylpyrrolidinecarboxylate (10 g, 24.61 mmol), (R)-(5-chloro
(6-(2-methylpivaloylpiperazinyl)nicotinamido)(trifluoromethoxy)phenyl)boronic
acid (14.16 g, 26.1 mmol), sodium bicarbonate (7.24 g, 86 mmol), bis(di-tert-butyl(4-
dimethylaminophenyl)phosphine)dichloropalladium(II) (0.17 g, 0.246 mmol), 2-
methyltetrahydrofuran (120 mL) and water (44.3 mL) to give a suspension. The reaction
mixture was degassed with nitrogen for 10 min then heated at 70 °C overnight. Water (60
mL) was added and the layers were separated. The organic layer was washed with brine,
dried over Na SO , and evaporated to give crude product (27.3 g). The crude product was
purified by flash chromatography (300 g silica gel, 20-100 % EtOAc (50 min), then 100
% EtOAc (20 min)) to give the title intermediate (18.8 g; 93 % yield) HPLC Method B:
Retention time 14.99 min.
(b) N-(5-chloro-4'-(2-((2S,4S)- 4-methylpyrrolidinyl)-1H-imidazolyl)
(trifluoromethoxy)-[1, 1'-biphenyl]- 4-yl)((R)methylpivaloylpiperazin
yl)nicotinamide
A solution of the product of the previous step (18.8 g, 22.81 mmol) and DCM (82
mL) was cooled to 5 °C and then TFA (26.4 mL) was added. The reaction mixture was
stirred overnight and concentrated. To the reaction mixture was added MTBE (300 mL ),
1 N HCl (200 mL), and water (100 mL). The organic phase was extracted with 0.5 N HCl
(100 mL). The combined aqueous phase was basified with 50 % NaOH aqueous solution
(17 mL), and extracted with isopropyl acetate (500 mL). The organic layer was dried over
Na SO and evaporated to give the title intermediate (13.6 g, 82 % yield)). HPLC Method
B: Retention time 11.75 min.
(c) [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(R)(2,2-dimethyl-propionyl)methyl-
piperazinyl]-pyridinecarbonyl}-amino)-2'-trifluoromethoxy-biphenylyl]-1H-
imidazolyl}methyl-pyrrolidinyl)oxo(tetrahydro-pyranyl)-ethyl]-
carbamic acid methyl ester
A solution of the product of the previous step (10 g, 13.81 mmol), (S)
((methoxycarbonyl)amino)(tetrahydro-2H-pyranyl)acetic acid (3.15 g, 14.50 mmol)
and DMF (120 mL) was cooled to 0-10 °C and then HCTU (6.00 g, 14.50 mmol) was
added, followed by DIPEA (4.82 ml, 27.6 mmol). The reaction mixture was stirred at RT
overnight. Ethyl acetate (250 mL) and water (150 mL) were added; the organic layer was
washed with sat. Na CO (100 mL) and brine, dried over Na SO , and evaporated to give
2 3 2 4
a first crude product (23.7 g). To the first crude product was added methanol (85 mL) and
2 N LiOH (7 mL). After 45 min, the reaction mixture was dried over Na SO and
evaporated to give a second crude product which was purified by flash chromatography
(300 g silica gel, 1-8 % methanol/DCM over 30 min then 8 % over 20 min) to give a solid
product (7.7 g). To the solid product was added THF (30 mL) and the resulting solution
was added dropwise to hexane (165 mL). The resulting mixture was filtered and dried
under vacuum overnight to provide the title compound (6.48 g, 49 % yield) as a solid.
HPLC Method B: Retention time 14.47 min.
Example 15A: [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(R)(2,2-dimethyl-
propionyl)methyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-
trifluoromethoxy-biphenylyl]-1H-imidazolyl}methoxy-pyrrolidinyl)-
oxo(tetrahydro-pyranyl)-ethyl]-carbamic acid methyl ester
To a solution of (S)-methoxycarbonylamino-(tetrahydro-pyranyl)-acetic acid
(9.4 mg, 0.046 mmol; Preparation 29) in DMA (1 mL) was added HATU (6.4 mg,
0.017 mmol). The reaction mixture was stirred at RT for 15 min, and N-{5-chloro-4'-[2-
((2S,4S)methoxy-pyrrolidinyl)-1H-imidazolyl]trifluoromethoxy-biphenyl
yl}[(R)(2,2-dimethyl-propionyl)methyl-piperazinyl]-nicotinamide tri-HCl
(12.0 mg, 0.014 mmol; Preparation 32) was added followed by DIPEA (12.3µL, 0.07
mmol). The reaction mixture was stirred at RT overnight, concentrated by rotary
evaporation, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by reverse phase
HPLC to provide the di-TFA salt of the title compound (9 mg, 56 % yield).
(m/z): [M+H] calcd for C H ClF N O 939.37 found 939.8.
46 54 3 8 8
Example 15B: [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(R)(2,2-dimethyl-
propionyl)methyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-
trifluoromethoxy-biphenylyl]-1H-imidazolyl}methoxy-pyrrolidinyl)-
oxo(tetrahydro-pyranyl)-ethyl]-carbamic acid methyl ester
(a) (2S,4S){4-[5'-Chloro-4'-({6-[(R) (3-hydroxy-2,2-dimethyl-propionyl)methyl-
piperazinyl]-pyridinecarbonyl}-amino)-2'-trifluoromethoxy-biphenylyl]-1H-
imidazolyl}methoxy-pyrrolidinecarboxylic acid tert-butyl ester
To a round bottom flask was added (2S,4S)[4-(4-bromo-phenyl)-1H-imidazol-
2-yl]methoxy-pyrrolidinecarboxylic acid tert-butyl ester (5.0 g, 11.8 mmol) and
(R)chloro(6-(2-methylpivaloylpiperazinyl)nicotinamido)
(trifluoromethoxy)phenylboronic acid (6.75 g, 12.4 mmol; Preparation 44), potassium
carbonate (5.73 g, 41.4 mmol), and bis(di-tert-butyl(4-dimethylaminophenyl)-
phosphine)dichloropalladium(II) (0.092 g, 0.130 mmol), followed by degassed
tetrahydrofuran (50 mL) and water (1.28 mL). The reaction mixture was degassed with
nitrogen for 5 min then heated at 65 °C for 4 h, and cooled to RT. Water (100 mL) was
added and the reaction mixture was extracted with EtOAc (200 mL). The organic layer
was washed with NaOH (2 x100 mL), water (2 x 200 mL) and brine, dried over Na SO
and evaporated to give crude product (12.25 g). The crude product was purified by flash
chromatography (150 g silica gel, 50-100 % EtOAc (10 min), then 100 % EtOAc (30
min)) to give the title intermediate (4.2 g; 41 % yield) HPLC Method B: Retention time
.29 min.
(b) N-{5-Chloro-4'-[2-((2S,4S)methoxy-pyrrolidinyl)-1H-imidazolyl]
trifluoromethoxy-biphenylyl}[(R)(2,2-dimethyl-propionyl)methyl-
piperazinyl]-nicotinamide
A solution of the product of the previous step (4.2 g, 5.00 mmol) and DCM
(18.01 mL) was cooled to 5 °C and then TFA (5.78 mL) was added. The reaction mixture
was stirred overnight and concentrated. Ethyl acetate (80 mL) was added; the reaction
mixture was washed with 1 N NaOH (2 x 80 mL), water, and brine; dried over Na SO ,
and evaporated to give the title intermediate (3.56 g, 96 % yield)). HPLC Method B:
Retention time 12.33 min.
(c) [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(R)(2,2-dimethyl-propionyl)methyl-
piperazinyl]-pyridinecarbonyl}-amino)-2'-trifluoromethoxy-biphenylyl]-1H-
imidazolyl}methoxy-pyrrolidinyl)-oxo(tetrahydro-pyranyl)-ethyl]-
carbamic acid methyl ester
A solution of the product of the previous step (3.56 g, 4.81 mmol), (S)
((methoxycarbonyl)amino)(tetrahydro-2H-pyranyl)acetic acid (1.097 g, 5.05 mmol)
and DMF (43 mL) was cooled to 0-10 °C and then HCTU (2.089 g, 5.05 mmol) was
added, followed by DIPEA (1.68 mL, 9.62 mmol). The reaction mixture was stirred at
RT for 3 h. Ethyl acetate (150 mL) and water (100 mL) were added; the organic layer
was washed with sat. Na CO (100 mL) and brine, dried over Na SO , and evaporated to
2 3 2 4
give the crude product (5.4 g), which was purified by flash chromatography (133 g silica
gel, EtOAc to 10% MeOH/EtOAc (15 min) then 10% MeOH/EOAc (15 min)) to give the
title compound (2.8 g, 61 % yield) which was dried under vacuum overnight. HPLC
Method B: Retention time 13.70 min.
Example 16: [(S)((2S,4S){4-[5'-Chloro-4'-({6-[(R)(3-hydroxy-2,2-
dimethyl-propionyl)methyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-
trifluoromethoxy-biphenylyl]-1H-imidazolyl}methoxy-pyrrolidinyl)-
oxo—1-(tetrahydro-pyranyl)-ethyl]-carbamic acid methyl ester
To a solution of (S)-methoxycarbonylamino-(tetrahydro-pyranyl)-acetic acid
(37.6 mg, 0.17 mmol) in DMA (1 mL) was added HATU (65.9 mg, 0.17 mmol). The
reaction mixture was stirred for 15 min and N-{5-chloro-4'-[2-((2S,4S)methoxy-
pyrrolidinyl)-1H-imidazolyl]trifluoromethoxy-biphenylyl}[(R)(3-
hydroxy-2,2-dimethyl-propionyl)methyl-piperazinyl]-nicotinamide 3 HCl (100 mg,
0.12mmol; Preparation 34) was added followed by DIPEA (0.10 mL, 0.58 mmol) and the
reaction mixture was stirred at RT overnight, concentrated by rotary evaporation,
dissolved in 1:1 acetic acid:water (4 mL) and purified by reverse phase HPLC. Fractions
containing the desired compound were combined and lyophilized to provide the di-TFA
salt of the title compound (65.2 mg) as a white powder. Impure fractions were
lyophilized, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by reverse phase
HPLC to provide additional di-TFA salt of the title compound (75 mg total, 55 % yield).
(m/z): [M+H] calcd for C H ClF N O 955.37 found 955.8.
46 54 3 8 9
Example 17: (R)[5-(5-Chloro-4'-{2-[(2S,4S)cyano((S)
methoxycarbonylaminomethyl-butyryl)-pyrrolidinyl]-1H-imidazolyl}
trifluoromethoxy-biphenylylcarbamoyl)-pyridinyl]methyl-piperazine
carboxylic acid tert-butyl ester
A solution of [(S)((2S,4S)cyano{4-[4-(4,4,5,5-tetramethyl-
[1,3,2]dioxaborolanyl)-phenyl]-1H-imidazolyl}-pyrrolidinecarbonyl)methyl-
propyl]-carbamic acid methyl ester (0.10 g, 0.19 mmol), (R)[5-(4-bromochloro
trifluoromethoxy-phenylcarbamoyl)-pyridinyl]methyl-piperazinecarboxylic acid
tert-butyl ester (113.9 mg, 0.19 mmol) and potassium carbonate (119.3 mg, 0.86 mmol)
in toluene (0.46 mL) and water (0.24 mL, 13.56 mmol) was degassed with nitrogen for 20
min and then Pd(dppf)Cl CH Cl (6.27 mg, 0.0076 mmol) was added and the reaction
2 2 2
was degassed with nitrogen for 15 min. The reaction mixture was heated at 100 °C for 12
h, concentrated under vacuum, and purified by reverse phase HPLC . The pure fractions
were combined and concentrated under vacuum to afford the di-TFA salt of the title
compound (13 mg, 6 % yield). (m/z): [M+H] calcd for C H ClF N O 908.34 found
44 49 3 9 7
908.7.
Example 18: ([(S)((2S,4S)Carbamoyl{4-[5'-chloro-4'-({6-[(R)(2,2-
dimethyl-propionyl)methyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-
trifluoromethoxy-biphenylyl]-1H-imidazolyl}-pyrrolidinecarbonyl)
methyl-propyl]-carbamic acid methyl ester
(a) ((S){(2S,4S)Carbamoyl[4-(5'-chloro-4'-{[6-((R)methyl-piperazinyl)-
pyridinecarbonyl]-amino}-2'-trifluoromethoxy-biphenylyl)-1H-imidazolyl]-
pyrrolidinecarbonyl}methyl-propyl)-carbamic acid methyl ester
A solution of (R)[5-(5-chloro-4'-{2-[(2S,4S)cyano((S)
methoxycarbonylaminomethyl-butyryl)-pyrrolidinyl]-1H-imidazolyl}
trifluoromethoxy-biphenylylcarbamoyl)-pyridinyl]methyl-piperazine
carboxylic acid tert-butyl ester 2 TFA (6.3 mg, 0.0055 mmol; Example 17) in 4.0 M HCl
in 1,4-dioxane (0.14 mL) was stirred at RT for 1 h and concentrated under vacuum to
provide the title intermediate as a yellow powder. (m/z): [M+H] calcd for
C H ClF N O 826.30 found 826.5.
39 43 3 9 6
(b) ([(S)((2S,4S)Carbamoyl{4-[5'-chloro-4'-({6-[(R)(2,2-dimethyl-propionyl)-
2-methyl-piperazinyl]-pyridinecarbonyl}-amino)-2'-trifluoromethoxy-biphenyl-
4-yl]-1H-imidazolyl}-pyrrolidinecarbonyl)methyl-propyl]-carbamic acid
methyl ester
The product of the previous step was dissolved in DMA (0.28 mL, 2.99 mmol),
and 2,2-dimethylpropanoyl chloride (0.68 µL, 0.0055 mmol) and DIPEA (4.83 µL, 0.028
mmol) were subsequently added. The solution was stirred at RT for 1 h, concentrated
under vacuum, dissolved in a 1:1 acetic acid:ACN solution (1.5 mL), and purified by
reverse phase HPLC to provide the di-TFA salt of the title compound (4 mg, 57 % yield).
(m/z): [M+H] calcd for C H ClF N O 910.36 found 910.8.
44 51 3 9 7
Example 19: Methyl ((S)((2S,4S)(4-(5'-chloro-4'-((6-((R)methyl
pivaloylpiperazinyl)pyridinyl)carbamoyl)-2'-(trifluoromethoxy)-[1,1'-
biphenyl]yl)-1H-imidazolyl)- 4-methylpyrrolidinyl)oxo(tetrahydro-2H-
pyranyl)ethyl)carbamate
(a) (R)-tert-butyl 4-(5-(5-Chloro-4'-(2-((2S,4S)((S)((methoxycarbonyl)amino)
(tetrahydro-2H-pyranyl)acetyl)methylpyrrolidinyl)-1H-imidazolyl)
(trifluoromethoxy)-[1,1'-biphenyl]ylcarboxamido)pyridinyl)
methylpiperazinecarboxylate
To a mixture of toluene (1 mL) and water (0.4 mL) was added methyl ((S)
((2S,4S)methyl(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)phenyl)-1H-
imidazolyl)pyrrolidinyl)oxo(tetrahydro-2H-pyranyl)ethyl)carbamate (90
mg, 0.16 mmol; Preparation 46), (R)-tert-butyl 4-(5-(4-bromochloro
(trifluoromethoxy)benzamido)pyridinyl)methylpiperazinecarboxylate (97 mg,
0.16 mmol; Preparation 49) and potassium carbonate (118 mg, 0.86 mmol). The reaction
mixture was sparged under nitrogen, Pd(dppf)Cl (7.17 mg, 9.77 µmol) was added and
the reaction mixture was sparged under nitrogen, sealed, heated at 90°C overnight, and
extracted with ethyl acetate, water, and brine. The organic layer was dried over sodium
sulfate, filtered, concentrated, and purified by silica gel chromatography (12 g column, 0-
100% ethyl acetate:hexanes) to produce the title intermediate (70.3 mg, 45.9 % yield) as a
yellow solid. (m/z): [M+H] calcd for C H ClF N O 939.37 found 939.30.
46 54 3 8 8
(b) Methyl ((S)((2S,4S)(4-(5'-chloro-4'-((6-((R)methylpiperazinyl)pyridin
yl)carbamoyl)-2'-(trifluoromethoxy)-[1,1'-biphenyl]yl)-1H-imidazolyl)
methylpyrrolidinyl)oxo(tetrahydro-2H-pyranyl)ethyl)carbamate
The product of the previous step (70.3 mg, 0.075 mmol) was treated with 4 M HCl
in dioxane (1 mL, 0.075 mmol) and stirred at RT for 1 h. The reaction mixture was
concentrated and evaporated with ethyl acetate (2 x) to produce the tri-HCl salt of the title
intermediate (70.5 mg, 99 % yield) as a yellow solid. (m/z): [M+H] calcd for
C H ClF N O 839.32 found 839.20.
41 46 3 8 6
(c) Methyl ((S)((2S,4S)(4-(5'-chloro-4'-((6-((R)methylpivaloylpiperazin
yl)pyridinyl)carbamoyl)-2'-(trifluoromethoxy)-[1,1'-biphenyl]yl)-1H-imidazol-
2-yl)- 4-methylpyrrolidinyl)oxo(tetrahydro-2H-pyranyl)ethyl)carbamate
To a solution of the product of the previous step (70.5 mg, 0.074 mmol) and
DIPEA (0.091 ml, 0.52 mmol) dissolved in DMF (0.5 ml) was added pivaloyl chloride
(9.0 mg, 0.075 mmol). The reaction mixture was stirred at RT for 30 min. The reaction
mixture was concentrated, dissolved in 1:1 acetic acid:water (1.5 mL) and purified by
reverse-phase HPLC. Fractions containing desired product were freeze dried to produce
the di-TFA salt of the title compound as a white powder (32.0 mg, 37.2 % yield).
(m/z): [M+H] calcd for C H ClF N O 923.38 found 923.30.
46 54 3 8 7
Example 20: Methyl ((S)((2S,4S)(4-(2'-chloro-4'-((6-((R)methyl
pivaloylpiperazinyl)pyridinyl)carbamoyl) -6'-(trifluoromethoxy)-[1,1'-
biphenyl]yl)-1H-imidazolyl) methylpyrrolidinyl)oxo(tetrahydro-2H-
pyranyl)ethyl)carbamate
(a) (2S,4S)-tert-butyl 2-(4-(2'-chloro-4'-( (6-((R)methylpivaloylpiperazin
yl)pyridinyl)carbamoyl)-6'-(trifluoomethoxy)-[1,1'-biphenyl]yl)-1H-imidazol
yl)methylpyrrolidinecarboxylate
To a mixture of (R)bromochloro-N-(6-(2-methylpivaloylpiperazin
yl)pyridinyl)(trifluoromethoxy)benzamide (80.3 mg, 0.14 mmol; Preparation 51)
and (2S,4S)-tert-butyl 4-methyl(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
yl)phenyl)-1H-imidazolyl)pyrrolidinecarboxylate (63.0 mg, 0.14 mmol) in a
mixture of toluene (0.9 mL) and water (0.3 mL) was added potassium carboante (86 mg,
0.63 mmol) . The reaction mixture was flushed with nitrogen, PdCl (dppf) (6.1 mg, 8.34
µmol) was added. The reaction mixturewas capped, heated at 100°C overnight, cooled to
RT and partitioned between EtOAc(5 mL) and water (2 mL). The organic layer was
dried over sodium sulfate, filtered and concentrated to give a brown oil, which was
purified by silica gel chromatography (12 g silica gel, 0-100 % EtOAc/hexanes). Desired
fractions were combined and concentrated to give the title intermediate (58.1 mg, 51 %
yield) as a yellowish oil. (m/z): [M+H] calcd for C H ClF N O 824.34 found 824.
42 49 3 7 5
(b) 2-chloro-N-(6-((R)methylpivaloylpiperazinyl) pyridinyl)-4'-(2-((2S,4S)- 4-
methylpyrrolidinyl)-1H-imidazolyl)(trifluoromethoxy)-[1, 1'-biphenyl]- 4-
carboxamide
To the product of the previous step (58.1 mg, 0.07 mmol) was added 4.0 N HCl in
dioxane (0.18 mL, 0.70 mmol). After 30 min, the reaction mixture was concentrated and
evaporated with EtOAc (3 x 3 mL) to give the di-HCl salt of the title intermediate as a
yellowish solid. (m/z): [M+H] calcd for C H ClF N O 724.29 found 724.
37 41 3 7 3
(c) Methyl ((S)((2S,4S)(4-(2'-chloro-4'-((6-((R)methylpivaloylpiperazin
yl)pyridinyl)carbamoyl) -6'-(trifluoromethoxy)-[1,1'-biphenyl]yl)-1H-imidazol-
2-yl) methylpyrrolidinyl)oxo(tetrahydro-2H-pyranyl)ethyl)carbamate
To a mixture of the product of the previous step (65.8 mg, 0.083 mmol) and (S)
((methoxycarbonyl)amino)(tetrahydro-2H-pyranyl)acetic acid (19.7 mg, 0.091
mmol) in DMA (0.5 mL) at RT was added HATU (34.5 mg, 0.091 mmol) and DIPEA
(0.043 mL, 0.248 mmol). The reaction mixture was stirred at RT overnight, concentrated,
dissolved in 1:1 acetic acid:water (1.5 mL), filtered and purified by reverse phase HPLC.
Desirred fractions were combined and freeze dried to give the di-TFA salt of the title
compound (38.9 mg, 37 % yield) as a white solid. (m/z): [M+H] calcd for
C H ClF N O 923.38 found 923.6.
46 54 3 8 7
Example 21 Methyl ((S)((2S,4S)(4-(3'-fluoro-4'-((6-((R)methyl
pivaloyl-piperazinyl)pyridinyl)carbamoyl)-2'-(trifluoromethoxy)- [1,1'-
biphenyl]yl) -1H-imidazolyl)methylpyrrolidinyl)oxo(tetrahydro-2H-
pyranyl)ethyl)carbamate
O F N
HN N
(a) (2S,4S)-tert-butyl 2-(4-(3'-fluoro-4'-((6-((R)methylpivaloylpiperazin
yl)pyridinyl)carbamoyl)-2'-(trifluoromethoxy)-[1,1'-biphenyl]yl)-1H-imidazol-
2-yl)methylpyrrolidinecarboxylate
To a solution of (2S,4S)-tert-butyl 4-methyl(4-(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolanyl)phenyl)-1H-imidazolyl)pyrrolidinecarboxylate (68.6 mg, 0.15
mmol) and (R)bromofluoro-N-(6-(2-methylpivaloylpiperazinyl)pyridinyl)-
3-(trifluoromethoxy)benzamide (85 mg, 0.15 mmol, Preparation 52) and potassium
carbonate (110 mg, 0.80 mmol) in a mixture of toluene (1.8 mL) and water (0.6 mL) was
added PdCl (dppf) (6.7 mg, 9.08 µmol). The mixture was sparged under nitrogen for 2
min and heated at 100 °C overnight and extracted with EtOAc and water. The organic
layer was dried over sodium sulfate, filtered, concentrated, and purified by silica gel
chromatography (12 g silica, 0-100% EtOAc:hexanes over 20 min), to provide the title
intermediate (86.9 mg, 71 % yield) as a yellow solid. (m/z): [M+H] calcd for
C H F N O 808.37 found 808.7.
42 49 4 7 5
(b) 3-fluoro-N-(6-((R)methylpivaloylpiperazinyl)pyridinyl)-4'-(2-((2S,4S)
methylpyrrolidinyl) -1H-imidazolyl)(trifluoromethoxy)-[1,1'-biphenyl]
carboxamide
To the product of the previous step (86.9 mg, 0.11 mmol) was added 4 N HCl in
dioxane (2 mL, 8.00 mmol). The reaction mixture was stirred at RT for 1 h, concentrated,
and evaporated with EtOAc (2 x) to produce the di-HCl salt of the title intermediate (83
mg, 99 % yield) as a yellow solid. (m/z): [M+H] calcd for C H F N O 708.32 found
37 41 4 7 3
708.3.
(c) Methyl ((S)((2S,4S)(4-(3'-fluoro-4'-((6-((R)methylpivaloyl-piperazin
yl)pyridinyl)carbamoyl)-2'-(trifluoromethoxy)- [1,1'-biphenyl]yl) -1H-imidazol-
2-yl)methylpyrrolidinyl)oxo(tetrahydro-2H-pyranyl)ethyl)carbamate
To a solution of the product of the previous step (83 mg, 0.11 mmol) and DIPEA
(0.094 mL, 0.54 mmol) in DMF (1 mL) was added (S)((methoxycarbonyl)amino)
(tetrahydro-2H-pyranyl)acetic acid (23 mg, 0.108 mmol) and HATU (51 mg, 0.14
mmol). The reaction mixture was stirred at RT for 1 h, concentrated, dissolved in 1:1
acetic acid:water (1.5 mL) and purified by preparative HPLC to provide the di-TFA salt
of the title compound (67.1 mg). (m/z): [M+H] calcd for C H F N O 907.41 found
46 54 4 8 7
907.6.
Using synthetic methods similar to those exemplified above, the compounds of
Examples 22-24 may be prepared.
Example 22: Methyl (S)((2S,4S)(4-(5'-chloro-4'-(6-((R)methyl
pivaloylpiperazinyl)nicotinamido)-2'-(trifluoromethoxy)biphenylyl)-1H-
imidazolyl)methylpyrrolidinyl)((2S,6S)-2,6-dimethyltetrahydro-2H-
pyranyl)oxoethylcarbamate
Example 23: Methyl (S)((2S,4S)(4-(5'-chloro-4'-(6-((R)methyl
pivaloylpiperazinyl)pyridinylcarbamoyl)-2'-(trifluoromethoxy)biphenylyl)-
1H-imidazolyl)methylpyrrolidinyl)((2S,6S)-2,6-dimethyltetrahydro-2H-
pyranyl)oxoethylcarbamate
Example 24: Methyl (S)((2S,5S)(4-(3'-fluoro-4'-(6-((R)methyl
pivaloylpiperazinyl)pyridinylcarbamoyl)-2'-(trifluoromethoxy)biphenylyl)-
1H-imidazolyl)methylpyrrolidinyl)oxo(tetrahydro-2H-pyran
yl)ethylcarbamate
O F N
HN N
Also using similar synthetic methods, the compounds of Tables 1-29 were
prepared where a blank in any column denotes hydrogen and the symbol (R) or (S) in any
column denotes the orientation of the corresponding chiral carbon atom.
Table 1
HN R
Calc Found
7a 7d (#) 9
Ex No. R R R Formula
[M+H] [M+H]
1-1 OCF F NHCH C H F N O 838.36 838.8
3 3 41 47 4 9 6
1-2 OCF3 F (a) C52H64F4N10O9 1049.48 1050.2
1-3 OCF F C H F N O 849.36 850.0
3 43 48 4 8 6
1-4 CF F (a) C H F N O 1033.48 1032.6
3 52 64 4 10 8
1-5 CF F C H F N O 861.40 860.6
3 45 52 4 8 5
1-6 CF F CH (a) C H F N O 1047.50 1046.6
3 3 53 66 4 10 8
1-7 CF F CH C H F N O 875.42 874.6
3 3 46 54 4 8 5
1-8 CF F CH NHCH C H F N O 836.38 835.6
3 3 3 42 49 4 9 5
1-9 CF F NHCH C H F N O 822.36 821.6
3 3 41 47 4 9 5
1-10 OCF F C H F N O 877.39 877
3 45 52 4 8 6
1-11 CF Cl CH C H ClF N O 891.39 891.6
3 3 46 54 3 8 5
1-12 CF Cl CH NHCH C H ClF N O 852.35 852.6
3 3 3 42 49 3 9 5
1-13 OCF F CH C H F N O 891.41 890.6
3 3 46 54 4 8 6
1-14 OCF F CH C H F N O 889.37 888.6
3 3 44 48 4 10 6
1-15 OCF F CH C H F N O 863.38 862.6
3 3 44 50 4 8 6
1-16 OCF F CH NHCH C H F N O 852.37 851.6
3 3 3 42 49 4 9 6
1-17 OCF Cl NHCH C H ClF N O 854.33 854.6
3 3 41 47 3 9 6
1-18 OCF Cl C H ClF N O 891.32 891.6
3 43 46 3 10 6
Calc Found
7a 7d 9
Ex No. R R R Formula
[M+H] [M+H]
1-19 OCF Cl CH C H ClF N O 905.34 905.6
3 3 44 48 3 10 6
1-20 OCF Cl CH C H ClF N O 907.38 907.6
3 3 46 54 3 8 6
1-21 CF F (CH C H F N O 873.37 873.6
3 3 44 48 4 10 5
1-22 OCF Cl C H ClF N O 965.4 966.0
3 47 56 3 10 7
1-23 OCF Cl CH C H ClF N O 979.41 980.0
3 3 48 58 3 10 7
1-24 OCF F CH C H F N O 963.44 963.6
3 3 48 58 4 10 7
1-25 OCF F C H F N O 875.35 875.8
3 43 46 4 10 6
1-26 OCF F C H F N O 992.46 993.0
3 50 61 4 9 8
1-27 OCF F C H F N O 892.41 892.8
3 45 53 4 9 6
1-28 OCF F C H F N O 949.43 949.6
3 47 56 4 10 7
1-29 CF F C H F N O 859.36 858.8
3 43 46 4 10 5
1-30 CF Cl NHCH C H ClF N O 838.33 838.8
3 3 41 47 3 9 5
1-31 CF Cl C H ClF N O 877.37 877.8
3 45 52 3 8 5
1-32 CF Cl C H ClF N O 875.33 875.8
3 43 46 3 10 5
1-33 OCF3 Cl C44H48ClF3N10O6 905.34 905.8
Calc Found
7a 7d 9
Ex No. R R R Formula
[M+H] [M+H]
1-34 OCF Cl C H ClF N O 905.34 905.8
3 44 48 3 10 6
1-35 OCF Cl C H ClF N O 891.32 891.8
3 43 46 3 10 6
1-36 OCF Cl C H ClF N O 905.34 905.8
3 44 48 3 10 6
1-37 OCF Cl C H ClF N O 952.37 952.8
3 46 53 3 9 8
1-38 OCF Cl C H ClF N O 951.38 952.0
3 46 54 3 10 7
1-39 OCF3 Cl C45H53ClF3N9O8S 972.34 972.8
1-40 OCF Cl C H ClF N O 905.34 905.8
3 44 48 3 10 6
1-41 OCF Cl C H ClF N O 893.37 893.8
3 45 52 3 8 6
1-42 OCF Cl C H ClF N O 865.33 865.8
3 43 48 3 8 6
1-43 OCF Cl CH C H ClF N O 879.35 879.8
3 3 44 50 3 8 6
1-44 OCF Cl CH C H ClF N O 965.40 966.0
3 3 47 56 3 10 7
1-45 OCF Cl CH C H ClF N OS 986.35 986.8
3 3 46 55 3 9 8
1-46 OCF Cl CH C H ClF N O 966.38 966.8
3 3 47 55 3 9 8
(R) N
1-47 OCF Cl C H ClF N O 936.37 936.8
3 46 53 3 9 7
Calc Found
7a 7d 9
Ex No. R R R Formula
[M+H] [M+H]
1-48 OCF Cl C H ClF N O 950.39 950.8
3 47 55 3 9 7
(R) N
1-49 OCF Cl C H ClF N O 964.40 965.0
3 48 57 3 9 7
1-50 OCF Cl C H ClF N O 978.42 979.0
3 49 59 3 9 7
1-51 OCF Cl C H ClF N O 962.39 963.0
3 48 55 3 9 7
1-52 CF3 F C43H48F4N8O5 833.37 833.8
1-53 CF F C H F N O 869.35 869.8
3 43 46 6 8 5
1-54 CF Cl C H ClF N O 849.34 849.8
3 43 48 3 8 5
1-55 CF Cl C H ClF N O 885.32 885.8
3 43 46 5 8 5
1-56 OCF Cl C H Cl F N O 933.26 934.8
3 43 46 3 3 8 6
1-57 OCF Cl C H Cl F N O 933.26 934.8
3 43 46 3 3 8 6
1-58 CF F C H F N O 849.40 849.8
3 44 52 4 8 5
1-59 OCF Cl C H Cl F N O 917.29 917.8
3 43 46 2 4 8 6
1-60 OCF F C H ClF N O 901.32 901.8
3 43 46 5 8 6
1-61 CF Cl C H ClF N O 865.37 865.8
3 44 52 3 8 5
1-62 CF C H F N O 843.41 843.8
3 45 53 3 8 5
1-63 CF C H F N O 831.41 831.8
3 44 53 3 8 5
1-64 CF N(CH ) C H F N O 818.39 818.8
3 3 2 42 50 3 9 5
1-65 CF C H F N O 815.38 815.8
3 43 49 3 8 5
1-66 OCF Cl CH C H ClF N O 839.32 839.8
3 3 41 46 3 8 6
Calc Found
7a 7d 9
Ex No. R R R Formula
[M+H] [M+H]
1-67 OCF Cl C H ClF N O 895.38 895.8
3 45 54 3 8 6
1-68 OCF Cl C H ClF N O 867.35 867.8
3 43 50 3 8 6
1-69 OCF Cl C H ClF N O 881.37 881.8
3 44 52 3 8 6
1-70 OCF Cl C H ClF N O 879.35 879.8
3 44 50 3 8 6
1-71 OCF Cl C H ClF N O 881.37 881.8
3 44 52 3 8 6
1-72 OCF Cl C H ClF N O 882.36 882.8
3 43 51 3 9 6
1-73 OCF Cl C H ClF N O 853.33 853.8
3 42 48 3 8 6
1-74 OCF C H F N O 859.40 859.6
3 45 53 3 8 6
1-75 OCF C H F N O 847.40 847.5
3 44 53 3 8 6
1-76 Cl F C H ClFN O 827.37 827.8
44 52 8 5
1-77 Cl F C H Cl FN O 867.26 867.8
42 46 3 8 5
1-78 Cl F C H ClFN O 815.37 815.8
43 52 8 5
1-79 OCF F C H F N O 863.38 863.8
3 44 50 4 8 6
1-80 OCF Cl C H ClF N O 879.35 879.8
3 44 50 3 8 6
1-81 F F C H F N O 811.40 811.8
44 52 2 8 5
1-82 F F C H F N O 799.40 799.8
43 52 2 8 5
1-83 F F C H F N O 783.37 783.8
42 48 2 8 5
1-84 Cl F C H ClFN O 825.36 825.8
44 50 8 5
1-85 OCF Cl C H ClF N O 922.39 922.8
3 46 55 3 9 6
1-86 OCF Cl C H ClF N O 881.37 881.8
3 44 52 3 8 6
1-87 OCF Cl C H ClF N O 891.35 891.8
3 45 50 3 8 6
1-88 OCF F C H F N O 875.38 875.8
3 45 50 4 8 6
Calc Found
7a 7d 9
Ex No. R R R Formula
[M+H] [M+H]
1-89 CF Cl C H ClF N O 875.35 875.8
3 45 50 3 8 5
1-90 F F C H F N O 809.39 809.8
44 50 2 8 5
1-91 OCF Cl C H ClF N O 893.37 893.8
3 45 52 3 8 6
1-92 OCF F 3 C H D F N O 883.44 883.8
3 45 46 6 4 8 6
1-93 CF C H D F N O 849.45 849.8
3 45 47 6 3 8 5
1-94 OCF Cl C H ClF N O 883.36 883.8
3 42 50 3 10 6
1-95 OCF F C H F N O 867.39 867.8
3 42 50 4 10 6
1-96 OCF Cl C H ClF N O 885.34 885.8
3 43 49 4 8 6
1-97 OCF Cl C H ClF N O 923.30 923.8
3 42 45 6 8 7
1-98 OCF Cl C H ClF N O 879.35 879.8
3 44 50 3 8 6
1-99 OCF Cl C H ClF N O 933.32 933.8
3 44 47 6 8 6
1-100 Cl F C H ClD FN O 830.42 833.8
44 46 6 8 5
1-101 OCF F C H F N O 881.39 881.8
3 OH 44 52 4 8 7
(b) Stereoisomers separated but unassigned
(#) For all compounds, when the substitutent R is present, the orientation of
the chiral carbon atom bearing the substitutent R is (S).
Table 2
O
Calc Found
7a 7c 9 10
Ex No. R R R R Formula
[M+H] [M+H]
2-1 C H N O 802.41 802.4
43 51 11 5
2-2 C H N O 861.47 861.4
47 60 10 6
2-3 C H N O 804.45 805.4
45 57 9 5
2-4 CH C H N O 818.46 818.4
3 46 59 9 5
2-5 CH NHCH C H N O 779.43 779.4
3 3 42 54 10 5
2-6 OCF Cl C H ClF N O 922.39 922.8
3 46 55 3 9 6
2-7 OCF Cl C H ClF N O 910.39 910.8
3 45 55 3 9 6
2-8 OCF Cl Cl C H Cl F N O 956.35 957.8
3 46 54 2 3 9 6
Table 3
Calc Found
Ex No. R Formula
[M+H] [M+H]
3-1 C H F N O 875.42 874.6
46 54 4 8 5
3-2 C H F N O 1,047.50 1046.6
53 66 4 10 8
3-3 C H F N O 847.38 846.8
44 50 4 8 5
3-4 NHCH3 C42H49F4N9O5 836.38 835.6
Table 4
O
HN R
Calc Found
7a 7d (#) 9 10
Ex No. R R R R Formula
[M+H] [M+H]
4-1 C H N O 775.42 775.4
44 54 8 5
4-2 C H N O 947.51 947.6
51 66 10 8
4-3 OCF C H F N O 1031.49 1031.4
3 52 65 3 10 9
Calc Found
7a 7d 9 10
Ex No. R R R R Formula
[M+H] [M+H]
4-4 OCF C H F N O 946.44 945.6
3 48 58 3 9 8
4-5 OCF C H F N O 960.45 959.6
3 49 60 3 9 8
4-6 OCF C H F N O 931.44 930.6
3 47 57 3 10 7
4-7 OCF C H F N O 1031.49 1,030.6
3 52 65 3 10 9
4-8 OCF CH C H F N O 960.45 960.8
3 3 49 60 3 9 8
4-9 OCF3 CH3 C48H59F3N10O7 945.45 946.0
4-10 OCF CH Cl C H ClF N O 907.38 907.8
3 3 46 54 3 8 6
4-11 OCF CH Cl C H ClF N O 879.35 879.8
3 3 44 50 3 8 6
4-12 OCF3 CH3 NHCH3 Cl C42H49ClF3N9O6 868.35 868.8
4-13 OCF CH Cl C H ClF N O 893.37 893.8
3 3 45 52 3 8 6
4-14 OCF CH NHCH C H F N O 834.38 834.8
3 3 3 42 50 3 9 6
4-15 OCF CH C H F N O 861.42 861.8
3 3 45 55 3 8 6
4-16 OCF CH C H F N O 845.39 845.8
3 3 44 51 3 8 6
4-17 OCF CH C H F N O 859.4 859.8
3 3 45 53 3 8 6
4-18 OCF CH C H F N O 942.44 943.0
3 3 49 58 3 9 7
4-19 OCF CH NH C H F N O 931.44 932.0
3 3 47 57 3 10 7
Calc Found
7a 7d 9 10
Ex No. R R R R Formula
[M+H] [M+H]
4-20 OCF CH C H F N O 959.47 960.0
3 3 49 61 3 10 7
4-21 OCF CH C H F N O 930.44 931.0
3 3 48 58 3 9 7
4-22 OCF CH C H F N O 881.37 881.8
3 3 44 49 5 8 6
4-23 OCF CH C H Cl F N O 913.31 913.8
3 3 44 49 2 3 8 6
4-24 OCF CH C H F N O 860.40 860.8
3 3 N 44 52 3 9 6
4-25 OCF CH C H F N O 862.42 862.8
3 3 44 54 3 9 6
4-26 OCF CH Cl C H ClF N O 895.38 895.8
3 3 45 54 3 8 6
4-27 OCF CH C H F N O 904.43 904.8
3 3 46 56 3 9 7
4-28 OCF CH C H F N O 890.41 891.0
3 3 45 54 3 9 7
4-29 OCF Cl C H ClF N O 893.37 893.8
3 45 52 3 8 6
4-30 OCF Cl C H Cl F N O 933.26 933.8
3 43 46 3 3 8 6
4-31 OCF Cl C H ClF N O 865.33 865.8
3 43 48 3 8 6
4-32 OCF C H Cl F N O 899.30 899.8
3 43 47 2 3 8 6
4-33 OCF N(CH ) C H F N O 834.38 834.8
3 3 2 42 50 3 9 6
4-34 OCF NHCH C H F N O 820.37 820.8
3 3 41 48 3 9 6
4-35 OCF C H F N O 831.37 831.8
3 43 49 3 8 6
4-36 OCF C H F N O 847.40 847.8
3 44 53 3 8 6
4-37 OCF CH Cl C H ClF N O 923.38 923.8
3 3 46 54 3 8 7
4-38 OCF CH C H F N O 889.41 890.0
3 3 46 55 3 8 7
4-39 OCF CH C H F N O 930.44 931.0
3 3 48 58 3 9 7
Calc Found
7a 7d 9 10
Ex No. R R R R Formula
[M+H] [M+H]
4-40 OCF CH C H F N O 916.43 917.0
3 3 47 56 3 9 7
4-41 OCF F C H F N O 865.39 865.8
3 44 52 4 8 6
4-42 OCF F C H F N O 865.39 865.8
3 44 52 4 8 6
4-43 OCF F C H F N O 877.39 877.8
3 45 52 4 8 6
4-44 OCF F Cl C H ClF N O 911.36 911.8
3 45 51 4 8 6
4-45 OCF F Cl C H ClF N O 899.36 899.8
3 44 51 4 8 6
4-46 OCF Cl C H ClF N O 881.37 881.8
3 44 52 3 8 6
4-47 OCF Cl Cl C H Cl F N O 915.33 915.8
3 44 51 2 3 8 6
(#) For all compounds, when the substitutent R is present, the orientation of the chiral
carbon atom bearing the substitutent R is (S).
Table 5
Calc Found
Ex No. Formula
[M+H] [M+H]
C H F N O 1075.48 1076.2
53 65 3 10 11
C H F N O 990.43 989.6
49 58 3 9 10
C H ClF N OS 913.34 913.8
44 52 3 8 6
C H ClF N OS 925.34 925.8
45 52 3 8 6
-5 Cl
C H ClD F N O 873.3 885.8
44 44 6 3 8 6
Cl O
C H ClFN O 815.37 815.8
43 52 8 5
-7 Cl
C H F N O 863.38 863.8
44 50 4 8 6
Calc Found
Ex No. Formula
[M+H] [M+H]
F O O
C H ClF N O 899.36 899.8
44 51 4 8 6
HN HN
C H ClF N O 912.39 912.8
48 53 3 9 4
-10
C H ClF N O 984.41 984.8
51 57 3 9 6
-11
C H ClF N O 925.36 925.8
45 52 3 8 8
HO CF
-12
C H ClF N O 911.38 911.6
45 54 3 8 7
HO CF
-13
C H ClF N O 927.37 927.6
45 54 3 8 8
Cl O
-14
C H Cl F N O 915.33 915.4
44 51 2 3 8 6
Calc Found
Ex No. Formula
[M+H] [M+H]
O Cl
-15
N C H ClF N O 953.39 953.6
47 56 3 8 8
-16 F
C H F N O 939.40 939.8
46 54 4 8 9
-17
C H ClF N O 943.37 943.6
45 54 3 8 9
HO 3
-18
C H ClF N O 927.37 927.6
45 54 3 8 8
-19
C H ClF N O 897.36 897.6
44 52 3 8 7
-20
C H ClF N O 939.37 939.6
46 54 3 8 8
Table 6
Calc Found
Ex No. Formula
[M+H] [M+H]
6-1 C H N O 819.41 820.0
45 54 8 7
6-2 C H N O 775.36 775.4
41 46 10 6
6-3 C H N O 976.53 977.0
52 69 11 8
6-4 C H N O 776.42 776.6
43 53 9 5
6-5 C H N O 804.45 804.6
45 57 9 5
6-6 C H F N O 1045.50 1044.6
53 67 3 10 9
6-7 C H F N O 960.45 959.6
49 60 3 9 8
Calc Found
Ex No. Formula
[M+H] [M+H]
6-8 C H F N O 873.42 872.8
46 55 3 8 6
6-9 C H F N OS 1063.46 1063.6
52 65 3 10 9
6-10 C H F N OS 978.41 978.6
48 58 3 9 8
6-11 C H F N O 860.4 860.8
44 52 3 9 6
6-12 C H F N O 899.44 900.0
48 57 3 8 6
6-13 C H F N O 986.47 987.0
51 62 3 9 8
6-14 C H F N O 1071.52 1072.0
55 69 3 10 9
Calc Found
Ex No. Formula
[M+H] [M+H]
HN N
6-15 C H F N OS 879.38 879.8
44 53 3 8 6
6-16 C H F N O 1030.49 1031.2
53 66 3 9 9
HN N
6-17 C H ClD F N O 928.43 928.8
46 49 6 3 9 6
HN N
6-18 C H F N OS 907.37 907.8
45 53 3 8 7
HN N
6-19 C H F N OS 895.37 895.8
44 53 3 8 7
HN N
6-20 C H D F N OS 901.32 913.8
45 47 6 3 8 7
6-21 C H F N OS 923.37 923.8
45 53 3 8 8
Calc Found
Ex No. Formula
[M+H] [M+H]
6-22 C H F N OS 911.37 911.8
44 53 3 8 8
6-23 C H F N O 861.42 861.8
45 55 3 8 6
HN N
6-24
C H F N O 893.39 893.6
45 52 4 8 7
6-25
C H F N O 909.38 909.6
45 52 4 8 8
HN N
6-26
C H ClF N O 881.37 881.4
44 52 3 8 6
6-27
C H ClF N O 911.38 911.6
45 54 3 8 7
Calc Found
Ex No. Formula
[M+H] [M+H]
HN N
6-28
C H ClF N O 923.38 923.6
46 54 3 8 7
6-29
C H F N O 937.42 937.6
47 56 4 8 8
Table 7
HN N
Ex Calc Found
1 2 3
R * R R Formula
No. [M+H] [M+H]
7-1 (S) C H ClF N O 882.36 882.8
43 51 3 9 6
7-2 (R) C H ClF N O 882.36 882.8
43 51 3 9 6
7-3 (S) C H ClF N O 866.33 866.8
42 47 3 9 6
7-4 (S) C H ClF N O 910.39 910.8
45 55 3 9 6
7-5 (S) C H ClF N O 896.38 896.8
44 53 3 9 6
7-6 (S) C H ClF N O 924.41 924.8
46 57 3 9 6
7-7 (S) C H ClF N O 882.36 882.8
43 51 3 9 6
7-8 (S) C H ClF N O 896.38 896.8
44 53 3 9 6
7-9 (S) C H ClF N O 884.34 884.8
42 49 3 9 7
7-10 (R) C H ClF N O 882.36 882.8
43 51 3 9 6
7-11 (R) CH CH C H ClF N O 872.36 872.8
3 3 45 49 3 9 4
7-12 (R) C H C H C H ClF N O 900.39 900.8
2 5 2 5 47 53 3 9 4
7-13 C H (S) C H ClF N O 854.33 854.8
2 5 41 47 3 9 6
7-14 CH (S) CH C H ClF N O 854.33 854.8
3 3 41 47 3 9 6
7-15 (R) C H ClF N OS 886.3 886.8
41 47 3 9 6
Ex Calc Found
1 2 3
R * R R Formula
No. [M+H] [M+H]
7-16 (S) C H ClF N OS 908.29 908.8
43 45 3 9 6
7-17 (R) C H ClF N O 906.32 906.8
44 47 3 9 7
Table 8
HN R
Calc Found
7a 7c 9
Ex No. R R R Formula
[M+H] [M+H]
8-1 OCF Cl C H ClF N O 891.35 891.8
3 45 50 3 8 6
8-2 OCF Cl C H ClF N O 879.35 879.8
3 44 50 3 8 6
8-3 CF Cl C H ClF N O 847.32 847.8
3 43 46 3 8 5
8-4 CF Cl C H ClF N O 875.35 875.8
3 45 50 3 8 5
8-5 CF Cl C H ClF N O 863.35 863.8
3 44 50 3 8 5
8-6 CF Cl C H ClF N O 873.34 873.8
3 45 48 3 8 5
Table 9
Calc Found
7a 9 10
Ex No. R R R Formula
[M+H] [M+H]
9-1 OCF Cl C H ClF N O 879.35 879.8
3 44 50 3 8 6
9-2 OCF C H F N O 845.39 845.8
3 44 51 3 8 6
9-3 OCF C H F N O 857.39 857.8
3 45 51 3 8 6
9-4 OCF3 Cl C45H50ClF3N8O6 891.35 891.8
9-5 OCF C H F N O 855.37 855.8
3 45 49 3 8 6
Table 10
O
Calc Found
7a 9 10
Ex No. R R R Formula
[M+H] [M+H]
-1 OCF C H F N O 888.43 889.0
3 46 56 3 9 6
-2 OCF3 NHCH3 C42H51F3N10O6 849.39 849.8
-3 OCF Cl C H ClF N O 910.39 910.8
3 45 55 3 9 6
-4 OCF N(CH ) Cl C H ClF N O 897.37 897.8
3 3 2 43 52 3 10 6
-5 OCF Cl C H ClF N O 922.39 922.8
3 46 55 3 9 6
Table 11
Calc Found
7a 7d (#) 9 10
Ex No. R R R R Formula
[M+H] [M+H]
11-1 OCF CH C H Cl F N O 929.31 929.8
3 3 44 49 2 3 8 7
11-2 OCF CH NHCH C H F N O 850.38 850.8
3 3 3 42 50 3 9 7
11-3 OCF CH Cl C H ClF N O 923.38 923.8
3 3 46 54 3 8 7
11-4 OCF CH Cl C H Cl F N O 963.27 963.8
3 3 44 48 3 3 8 7
11-5 OCF CH Cl C H ClF N O 909.36 909.8
3 3 45 52 3 8 7
11-6 OCF CH Cl C H ClF N O 895.34 895.8
3 3 44 50 3 8 7
11-7 OCF CH Cl C H ClF N O 911.38 911.8
3 3 45 54 3 8 7
11-8 OCF CH NHCH Cl C H ClF N O 884.34 884.8
3 3 3 42 49 3 9 7
11-9 OCF CH N(CH ) Cl C H ClF N O 898.36 898.8
3 3 3 2 43 51 3 9 7
11-10 OCF Cl C H ClF N O 909.36 909.8
3 45 52 3 8 7
11-11 OCF Cl C H ClF N O 897.36 897.8
3 44 52 3 8 7
11-12 OCF Cl C H ClF N O 907.34 907.8
3 45 50 3 8 7
(#) For all compounds, when the substitutent R is present, the orientation of the chiral
carbon atom bearing the substitutent R is (S).
Table 12
HN R
Calc Found
Ex No. R Formula
[M+H] [M+H]
12-1 C42H49ClF3N9O7 884.34 884.8
12-2 C H ClF N O 954.38 954.8
46 55 3 9 8
12-3 C H ClF N O 939.41 939.8
47 58 3 8 7
12-4 C H ClF N O 927.37 927.8
45 54 3 8 8
12-5 C H ClF N O 911.38 911.8
45 54 3 8 7
12-6 C H ClF N O 937.37 937.8
45 52 3 10 7
12-7 C45H47ClF3N9O6 902.33 902.8
12-8 C H ClF N O 897.36 897.8
44 52 3 8 7
12-9 C H ClF N O 908.38 908.8
45 53 3 9 6
12-10 C H ClF N O 908.38 908.8
45 53 3 9 6
12-11 C H ClF N OS 912.32 912.8
43 49 3 9 6
12-12 C H ClF N O 906.36 906.8
(S) 45 51 3 9 6
Calc Found
Ex No. R Formula
[M+H] [M+H]
12-13 C H ClF N O 920.38 920.8
46 53 3 9 6
12-14 C H ClF N O 906.36 906.8
(S) 45 51 3 9 6
12-15 C H ClF N O 922.39 922.8
46 55 3 9 6
12-16 C H ClF N O 928.37 928.8
44 53 3 9 8
HN N
12-17 O C H ClF N O 925.33 925.8
43 48 3 10 8
12-18 C H ClF N O 925.37 925.8
HN N O 44 52 3 10 7
12-19 HN N S C H ClF N OS 973.33 973.8
44 52 3 10 8
12-20 C H ClF N O 910.39 910.8
45 55 3 9 6
12-21 C H ClF N O 907.38 907.8
46 54 3 8 6
12-22 C H ClF N O 910.39 910.8
45 55 3 9 6
12-23 C H ClF N O 896.38 896.8
44 53 3 9 6
12-24 C H ClF N O 896.38 896.8
HN 44 53 3 9 6
12-25 C H ClF N O 921.4 921.8
47 56 3 8 6
12-26
C H ClF N O 952.40 952.8
47 57 3 9 7
12-27
C H ClF N O 909.36 909.8
45 52 3 8 7
12-28
C H ClF N O 923.38 923.8
46 54 3 8 7
Calc Found
Ex No. R Formula
[M+H] [M+H]
12-29
O C H ClF N O 996.39 996.8
48 57 3 9 9
12-30
O C H ClF N O 907.34 908.8
45 50 3 8 7
12-31
O C H ClF N O 907.34 907.6
45 50 3 8 7
12-32
O C H ClF N O 911.38 911.8
45 54 3 8 7
12-33
C H ClF N O 996.39 996.6
48 57 3 9 9
N OH
12-34
C H ClF N O 1010.41 1010.8
49 59 3 9 9
12-25
C H ClF N O 954.38 954.6
OH 46 55 3 9 8
12-36
NH C H ClF N O 896.38 896.6
44 53 3 9 6
12-37
C H ClF N O 964.40 964.6
48 57 3 9 7
12-38
C H ClF N O 980.43 980.6
49 61 3 9 7
12-39
C H ClF N O 954.38 954.6
46 55 3 9 8
12-40
C H ClF N O 953.40 953.4
46 56 3 10 7
12-41
C H ClF N O 952.40 952.6
47 57 3 9 7
12-42
C H ClF N O 938.39 938.6
46 55 3 9 7
12-43
C H ClF N O 897.36 897.6
44 52 3 8 7
12-44
O C H ClF N O 909.36 909.6
45 52 3 8 7
Calc Found
Ex No. R Formula
[M+H] [M+H]
12-45
C H ClF N O 923.38 923.6
46 54 3 8 7
12-46
S C H ClF N OS 974.35 974.6
45 55 3 9 8
12-47
C H ClF N O 895.34 895.6
44 50 3 8 7
12-48
C H ClF N O 895.34 895.6
44 50 3 8 7
12-49
C H ClF N O 881.33 881.6
43 48 3 8 7
12-50
C H ClF N O 921.36 921.6
46 52 3 8 7
12-51
C H ClF N O 880.35 880.6
43 49 3 9 6
12-52
C H ClF N O 894.36 894.6
44 51 3 9 6
12-53
C H ClF N O 910.36 910.6
44 51 3 9 7
12-54
C H ClF N O 910.36 910.6
44 51 3 9 7
12-55
C H ClF N O 909.36 909.6
45 52 3 8 7
12-56
C H ClF N O 910.36 910.6
44 51 3 9 7
12-57
C H ClF N O 910.36 910.6
44 51 3 9 7
12-58
C H ClF N O 911.34 912.6
44 50 3 8 8
Table 13
HN R
Calc Found
7c 9
Ex No. G R R Formula
[M+H] [M+H]
13-1 Cl C H ClF N O 925.41 925.8
50 56 3 8 4
13-2 Cl C H ClF N O 891.42 891.8
47 58 3 8 4
13-3 Cl C H ClF N O 926.4 926.8
49 55 3 9 4
13-4 Cl C H ClF N O 984.41 984.8
O 51 57 3 9 6
13-5 (S) Cl C H ClF N O 897.36 897.8
44 52 3 8 7
13-6 Cl C H ClF N O 883.34 883.8
43 50 3 8 7
13-7 Cl C H ClF N OS 899.32 899.8
43 50 3 8 6
13-8 Cl C H ClF N O 897.36 879.8
44 52 3 8 7
Calc Found
7c 9
Ex No. G R R Formula
[M+H] [M+H]
13-9 Cl C H ClF N O 941.39 941.4
46 56 3 8 8
13-10 Cl C H ClF N O 882.36 882.8
43 51 3 9 6
13-11 Cl C H ClF N O 868.35 868.8
42 49 3 9 6
13-12 C H F N O 889.41 889.8
46 55 3 8 7
13-13 C H F N O 849.38 849.8
43 51 3 8 7
13-14 C H F N O 863.4 863.8
44 53 3 8 7
13-15 (S) C H F N O 863.4 863.8
44 53 3 8 7
13-16 (S) Cl OH C H ClF N O 913.36 913.8
44 52 3 8 8
13-17 Cl OH C H ClF N O 899.34 899.8
43 50 3 8 8
13-18 Cl OH C H ClF N O 913.36 913.8
44 52 3 8 8
13-19 Cl OH C H ClF N O 939.37 939.8
46 54 3 8 8
Calc Found
7c 9
Ex No. G R R Formula
[M+H] [M+H]
13-20 F C H F N O 867.37 867.8
43 50 4 8 7
13-21 F C H F N O 881.39 881.8
44 52 4 8 7
13-22 F C46H54F4N8O7 907.41 907.8
13-23 (S) F OH C H F N O 897.38 897.8
44 52 4 8 8
13-24 (S) F C H F N O 881.39 881.8
44 52 4 8 7
13-25 F OH C H F N O 897.38 897.8
44 52 4 8 8
13-26 F OH C H F N O 883.37 883.8
43 50 4 8 8
13-27 F OH C H F N O 923.4 923.8
46 54 4 8 8
13-28
(S) C H F N O 879.39 879.8
44 53 3 8 8
13-29
OH C H F N O 863.40 863.8
44 53 3 8 7
13-30
OH C H F N O 865.38 865.8
43 51 3 8 8
Calc Found
7c 9
Ex No. G R R Formula
[M+H] [M+H]
13-31
OH C H F N O 879.39 879.8
44 53 3 8 8
13-32
OH C H F N O 905.41 905.8
46 55 3 8 8
13-33
Cl C H ClF N O 910.39 910.8
45 55 3 9 6
13-34
Cl C H ClF N O 937.39 937.8
47 56 3 8 7
13-35
Cl C H ClF N O 935.38 935.8
47 54 3 8 7
13-36
Cl C46H54ClF3N8O8S 971.34 971.4
13-37
Cl C H ClF N O 923.38 923.8
46 54 3 8 7
13-38
Cl C H ClF N O 923.38 924.3
46 54 3 8 7
13-39
Cl C H ClF N O 921.40 921.6
47 56 3 8 6
Calc Found
7c 9
Ex No. G R R Formula
[M+H] [M+H]
13-40
Cl C H ClF N O 921.40 921.6
47 56 3 8 6
13-41
Cl C H ClF N O 907.38 907.6
46 54 3 8 6
13-42
Cl C H ClF N O 951.41 951.6
48 58 3 8 7
13-43
Cl C H ClF N O 951.41 951.6
48 58 3 8 7
13-44
Cl C H ClF N O 895.34 895.4
44 50 3 8 7
13-45
Cl OH C H ClF N O 911.34 912.6
44 50 3 8 8
(a) Stereoisomers separated but unassigned
Table 14
Calc Found
4 7c 8b 9
Ex No. R R * R R Formula
[M+H] [M+H]
14-1 CH Cl (R) CH OH C H ClF N O 897.36 897.8
3 2 44 52 3 8 7
14-2 CH Cl (S) CH OH C H ClF N O 897.36 897.8
3 2 44 52 3 8 7
14-3 CH Cl (R) CH OH OH C H ClF N O 913.36 913.8
3 2 44 52 3 8 8
14-4 CH Cl (S) CH OH OH C H ClF N O 913.36 913.8
3 2 44 52 3 8 8
14-5 OCH F (S) CH OH OH C H F N O 913.38 913.8
3 2 44 52 4 8 9
14-6 OCH F (S) CH OH OH C H F N O 913.38 913.8
3 2 44 52 4 8 9
Table 15
4 Cl
Calc Found
Ex No. R R Formula
[M+H] [M+H]
-1 C H ClF N O 941.39 941.8
46 56 3 8 8
-2 C H ClF N O 963.38 963.8
47 54 3 10 7
-3 OH C H ClF N O 926.35 926.8
44 51 3 9 8
-4 O N C H ClF N O 964.40 964.8
48 57 3 9 7
-5 O N C H ClF N O 952.40 952.8
47 57 3 9 7
-6 C H ClF N O 924.41 924.8
46 57 3 9 6
-7 C H ClF N O 938.42 938.8
47 59 3 9 6
-8 C H ClF N O 939.42 939.8
46 58 3 10 6
-9 C47H57ClF3N9O6 936.41 936.8
-10
O C H ClF N O 926.35 926.8
44 51 3 9 8
-11
C H ClF N O 892.35 892.8
44 49 3 9 6
-12
C44H49ClF3N9O7 908.34 908.8
-13
C H ClF N O 911.38 911.6
45 54 3 8 7
Table 16
HN R
Calc Found
1 (#) 7d 9
Ex No. R R R Formula
[M+H] [M+H]
16-1 Cl C H ClF N O 913.36 913.8
44 52 3 8 8
16-2 Cl C H ClF N O 899.34 899.8
43 50 3 8 8
16-3 Cl C H ClF N O 913.36 913.8
44 52 3 8 8
16-4 (S)
F C H F N O 883.37 883.8
43 50 4 8 8
16-5
F C H F N O 897.38 897.8
44 52 4 8 8
16-6
F C H F N O 897.38 897.8
44 52 4 8 8
16-7
Cl OH C H ClF N O 915.33 915.8
43 50 3 8 9
16-8 (S)
Cl C H ClF N O 929.35 929.8
44 52 3 8 9
16-9
Cl OH C H ClF N O 929.35 929.8
44 52 3 8 9
16-10
C H F N O 865.38 865.8
43 51 3 8 8
16-11 (S)
C H F N O 879.39 879.8
44 53 3 8 8
16-12
F OH C H F N O 899.36 899.8
43 50 4 8 9
16-13 (S)
F OH C H F N O 913.38 913.8
44 52 4 8 9
16-14
F OH C H F N O 913.38 913.8
44 52 4 8 9
16-15 (S)
C H F N O 881.37 881.8
43 51 3 8 9
16-16
OH C H F N O 895.39 895.8
44 53 3 8 9
Calc Found
1 (#) 7d 9
Ex No. R R R Formula
[M+H] [M+H]
16-17
OH C H F N O 895.39 895.8
44 53 3 8 9
16-18
C H F N O 879.39 879.8
44 53 3 8 8
(#) For all compounds, the orientation of the chiral carbon bearing the substituent R is (S)
Table 17
Calc Found
7a 9
Ex No. R R Formula
[M+H] [M+H]
17-1 CF C H ClF N O 877.37 877.8
3 45 52 3 8 5
17-2 CF C H ClF N O 865.37 865.8
3 44 52 3 8 5
17-3 OCF C H ClF N O 881.37 881.8
3 44 52 3 8 6
17-4 OCF C H ClF N O 893.37 893.8
3 45 52 3 8 6
Table 18
HN N
HN R
Ex Calc Found
1 (#) 7a 7d 9 10
R R R R R Formula
No. [M+H] [M+H]
18-1 OCF3 Cl C45H52ClF3N8O6 893.37 893.8
18-2 OCF Cl C H ClF N O 881.37 881.8
3 44 52 3 8 6
18-3 OCF C H F N O 859.40 859.8
3 45 53 3 8 6
18-4 OCF C H F N O 847.40 847.8
3 44 53 3 8 6
18-5 O OCF Cl C H ClF N O 923.38 923.6
3 46 54 3 8 7
18-6 OCF Cl C H ClF N O 951.41 951.6
3 48 58 3 8 7
(#) For all compounds, the orientation of the chiral carbon bearing the substituent R is (S)
Table 19
HN R
4 Cl
Calc Found
1 4 9
Ex No. R * R R Formula
[M+H] [M+H]
19-1
S (a) CH OH C H ClF N OS 971.34 971.4
3 46 54 3 8 8
19-2
O (S) CH C H ClF N O 907.38 906.6
3 46 54 3 8 6
Calc Found
1 4 9
Ex No. R * R R Formula
[M+H] [M+H]
19-3
(R) CH C H ClF N O 905.40 904.6
3 47 56 3 8 5
19-4
O (S) CH OH C H ClF N O 923.38 922.6
3 46 54 3 8 7
19-5
(R) CH C H ClF N O 921.40 920.6
3 OH 47 56 3 8 6
19-6
S (a) CH C H ClF N OS 955.35 955.5
3 46 54 3 8 7
19-7
(S) CH C H ClF N O 921.40 921.6
3 OH 47 56 3 8 6
19-8
(S) CH C H ClF N O 905.40 905.6
3 47 56 3 8 5
19-9
O (S) CH C H ClF N O 935.41 935.6
3 48 58 3 8 6
19-10
(R) CH C H ClF N O 935.41 935.6
3 48 58 3 8 6
19-11
(S) CH C H ClF N O 891.39 891.6
3 46 54 3 8 5
19-12
S (a) OCH C H ClF N OS 987.34 987.2
3 OH 46 54 3 8 9
19-13
O (S) OCH C H ClF N O 939.37 939.6
3 OH 46 54 3 8 8
19-14
(R) OCH OH C H ClF N O 937.39 937.6
3 47 56 3 8 7
19-15
(S) OCH OH C H ClF N O 937.39 937.6
3 47 56 3 8 7
19-16
O (S) OCH C H ClF N O 923.38 923.6
3 46 54 3 8 7
19-17
(S) OCH C H ClF N O 921.40 921.6
3 47 56 3 8 6
19-18
S (a) OCH C H ClF N OS 971.34 971.5
3 46 54 3 8 8
(a) Stereoisomers separated but unassigned
Table 20
Calc Found
8a 8b 9 10
Ex No. R * R # R R Formula
[M+H] [M+H]
-1
CH (R) O C H ClF N O 1038.40 1038.8
3 50 59 3 9 10
-2
CH (R) CH OH C H ClF N O 953.39 953.8
3 2 47 56 3 8 8
-3
CH3 (R) OH CH2OH C47H56ClF3N8O9 969.38 969.4
-4
CH (S) C H ClF N O 923.38 923.6
3 46 54 3 8 7
-5
CH (S) H ClF N O 923.38 923.6
3 C46 54 3 8 7
-6
CH (R) C H ClF N O 923.38 923.6
3 46 54 3 8 7
-7
CH OCH (R) C H ClF N O 953.39 953.6
2 3 47 56 3 8 8
Table 21
Calc Found
Ex No. R * Formula
[M+H] [M+H]
21-1
(R)C46H56F2N8O5 839.43 838.8
21-2
C H F N OS 889.38 888.6
45 54 2 8 7
21-3
(S) C H F N O 841.41 840.6
45 54 2 8 6
21-4
(S) C H F N O 839.43 839.6
46 56 2 8 5
Table 22
HN N
Calc Found
4 7a 7d 9 10
Ex No. R R R R R Formula
[M+H] [M+H]
22-1
CH C H N O 805.43 805.8
3 45 56 8 6
22-2
CH C H N O 817.43 817.8
3 46 56 8 6
22-3
CH OCF C H F N O 889.41 889.8
3 3 46 55 3 8 7
22-4
CH3 OCF3 C47H55F3N8O7 901.41 901.8
22-5
CH OCF Cl C H ClF N O 935.38 935.8
3 3 47 54 3 8 7
22-6
CH OCF Cl C H ClF N O 923.38 923.8
3 3 46 54 3 8 7
22-7
CH OCF Cl Cl C H Cl F N O 957.34 957.8
3 3 46 53 2 3 8 7
22-8
CH OCF Cl C H ClF N O 939.37 939.8
3 3 OH 46 54 3 8 8
22-9
CH OCF Cl OH Cl C H Cl F N O 973.33 973.8
3 3 46 53 2 3 8 8
22-10
CH3 Cl C45H55ClN8O6 839.39 838.6
22-11
CH Cl C H ClN O 851.39 850.6
3 46 55 8 6
22-12 C H F N O 905.41 905.8
46 55 3 8 8
OCH OCF
22-13 C H N O 821.43 821.8
45 56 8 7
22-14 C H F N O 921.40 921.6
46 55 3 8 9
OCH OCF
3 3 OH
22-15 C H N O 833.43 833.6
46 56 8 7
22-16 C H ClF N O 939.37 939.6
46 54 3 8 8
OCH OCF Cl
22-17 C H ClF N O 955.37 955.6
46 54 3 8 9
OCH OCF Cl OH
Table 23
Calc Found
Ex No. R * R Formula
[M+H] [M+H]
23-1 (R) C48H58ClF3N8O7 951.41 951.6
23-2 O (S) C H ClF N O 951.41 951.6
48 58 3 8 7
23-3 (S) C H ClF N O 921.40 921.6
47 56 3 8 6
Table 24
Ex Calc Found
4 8a 8b
R ** R * R # Formula
No. [M+H] [M+H]
24-1 CH3 (S) CH3 (S) C46H54ClF3N8O7 923.38 923.6
24-2 CH (S) CH (S) C H ClF N O 923.38 923.6
3 3 46 54 3 8 7
24-3 CH (S) CH (R)C H ClF N O 923.38 923.6
3 3 46 54 3 8 7
24-4 CH (S) CH OCH (R)C H ClF N O 953.39 953.6
3 2 3 47 56 3 8 8
24-5 CH (R) CH (R) C H ClF N O 923.38 923.6
3 3 46 54 3 8 7
24-6 CH OCH (S) CH (R) C H ClF N O 953.39 953.6
2 3 3 47 56 3 8 8
Table 25
HN N
Calc Found
1 4 7a 7b
Ex No. R * R R R Formula
[M+H] [M+H]
(S) CH OCF F C H F N O 865.39 865.6
3 3 44 52 4 8 6
-1
O (S) CH OCF F C H F N O 907.41 907.6
3 3 46 54 4 8 7
-2
(S) CH OCF Cl C H ClF N O 923.38 923.6
3 3 46 54 3 8 7
-3
(S) CH OCF Cl C H ClF N O 881.37 881.4
3 3 44 52 3 8 6
-4
O (S) CH OCHF C H F N O 871.42 871.6
3 2 46 56 2 8 7
-5
-6 O (S) CH OCH OCF Cl C H ClF N O 953.39 953.6
3 2 3 47 56 3 8 8
-7 (S) CH OCH OCF Cl C H ClF N O 911.38 911.6
3 2 3 45 54 3 8 7
Table 26
Calc Found
1 (#) 7a 7d 9
Ex No. R * R R R Formula
[M+H] [M+H]
26-1 (R) C H N O 850.42 850.4
45 55 9 8
26-2 (S) C H N O 775.36 775.4
41 46 10 6
26-3 (S) NHCH C H N O 738.37 738.2
3 39 47 9 6
26-4 (S) C H N O 777.40 777.4
43 52 8 6
26-5 (R) C H N O 775.36 775.2
41 46 10 6
26-6 (S) OCF F C H F N O 867.37 867.8
3 43 50 4 8 7
26-7 (S) OCF F C H F N O 883.37 883.8
3 OH 43 50 4 8 8
26-8 (S) OCF Cl C H ClF N O 883.34 883.8
3 43 50 3 8 7
26-9 (S) OCF Cl OH C H ClF N O 899.34 899.8
3 43 50 3 8 8
26-10 O (S) OCF Cl C H ClF N O 925.36 925.8
3 45 52 3 8 8
26-11 O (S) OCF Cl OH C H ClF N O 941.35 941.8
3 45 52 3 8 9
(#) For all compounds, the orientation of the chiral carbon bearing the substituent R is (S)
Table 27
HN R
Calc Found
7d 9
Ex No. R R Formula
[M+H] [M+H]
27-1 Cl C45H52ClF3N8O7 909.36 909.8
27-2 Cl OH C H ClF N O 913.36 913.8
44 52 3 8 8
27-3 F C H F N O 881.39 881.8
44 52 4 8 7
27-4 F C H F N O 893.39 893.8
45 52 4 8 7
27-5 Cl (S) C H ClF N O 922.36 922.8
45 51 3 9 7
27-6 F C H F N O 897.38 897.8
OH 44 52 4 8 8
27-7 OH C H F N O 879.39 879.8
44 53 3 8 8
C H F N O 863.40 863.8
27-8 44 53 3 8 7
Table 28
Calc Found
7d 8d(#) 9 10
Ex No. R R R R Formula
[M+H] [M+H]
28-1 F C46H54F4N8O8 923.40 923.8
28-2 C H F N O 905.41 905.8
46 55 3 8 8
28-3 F H F N O 939.40 939.8
OH C46 54 4 8 9
28-4 OH C H F N O 921.40 921.8
46 55 3 8 9
28-5 Cl CH C H ClF N O 969.38 969.8
3 OH 47 56 3 8 9
28-6 Cl CH C H ClF N O 965.39 965.8
3 48 56 3 8 8
28-7 Cl CH3 C47H56ClF3N8O8 953.39 953.8
28-8 Cl CH NHCH C H ClF N O 926.35 926.8
3 3 44 51 3 9 8
28-9 Cl CH C H ClF N O 968.40 968.8
3 47 57 3 9 8
28-10 Cl CH C H ClF N O 937.36 937.8
3 46 52 3 8 8
28-11 Cl C H ClF N O 951.37 951.8
47 54 3 8 8
28-12 Cl C H ClF N O 954.38 954.8
46 55 3 9 8
28-13 Cl NHCH C H ClF N O 912.33 912.8
3 43 49 3 9 8
Calc Found
7d 8d(#) 9 10
Ex No. R R R R Formula
[M+H] [M+H]
28-14 Cl C H ClF N O 923.34 923.8
45 50 3 8 8
28-15 Cl CH OH C H ClF N O 969.38 969.8
2 47 56 3 8 9
28-16 Cl OH CH OH C H ClF N O 985.38 985.8
2 47 56 3 8 10
28-17 Cl CH C H ClF N O 1,052.42 1053.0
3 51 61 3 9 10
28-18 Cl CH C H ClF N O 1,038.40 1039.0
3 50 59 3 9 10
28-19 Cl CH C H ClF N O 1,065.45 1066.0
3 52 64 3 10 9
28-20 Cl C H ClF N O 955.37 955.6
46 54 3 8 9
28-21 Cl O C H ClF N O 967.37 967.6
47 54 3 8 9
28-22 Cl C H ClF N O 981.38 981.5
48 56 3 8 9
28-23 Cl C H ClF N O 969.35 969.6
46 52 3 8 10
(#) When the substituent R is other than hydrogen, the orientation of the chiral carbon
bearing the substituent R is (S)
Table 29
HN R
Calc Found
Ex No. R R Formula
[M+H] [M+H]
29-1 O C45H51ClF4N8O7 927.35 927.6
29-2 C H ClF N O 885.34 885.4
43 49 4 8 6
29-3 C H ClF N O 901.34 901.6
OH 43 49 4 8 7
29-4 O OH C H ClF N O 943.35 943.6
45 51 4 8 8
Biological Assays
The hepatitis C virus has been classified into six major different genotypes on the
basis of nucleotide sequence, and further divided into subtypes within genotypes.
Compounds of the invention demonstrated inhibition of HCV replication in one or more
of the following HCV replicon assays.
Assay 1: HCV Genotype 1b Replicon Assay
The HCV genotype 1b replicon cell line was obtained from Apath LLC
(Brooklyn, NY) (APC144; Huh7 cell background). This subgenomic replicon contains the
N-terminus of the HCV core protein fused to the neomycin-resistance selectable marker.
The EMCV IRES lies downstream and drives expression of humanized Renilla luciferase
fused to the non-structural proteins NS3-NS5B. This cell line was used to determine
compound potency using the luciferase activity readout as a measurement of compound
inhibition of replicon levels.
Cells were grown at 37°C in a 5% CO humidified incubator in DMEM
(Invitrogen) with 10% FBS (HyClone), 1x NEAA (Invitrogen), 1x Pen-Strep
(Invitrogen), and 500µg/mL G418 (Invitrogen). On day 1 of the assay, cells were plated
at 10,000 cells/well in white 96-well tissue culture plates (Costar) in 200µL media
lacking G418. Four hours later, once the cells have adhered, the media was removed and
replaced with media (no G418) containing dose-responses of test compounds.
Compounds were initially diluted in DMSO and then diluted another 200 x in media to
bring the final DMSO concentration down to 0.5%. The cells were incubated with test
compounds for 48 hours. At the end of the incubation period, media and compound were
removed from the plates and the luciferase activity was determined using Promega
Renilla-Glo reagents.
To analyze the data, the luciferase activity was plotted vs. the compound
concentration, and EC values were determined from a 4-parameter robust fit model with
the GraphPad Prism software package (GraphPad Software, Inc., San Diego, CA).
Results are expressed as the negative decadic logarithm of the EC value, pEC .
50 50
Test compounds having a higher pEC value in this assay show greater inhibition
of HCV genotype 1b replication. Compounds of the invention tested in this assay
typically exhibited pEC values between about 7 and about 12.
Assay 2: HCV Genotype 1a Replicon Assay
The HCV genotype 1a replicon cell line was obtained from Apath LLC (APC89;
Huh7.5 cell background). This subgenomic replicon contains the N-terminus of the HCV
core protein fused to the neomycin-resistance selectable marker. The EMCV IRES lies
downstream and drives expression of the non-structural proteins NS3-NS5B. Compound
potencies were determined using the NS3-specific protease activity in lysates as a
measurement of compound inhibition of replicon levels.
Cells were grown at 37°C in a 5% CO humidified incubator in DMEM
(Invitrogen) with 10% FBS (HyClone), 1x NEAA (Invitrogen), 1x Pen-Strep
(Invitrogen), and 850µg/mL G418 (Invitrogen). On day 1 of the assay, cells were plated
at 15,000 cells/well in black 96-well tissue culture plates (Costar) in 200µL media lacking
G418. Four hours later, once the cells had adhered, the media was removed and replaced
with media (no G418) containing dose-responses of test compounds. Compounds were
initially diluted in DMSO and then diluted another 200x in media to bring the final
DMSO concentration down to 0.5%. The cells were incubated with test compounds for 48
or 72 hours. At the end of the incubation period, media and compound were removed
from the plates.
To determine the NS3-specific protease activity in lysates, the cells were lysed at
room temperature in 50µL/well of 50mM Hepes pH 7.5, 150mM NaCl, 15% Glycerol,
0.15% Triton X-100, 10mM DTT for 20 minutes with shaking. 50µL of an NS3/4a
protease-specific FRET substrate (Anaspec RET S1 Cat#22991) was then added to the
wells at a final concentration of 15µM. The plates were incubated at 37°C for 20 minutes,
which corresponds to a timepoint at which the protease activity is still in the linear phase.
Protease activity was determined by measuring fluorescence (Excitation: 340 nm;
Emission: 509nm).
To analyze the data, the fluorescence was plotted vs. the compound concentration,
and EC50 values were determined from a 4-parameter robust fit model using GraphPad
Prism software. Compounds of the invention tested in this assay typically exhibited
pEC values between about 6 and about 11.5.
Assay 3: Replicon Assays Against Resistant Mutants
To create replicon cells with resistant mutations of interest, the mutation was first
introduced into the parental plasmid by site-directed mutagenesis. Mutations in
genotype 1b included L31V, Y93H, and the L31V/Y93H double mutant. Mutations in
genotype 1a included Q30R and L31V. The replicon plasmid was then linearized and in
vitro transcribed to RNA. The RNA was used to stably transfect Huh7 cells by
electroporation, and new cell lines were selected with 500µg/mL G418. Potencies of test
compounds against these mutant cell lines were determined as previously described above
for the HCV Genotype 1b and 1a replicon assays.
Potencies of test compounds against additional mutations of interest were
determined using transient transfection assays. These mutants included genotype 1a
Y93C, Y93H, M28T, Q30E, Q30K, L31M, and Y93N. The mutation was first introduced
into the parental plasmid by site-directed mutagenesis. The replicon plasmid was then
linearized and in vitro transcribed to RNA. The RNA was used to transiently transfect
Huh-LUNET cells (obtained from ReBLikon GmbH, Schriesheim, Germany) by
electroporation, and the potencies of test compounds against the mutants were determined
as previously described.
Assay 4: Replicon Assays Against NS5A Sequences of Other Genotypes
Potencies of test compounds against NS5A sequences of other genotypes were
determined by creating intergenotypic chimeras. The entire NS5A gene from genotypes
2a, 2b, 3a, 4a, 5a, and 6a, or the nucleotide sequence encoding amino acids 11-118 of
NS5A, was subcloned into a genotype 1b replicon. For genotype 2a, intergenotypic
chimeras with both the JFH and the J6 strain were created. In general, NS5A inhibitors
have been shown to exhibit significantly weaker potency against the J6 strain due to the
presence of a naturally occurring L31M sequence variant. Since the majority of genotype
2a sequences in public databases contain the L31M sequence variant, the use of the J6
genotype 2a sequence may better reflect the antiviral potency of NS5A inhibitors.
These chimeric replicon plasmids were then linearized and in vitro transcribed to
RNA. The RNA was used to transiently or stably transfect Huh-LUNET cells by
electroporation, and the potencies of test compounds against the chimeras were
determined as previously described.
Assay 5: Colony Formation Assays
Colony formation assays were used to compare test compounds with respect to
their overall genetic barrier to resistance. Genotype 1b and genotype 1a replicon cells
were grown in the presence of various concentrations of test compounds and 500 µg/mL
or 850 µg/mL geneticin selection, respectively. Media, including test compound, was
replaced twice per week. After 3-4 weeks, most cells had been killed and resistant
colonies were visualized by staining with crystal violet. Compounds with enhanced
potency against the key resistant mutants showed significantly fewer colonies, consistent
with an improved overall genetic barrier to resistance.
Assay Results
All of the compounds of Examples 1 to 21 and Tables 1 to 29 were tested in one
or more of the assays described above. Representative results for the compounds of
Examples 1 to 21 in the HCV genotype 1a, 1b, 2a (J6 strain), 3a, and the resistant mutant
1a Y93H replicon assays, as well as results for the HCV genotype 1a and 1b replicon
assays for the compounds of Tables 1 to 29 are given below. In the following tables, A
represents a pEC value between 6 and 8 (EC between 1 µM and 10 nM), B represents
50 50
pEC between 8 and 9 (EC between 1 and 10 nM), C represents pEC between and 9
50 50 50
and about 10, (EC between 1 nM and 0.1 nM), and D represents pEC >10 (EC < 0.1
50 50 50
nM).
Example Genotype Genotype Genotype Genotype Genotype
No. 1a 1b 1a Y93H 2a (J6) 3a
1 D D A A A
2 D D B B
3 D D
4 D D C B B
C D
6 C D
7 D D A A
8 D D A A A
9 D D A A
D D B B B
11 D D A B B
12 D D B B B
13 D D B C C
14 D D B C C
D D B C C
16 D D B B B
17 C A A A
18 D D B C B
19 D D A B B
D D B B B
21 D D C C C
Example Genotype Genotype Example Genotype Genotype
No. 1a 1b No. 1a 1b
Table 1 1-37 D
1-1 D D 1-38 D
1-2 D 1-39 D
1-3 D D 1-40 D D
1-4 D 1-41
1-5 D D 1-42 D
1-6 D 1-43 D D
1-7 D D 1-44 D
1-8 D D 1-45 D
1-9 D D 1-46 D
1-10 D D 1-47 D
1-11 D D 1-48 D
1-12 D D 1-49 D
1-13 D D 1-50 D
1-14 D D 1-51 D
1-15 D D 1-52 C
1-16 D D 1-53 D D
1-17 D D 1-54 D
1-18 D D 1-55 D D
1-19 D D 1-56 D
1-20 D D 1-57 D
1-21 D 1-58 D
1-22 D 1-59 D
1-23 D 1-60 D
1-24 D 1-61 D D
1-25 D 1-62 D D
1-26 D 1-63 D
1-27 C 1-64 C
1-28 D 1-65 C
1-29 D 1-66 C
1-30 D D 1-67 D
1-31 D 1-68 C
1-32 D 1-69 D
1-33 C 1-70 D
1-34 D D 1-71 C
1-35 D D 1-72 D
1-36 D D 1-73 D
Example Genotype Genotype Example Genotype Genotype
No. 1a 1b No. 1a 1b
1-74 D 2-8 D
1-75 D D
1-76 D Table 3
1-77 D 3-1 D D
3-2 D
1-78 C D
3-3 C
1-79 C
3-4 C
1-80 C
1-81 D D
Table 4
1-82 C D
4-1 D D
1-83 C
4-2 D D
1-84 C
4-3 D
1-85 B
4-4 D D
1-86 D
4-5 D D
1-87 D
4-6 D D
1-88 D
4-7 D D
1-89 D
4-8 D D
1-90 C
4-9 D
1-91 D
4-10 D D
1-92 D D
4-11 D D
1-93 D D
4-12 D D
1-94 D
4-13 C
1-95 C
4-14 C D
1-96 D D
4-15 D
1-97 C
4-16 C D
1-98 C
4-17 C D
1-99 D
4-18 D D
1-100 D
4-19 D D
1-101 D D
4-20 C D
4-21 D D
Table 2
4-22 C
2-1 C D
4-23 C
2-2 C C
4-24 C
2-3 D D
2-4 D 4-25 C
2-5 C D 4-26 D
4-27 C
2-6 D
4-28 D
2-7 C
Example Genotype Genotype Example Genotype Genotype
No. 1a 1b No. 1a 1b
4-29 D 5-17 D
4-30 C 5-18 D D
4-31 C 5-19 D
4-32 C 5-20 D
4-33 C
Table 6
4-34 C
6-1 C D
4-35 C
6-2 C
4-36 C
6-3 C
4-37 D D
4-38 C 6-4 A
4-39 C 6-5 C D
6-6 C
4-40 D
6-7 D
4-41 C
6-8 C
4-42 D D
6-9 D D
4-43 C
6-10 D D
4-44 D
6-11 C D
4-45 C
4-46 D D 6-12 C D
6-13 D
4-47 C
6-14 D
Table 5 6-15 C
-1 D 6-16 B
-2 D 6-17 D
-3 D D 6-18 C
-4 D D 6-19 C
-5 D D 6-20 B
-6 C D 6-21 C
-7 D D 6-22 B
-8 D D 6-23 B
-9 D D 6-24 B
-10 A 6-25 B
-11 D 6-26 B
-12 D 6-27 C
-13 D 6-28 D D
-14 C 6-29 D
-15 D
-16 D
Table 7
Example Genotype Genotype Example Genotype Genotype
No. 1a 1b No. 1a 1b
7-1 D 10-5 D
7-2 A
7-3 D Table 11
7-4 B 11-1 C
11-2 C
7-5 B
11-3 D
7-6 A
11-4 D
7-7 D
11-5 D
7-8 B
11-6 D
7-9 D
7-10 D 11-7 D
7-11 D 11-8 D
11-9 C
7-12 D
11-10 D
7-13 D
11-11 D
7-14 D
11-12 D
7-15 D D
7-16 D
Table 12
7-17 B
12-1 D D
12-2 C
Table 8
12-3 D
8-1 D D
12-4 D
8-2 D D
12-5 D
8-3 C
12-6 D
8-4 D D
12-7 C
8-5 C
12-8 D D
8-6 C
12-9 D
Table 9 12-10 D
9-1 C 12-11 D
9-2 C 12-12 D
9-3 C 12-13 B
9-4 D D 12-14 D
9-5 C 12-15 D
12-16 C
Table 10
12-17 D D
-1 D D
12-18 D
-2 C 12-19 D
-3 D 12-20 D
-4 C
Example Genotype Genotype Example Genotype Genotype
No. 1a 1b No. 1a 1b
12-21 D 12-58 C
12-22 C
12-23 D Table 13
12-24 D D 13-1 D D
13-2 A
12-25 D
13-3 C
12-26 D
13-4 C
12-27 C
13-5 D D
12-28 D
13-6 D
12-29 D
12-30 C 13-7 D
12-31 D 13-8 D
13-9 D
12-32 D D
13-10 D
12-33 C
13-11 D D
12-34 C
13-12 D D
12-35 D
13-13 D
12-36 A
13-14 D
12-37 C
12-38 C 13-15 D
13-16 D D
12-39 D
13-17 D D
12-40 D
13-18 D D
12-41 C
13-19 D D
12-42 D
13-20 D D
12-43 D
13-21 D D
12-44 D
12-45 D 13-22 D D
13-23 D
12-46 D
13-24 D D
12-47 D D
13-25 C
12-48 D
13-26 D
12-49 D
13-27 D D
12-50 D D
13-28 D D
12-51 C
12-52 C 13-29 D D
12-53 D 13-30 D D
13-31 D D
12-54 C
13-32 D
12-55 D
13-33 D
12-56 D
13-34 D D
12-57 D
Example Genotype Genotype Example Genotype Genotype
No. 1a 1b No. 1a 1b
13-35 D D 16-3 D D
13-36 B 16-4 D D
13-37 B 16-5 D D
13-38 D D 16-6 D
13-39 B 16-7 D D
13-40 A 16-8 D
13-41 D 16-9 D
13-42 D D 16-10 C
13-43 B 16-11 D
13-44 C 16-12 C
13-45 C 16-13 D D
16-14 D D
Table 14
16-15 C D
14-1 C
16-16 D
14-2 C
16-17 D
14-3 C
16-18 D
14-4 B
14-5 Table 17
14-6 17-1 D D
17-2 D D
Table 15 17-3 D D
-1 C
17-4 D D
-2 C
-3 D D Table 18
-4 D 18-1 C
-5 D 18-2 C
-6 18-3 C
-7 D 18-4 C
-8 C 18-5 D D
-9 D 18-6 D D
-10 B
Table 19
-11 D D
19-1 D
-12 D D
19-2 D D
-13 D
19-3 A
Table 16 19-4 D
16-1 D D 19-5 A
16-2 D D 19-6 D D
Example Genotype Genotype Example Genotype Genotype
No. 1a 1b No. 1a 1b
19-7 B 22-8 D D
19-8 B 22-9 D D
19-9 D D 22-10 D D
19-10 A 22-11 D D
19-11 D 22-12 D D
19-12 D 22-13 D D
19-13 D 22-14 D
19-14 A 22-15 D
19-15 D 22-16 D D
19-16 D 22-17 D
19-17 C
19-18 C Table 23
23-1 A
23-2 D
Table 20 23-3 C
-1 D D
-2 D D Table 24
-3 D D 24-1 C D
-4 D D 24-2 C D
-5 D D 24-3 C D
-6 D D 24-4 C D
-7 D D 24-5 C
24-6 D D
Table 21
21-1 A
Table 25
21-2 A 25-1 C
21-3 D D 25-2 D D
21-4 C 25-3 C
-4 C
Table 22 25-5 D
22-1 D D 25-6 C
22-2 D 25-7 B
22-3 D D
22-4 D D Table 26
22-5 D D 26-1 A
22-6 D D 26-2 B
22-7 D D 26-3 B
Example Genotype Genotype Example Genotype Genotype
No. 1a 1b No. 1a 1b
26-4 C D 28-6 D D
26-5 A 28-7 D D
26-6 C 28-8 D
26-7 C D 28-9 D
26-8 C 28-10 D
26-9 C 28-11 D D
26-10 A 28-12 D
26-11 A 28-13 D
28-14 D
28-15 D D
Table 27
27-1 D D 28-16 D D
27-2 D 28-17 D D
27-3 D D 28-18 D D
27-4 D 28-19 C D
27-5 D D 28-20 D D
27-6 D D 28-21 D D
27-7 D 28-22 D D
27-8 D D 28-23 C
Table 28 Table 29
28-1 D D 29-1 D
28-2 D D 29-2 C
28-3 D D 29-3 C
28-4 D 29-4 D
28-5 D
While the present invention has been described with reference to specific aspects or
embodiments thereof, it will be understood by those of ordinary skill in the art that various
changes can be made or equivalents can be substituted without departing from the true spirit
and scope of the invention. Additionally, to the extent permitted by applicable patent statutes
and regulations, all publications, patents, and patent applications cited herein are hereby
incorporated by reference in their entirety as though individually incorporated by reference.
Claims (23)
1. A compound of formula (I): 5 (I) wherein R is selected from C alkyl, C alkoxy, phenyl, C cycloalkyl, heterocycle, and 1-6 1-6 3-6 heteroaryl, wherein C alkyl is optionally substituted with –OR amino, –SR , heterocycle, 1-6 , or heteroaryl, C alkoxy is optionally substituted with –OR , and heterocycle is optionally 10 substituted with –OR amino,–C(O)OC alkyl, or with one or two C alkyl; , 1-6 1-3 is selected from hydrogen and C alkyl; R 1-6 3 m n R is selected from hydrogen, C alkyl, -C(O)OC alkyl, -C(O)NR R , 1-6 1-6 -C(O)C cycloalkyl, and -S(O) C alkyl; 3-6 2 1-3 or R and R together with the nitrogen atom to which they are attached form a 15 heterocycle; 4 b c d e R is selected from C alkyl, -NR R , -OR , -SR , -S(O)C alkyl, -S(O) C alkyl, 1-6 1-3 2 1-3 a b 5 6 -CN, -C(O)NR R , heterocycle, heteroaryl, and halo; and R and R are hydrogen; 4 5 6 or R and R are independently C alkyl or halo and R is hydrogen; 4 5 6 or R and R taken together form –(CH ) –, wherein n is 2, 3, 4, or 5 and R is 20 hydrogen; 4 5 6 or R and R taken together form –O-(CH ) -O- and R is hydrogen; 4 5 6 or R is hydrogen and R and R taken together form –(CH ) –, wherein m is 1, 2, 3, or 4; 4 5 6 or R and R are each hydrogen and R is C alkyl; 25 is selected from halo, C alkyl, and C alkoxy wherein C alkyl and C alkoxy R 1-3 1-3 1-3 1-3 are optionally substituted with one, two, three, four, or five halo; R is C alkyl, optionally substituted with -OR ; 9 f g R is selected from C alkyl, C cycloalkyl, C alkoxy, -NR R , heteroaryl, 1-6 3-6 1-6 heterocycle, and –CH -heteroaryl; wherein: C alkyl is optionally substituted with one or two substituents independently h j k 5 selected from –OR , -NR R , -NHC(O)C1-3alkyl, -NHC(O)OC1-3alkyl, -NHC(O)C cycloalkyl, C cycloalkyl, and halo; 3-6 3-6 C alkoxy is optionally substituted with –OR ; any C cycloalkyl is optionally substituted with one, two, or three substituents a b h independently selected from C alkyl, halo, -NR R , – OR , and -CD , wherein any 1-3 3 10 C alkyl is optionally substituted with one, two, or three halo; any heterocycle is optionally substituted with one, two, or three substituents independently selected from C1-3alkyl, halo, -C(O)OC1-3alkyl, -C(O)C1-6alkyl, -C(O)C cycloalkyl, –C(O)NHC alkyl, -C(O)NHC cycloalkyl,–S(O) C alkyl, 3-6 1-6 3-6 2 1-6 and -C(O)NH ; 15 wherein any –C(O)C alkyl is optionally substituted with h j k -NHC(O)OC alkyl, -OR , -NR R , or heterocycle, any -C(O)C cycloalkyl is optionally substituted with one or two C alkyl, and any –C(O)NHC alkyl is optionally substituted with –OR or 20 C cycloalkyl; any heteroaryl is optionally substituted with one or two C alkyl; a b e h j k m n R , R , R , R , R , R , R , and R are each independently hydrogen or C alkyl; R is hydrogen or C alkyl, wherein C alkyl is optionally substituted with –OR or 1-6 1-6 amino; 25 is hydrogen or C alkyl, wherein C alkyl is optionally substituted with –OR or R 1-6 1-6 with heteroaryl optionally substituted with C1-3alkyl; R is hydrogen or C alkyl, wherein C alkyl is optionally substituted with –OR ; 1-6 1-6 g a b R is selected from hydrogen, C alkyl, C alkoxy, C cycloalkyl, NR R , and 1-6 1-6 3-6 heterocycle, wherein C alkyl is optionally substituted with –OR and heterocycle is 30 optionally substituted with =O; R is selected from hydrogen, halo, and C alkyl, wherein C alkyl is optionally 1-3 1-3 substituted with one, two, or three halo, or with –OR ; A is –NHC(O)- or –C(O)NH- a is 0, 1, or 2; and 5 b is 0, 1 or 2; or a pharmaceutically-acceptable salt or stereoisomer thereof.
2. The compound of Claim 1 wherein R is selected from C alkyl, phenyl, 10 C cycloalkyl, and heterocycle, wherein C alkyl is optionally substituted with –OR , and 5-6 1-3 any heterocycle has six ring atoms and is optionally substituted with one or two C alkyl.
3. The compound of Claim 1 wherein R is selected from C alkyl and –OR ; and R and R are each hydrogen.
4. The compound of Claim 1 wherein R is selected from C alkyl, f g f g C cycloalkyl, NR R , wherein R and R are independently hydrogen or C alkyl, 3-6 1-3 heteroaryl, and heterocycle, wherein C alkyl is optionally substituted with -OR , C cycloalkyl is optionally substituted with one or two C alkyl or halo, any heteroaryl has 3-6 1-3 20 five or six ring atoms, and any heterocycle has five ring atoms and is optionally substituted with one or two substituents selected from C alkyl, -C(O)OC alkyl , -C(O)C alkyl, and 1-3 1-3 1-6 -C(O)NHC alkyl 1-6 .
5. The compound of Claim 1, wherein: 25 is selected from C alkyl, phenyl, C cycloalkyl, and heterocycle, wherein R 1-3 5-6 C1-3alkyl is optionally substituted with –OR , and any heterocycle has six ring atoms and is optionally substituted with one or two C alkyl; R is –C(O)OC alkyl; R is selected from C alkyl and –OR ; 30 R and R are each hydrogen; R is selected from halo, C alkyl, and C alkoxy wherein C alkyl and C alkoxy 1-3 1-3 1-3 1-3 are substituted with two or three halo; 9 f g f g R is selected from C alkyl, C cycloalkyl, NR R , wherein R and R are 1-6 3-6 independently hydrogen or C alkyl, heteroaryl, and heterocycle, wherein C alkyl is 1-3 1-6 5 optionally substituted with - OR C3-6cycloalkyl is optionally substituted with one or two C1- alkyl or halo, any heteroaryl has five or six ring atoms, and any heterocycle has five ring atoms and is optionally substituted with one or two substituents selected from C alkyl, -C(O)OC alkyl , -C(O)C alkyl, and -C(O)NHC alkyl; 1-3 1-6 1-6 10 h R is hydrogen or C alkyl, wherein C alkyl is optionally substituted with –OR ; 1-3 1-3 10 a is 1 or 2; and b is 1 or 2.
6. The compound of Claim 5 wherein A is –NHC(O)-. 15
7. The compound of Claim 5 wherein A is –C(O)NH-.
8. The compound of Claim 1 wherein the compound is a compound of formula (IV): NH R (IV) wherein: R is selected from C alkyl, optionally substituted with hydroxy or methoxy, and tetrahydropyranyl; 25 R is hydrogen; R is -C(O)OC alkyl; R is methyl or methoxy; R is selected from fluoro, chloro, -CF and –OCF ; 3, 3 R is independently methyl or hydroxymethyl; R is selected from –NHCH cyclopropyl, 2,2-dimethylcyclopropyl, tert-butyl, 3-hydroxy-2,2-dimethylpropyl, and imidazolyl; 5 R is hydrogen or hydroxymethyl; a is 1 or 2; and b is 1 or 2; or a pharmaceutically-acceptable salt thereof. 10
9. The compound of Claim 1 wherein the compound is a compound of formula (V): R N O HN N N wherein: 15 R is selected from C alkyl, optionally substituted with hydroxy or methoxy, and tetrahydropyranyl; R is hydrogen; R is -C(O)OC alkyl; R is methyl or methoxy; 20 R is selected from fluoro, chloro, -CF and –OCF ; 3, 3 R is independently methyl or hydroxymethyl; R is selected from –NHCH cyclopropyl, 2,2-dimethylcyclopropyl, tert-butyl, 3-hydroxy-2,2-dimethylpropyl, and imidazolyl; R is hydrogen or hydroxymethyl; 25 a is 1 or 2; and b is 1 or 2; or a pharmaceutically-acceptable salt thereof.
10. The compound of claim 8 or claim 9, wherein R is tetrahydropyranyl.
11. The compound of Claim 1 wherein the compound is selected from O N N O N N N HN N HN HN 3 O N Cl N Cl F NH O O N O NH O 3 CF HN N N N Cl O NH O N O CF CF HO 3 HO 3 O N O N N N N N HN HN NH NH Cl Cl O NH NH and pharmaceutically-acceptable salts thereof.
12. The compound of Claim 11 wherein the compound is selected from CF CF N O N O N N N N HN HN NH NH F Cl HN HN CF CF O N O N N N N HN HN NH NH Cl Cl NH NH O O O O O NH and pharmaceutically-acceptable salts thereof.
13. The compound of claim 1, which is: or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 13 and a pharmaceutically-acceptable carrier.
15. The pharmaceutical composition of Claim 14 further comprising one or more 10 other therapeutic agents useful for treating hepatitis C viral infections.
16. The pharmaceutical composition of Claim 15 wherein the one or more other therapeutic agents is selected from HCV NS3 protease inhibitors, and HCV NS5B nucleoside and non-nucleoside polymerase inhibitors.
17. A process for preparing a compound of formula (1-5) where G represents the group , and 1 2 3 4 5 6 7 8 9 wherein R , R , R , R , R , R , R , R , R , a, and b are defined as in Claim 1, or a pharmaceutically-acceptable salt or stereoisomer thereof, the process comprising: (d) reacting a compound of formula 3-3 5 with a compound of formula 3-4 wherein Pg is an amino-protecting group, to provide a protected intermediate 1-3 10 (e) deprotecting intermediate 1-3 to provide a deprotected intermediate 1-4: (f) reacting intermediate 1-4 with a carboxylic acid or carboxylic acid chloride: HO R Cl R 15 to provide a compound of formula 1-5 or a pharmaceutically-acceptable salt or stereoisomer thereof.
18. The process of Claim 17, wherein R is C alkyl or tetrahydropyranyl, R is 3 4 5 6 7 hydrogen, R is -C(O)OC alkyl, R is methyl or methoxy, R and R are both hydrogen, R is fluoro, chloro, or –OCF , R is methyl, R is tert-butyl or 3-hydroxy-2,2-dimethylpropyl, a is 1 or 2, and b is 1.
19. A compound of formula 3-4: 7 8 9 wherein Pg is an amino-protecting group, R is fluoro, chloro, or –OCF , R is methyl, R is tert-butyl or 3-hydroxy-2,2-dimethylpropyl, a is 1 or 2, and b is 1. 15
20. Use of a compound as claimed in any one of Claims 1 to 13 for manufacture of a medicament for inhibiting replication of the hepatitis C virus in a mammal.
21. Use of a compound as claimed in any one of Claims 1 to 13 in combination with at least one other therapeutic agent for manufacture of a medicament for inhibiting 20 replication of the hepatitis C virus in a mammal.
22. The use of Claim 21 wherein the other therapeutic agent is selected from HCV NS3 protease inhibitors, HCV NS5B nucleoside, non-nucleoside polymerase inhibitors, interferons, pegylated interferons, cyclophilin inhibitors, HCV NS5A inhibitors, and 25 ribavirin.
23. Use of a compound as claimed in any one of Claims 1 to 13 for manufacture of a medicament for the treatment of a hepatitis C viral infection in a mammal.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161555056P | 2011-11-03 | 2011-11-03 | |
US61/555,056 | 2011-11-03 | ||
US201261600089P | 2012-02-17 | 2012-02-17 | |
US61/600,089 | 2012-02-17 | ||
US201261637961P | 2012-04-25 | 2012-04-25 | |
US61/637,961 | 2012-04-25 | ||
PCT/US2012/063181 WO2013067267A1 (en) | 2011-11-03 | 2012-11-02 | Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ623846A NZ623846A (en) | 2016-07-29 |
NZ623846B2 true NZ623846B2 (en) | 2016-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9669027B2 (en) | Hepatitis C virus inhibitors | |
JP5891235B2 (en) | Novel inhibitor of hepatitis C virus | |
US9365549B2 (en) | Hepatitis C virus inhibitors | |
CA2869640C (en) | Piperazine-piperidine compounds as hepatitis c virus inhibitors | |
NZ623846B2 (en) | Rod-like hepatitis c virus inhibitors containing the fragment {2-[4-(bi phenyl-4-yl) -1h-imidazo-2-yl] pyrrolidine-1-carbonlymethyl} amine |